Oxosterols and methods of use thereof

By providing new oxysterol compounds, the shortcomings of existing aoxysterols in regulating NMDA receptors are addressed, achieving more efficient prevention and treatment of NMDA-mediated disorders and other neurological diseases.

CN118994288APending Publication Date: 2024-11-22SAGE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411074416.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-05-06
Filing Date
2016-07-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing oxysterols have shortcomings in efficacy, pharmacokinetics, oral bioavailability, formulation and safety in regulating NMDA receptors, making it difficult to effectively prevent and treat diseases related to NMDA expression and function.

Method used

A novel oxysterol compound is provided, including specific compounds of formula (I) and pharmaceutically acceptable salts thereof, for use as pharmaceutical compositions, by oral or other routes of administration, for the prevention and treatment of NMDA-in-mediated and other related disorders.

Benefits of technology

These compounds have improved in vivo efficacy, pharmacokinetics, oral bioavailability, formulation and safety, and are able to more effectively prevent and treat NMDA-mediated disorders and other neurological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994288A_ABST
    Figure CN118994288A_ABST
Patent Text Reader

Abstract

The present invention relates to oxysterols and methods of use thereof. In particular, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same; wherein R1, R2 and R3 are as defined herein. The compounds of the invention are intended for the prevention and treatment of various conditions. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application date of July 6, 2016, application number 202110635348.8, and invention name: "Oxysterols and methods of use thereof".

[0002] Related Applications

[0003] Priority is claimed herein to U.S. Provisional Application No. 62 / 189,068, filed on July 6, 2015, and U.S. Provisional Application No. 62 / 332,931, filed on May 6, 2016, each of which is incorporated herein by reference in its entirety. Background Art

[0004] NMDA receptors are heteromeric complexes that consist of NR1, NR2 and / or NR3 subunits and have different recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine and binding sites for glutamate agonists and modulators. NMDA receptors are expressed in peripheral tissues and the CNS, where they participate in excitatory synaptic transmission. Activation of these receptors contributes to synaptic plasticity in some cases and leads to excitotoxicity in other cases. These receptors are ligand-gated ion channels that allow Ca to flow into and out of the synapses after binding glutamate and glycine. 2+ Through, and is important for excitatory neurotransmission and normal CNS function. Positive modulators can be effectively used as therapeutic agents, which have potential clinical uses as cognitive enhancers and in the treatment of psychiatric diseases in which glutamatergic transmission is reduced or defective (see, for example, Horak et al., J. of Neuroscience, 2004, 24 (46), 10318-10325). In contrast, negative modulators can be used as therapeutic agents, which have potential clinical uses in the treatment of psychiatric diseases in which glutamatergic transmission is pathologically increased (e.g., the treatment of refractory depression).

[0005] Oxysterols are derived from cholesterol and have been shown to effectively and selectively regulate NMDA receptor function. New and improved oxysterols are needed that regulate NMDA receptors to prevent and treat disorders associated with NMDA expression and function. Compounds, compositions, and methods described herein are all directed to this goal. Summary of the invention

[0006] Provided herein are substituted oxysterols for preventing and / or treating a wide range of disorders, including but not limited to NMDA-mediated disorders. These compounds are expected to show improvements in in vivo efficacy, pharmacokinetic (PK) properties, oral bioavailability, formulation, stability and / or safety compared to other oxysterols. Provided herein are pharmaceutical compositions comprising compounds of the invention and their use and methods of treatment.

[0007] In one aspect, provided herein are compounds of formula (I):

[0008]

[0009] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen or C 1-6 Alkyl; R 2 C 1-6 Alkyl, carbocyclic or heterocyclic; R 5 is absent or is hydrogen; and represents a single bond or a double bond, where When it is a double bond, the other is a single bond, and R 5 Does not exist.

[0010] In some embodiments, R 1 For hydrogen.

[0011] In some embodiments, R 1 C 1-6 In some embodiments, R 1 To replace C 1-6 In some embodiments, R 1 For unsubstituted C 1-6 In some embodiments, R 1 is methyl (e.g., -CH3, -CF3, or -CH2OCH3), ethyl, or isopropyl. 1 is methyl (eg, -CH3) or ethyl (eg, -CH2CH3).

[0012] In some embodiments, R 2 C 1-6 In some embodiments, R 2 To replace C 1-6 In some embodiments, R 2 For unsubstituted C 1-6 In some embodiments, R 2 C 1-4 In some embodiments, R2 To replace C 1-4 In some embodiments, R 2 For unsubstituted C 1-4 In some embodiments, R 2 C 1-3 In some embodiments, R 2 To replace C 1-3 In some embodiments, R 2 For unsubstituted C 1-3 In some embodiments, R 2 is methyl, ethyl (e.g., -CH2CH3, -CH2CF3, -CH(CH3)(CF3)), isopropyl, tert-butyl or cyclopropyl. In some embodiments, R 2 In some embodiments, R 2 It is -CH2CF3 or -CH(CH3)(CF3).

[0013] In some embodiments, R 1 and R 2 C 1-6 In some embodiments, R 1 C 1-6 Alkyl and R 2 C 1-6 In some embodiments, R 1 is methyl or ethyl, and R 2 is unsubstituted or substituted C 1-6 In some embodiments, R 1 is methyl or ethyl, and R 2 It is a carbocyclic group or a heterocyclic group.

[0014] In some embodiments, Represents a single bond.

[0015] In some embodiments, the compound of formula (I) is a compound of formula (IA) or formula (IB):

[0016] or In some embodiments, the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii):

[0017] or In some embodiments, the compound of formula (I) is a compound of formula (IC):

[0018]

[0019] In some embodiments, the compound of formula (IC) is a compound of formula (ICi) or (IC-ii):

[0020]

[0021] In some embodiments, the compound of formula (ICi) is a compound of formula (ICia) or (ICib):

[0022]

[0023] In some embodiments, the compound of formula (IC-ii) is a compound of formula (IC-ii-a) or (IC-ii-b):

[0024]

[0025] In some embodiments, R 2 C 1-6 In some embodiments, R 2 To replace C 1-6 In some embodiments, R 2 C 1-6 Halogenated alkyl.

[0026] In some embodiments, the compound of formula (I) is a compound of formula (II):

[0027]

[0028] or a pharmaceutically acceptable salt thereof.

[0029] In some embodiments, the compound of formula (II) is a compound of formula (II-A) or formula (II-B):

[0030]

[0031] In some embodiments, the compound of formula (II) is a compound of formula (II-C) or formula (II-D):

[0032]

[0033] In some embodiments, the compound of formula (II) is a compound of formula (II-E):

[0034]

[0035] In some embodiments, the compound of formula (II-E) is a compound of formula (II-Ei) or formula (II-E-ii):

[0036]

[0037] In some embodiments, the compound of formula (II-Ei) is a compound of formula (II-Eia) or formula (II-Eib):

[0038]

[0039] In some embodiments, the compound of formula (II-E-ii) is a compound of formula (II-E-ii-a) or formula (II-E-ii-b):

[0040]

[0041] In some embodiments, the compound of formula (I) is a compound of formula (VII):

[0042]

[0043] or a pharmaceutically acceptable salt thereof.

[0044] In some embodiments, the compound of formula (VII) is a compound of formula (VII-A) or formula (VII-B):

[0045]

[0046] In some embodiments, the compound of formula (VII) is a compound of formula (VII-C) or formula (VII-D):

[0047]

[0048] In some embodiments, the compound of formula (VII) is a compound of formula (VII-E):

[0049]

[0050] In some embodiments, the compound of formula (VII-E) is a compound of formula (VII-Ei) or formula (VII-E-ii):

[0051]

[0052] In some embodiments, the compound of formula (VII-Ei) is a compound of formula (VII-Eia) or formula (VII-Eib):

[0053]

[0054] In some embodiments, the compound of formula (VII-E-ii) is a compound of formula (VII-E-ii-a) or formula (VII-E-ii-b):

[0055]

[0056] In some embodiments, the compound of formula (I) is a compound of formula (III):

[0057]

[0058] or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the compound of formula (III) is a compound of formula (III-A) or formula (III-B):

[0060]

[0061] In some embodiments, the compound of formula (I) is a compound of formula (IV):

[0062]

[0063] or a pharmaceutically acceptable salt thereof.

[0064] In some embodiments, the compound of formula (IV) is a compound of formula (IV-A) or formula (IV-B):

[0065]

[0066] or a pharmaceutically acceptable salt thereof.

[0067] In some embodiments, R 2 In some embodiments, R 2 is a carbocyclic group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl).

[0068] In some embodiments, R 2 In some embodiments, R 2 is an oxygen-containing heterocycle (eg, tetrahydropyran).

[0069] In some embodiments, the compound of formula (I) is a compound of formula (V):

[0070]

[0071] or a pharmaceutically acceptable salt thereof, wherein X is -CH2-, -O-, -S- or -NR A -, and m is an integer selected from 0, 1, 2, 3, 4 or 5; wherein R A is hydrogen, alkyl, -C(O)R C 、-C(O)N(R C )2, or -SO2N(R C )2; and each R Cis independently hydrogen, alkyl, aryl or heteroaryl. In some embodiments, X is -CH2-, -O-, -S- or -NH-.

[0072] In some embodiments, the compound of Formula (V) is a compound of Formula (VAi) or Formula (VA-ii):

[0073]

[0074] In some embodiments, the compound of formula (V) is a compound of formula (VB):

[0075]

[0076] In some embodiments, X is -CH2-.

[0077] In some embodiments, X is -O-.

[0078] In some embodiments, m is 0, 1, 2, or 3.

[0079] In some embodiments, the compound of formula (V) is a compound of formula (VBi):

[0080]

[0081] or a pharmaceutically acceptable salt thereof.

[0082] In some embodiments, the compound of formula (V) is a compound of formula (VC):

[0083]

[0084] In some embodiments, the compound of formula (I) is a compound of formula (VI):

[0085]

[0086] or a pharmaceutically acceptable salt thereof.

[0087] In some embodiments, the compound of formula (I) is a compound of formula (VI-A) or formula (VI-B):

[0088]

[0089] or a pharmaceutically acceptable salt thereof.

[0090] In some embodiments, R 1 C 1-6 In some embodiments, R 1 is methyl (e.g., -CH3, -CF3, or -CH2OCH3), ethyl, or isopropyl.1 is methyl, ethyl or isopropyl. 1 is methyl (eg, -CH3). 1 is ethyl (eg, -CH2CH3).

[0091] In some embodiments, the compound of formula (I) is selected from:

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100] or a pharmaceutically acceptable salt thereof.

[0101] In one aspect, provided herein is a pharmaceutical composition comprising a compound described herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier.

[0102] In one aspect, provided herein is a method of inducing sedation or anesthesia, comprising administering to a subject an effective amount of a compound described herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof.

[0103] In one aspect, provided herein are methods for treating or preventing a disorder described herein, comprising administering to a subject in need thereof an effective amount of a compound described herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition thereof.

[0104] In some embodiments, the disorder is a gastrointestinal (GI) disorder, e.g., constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) (e.g., ulcerative colitis, Crohn's disease), structural disorders affecting the gastrointestinal tract, anal disorders (e.g., hemorrhoids, internal hemorrhoids, external hemorrhoids, anal fissures, perianal abscesses, anal fistulas), colon polyps, cancer, colitis.

[0105] In some embodiments, the disorder is inflammatory bowel disease.

[0106] In some embodiments, the disorder is cancer, diabetes, or a sterol synthesis disorder.

[0107] In one aspect, provided herein is a method for treating or preventing CNS-related disorders, comprising administering to a subject in need thereof an effective amount of a compound as described herein (e.g., a compound of formula (I), or a pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof. In some embodiments, the CNS-related disorder is an adjustment disorder, an anxiety disorder (including obsessive-compulsive disorder, post-traumatic stress disorder, and social phobia), a cognitive disorder (including Alzheimer's disease and other forms of dementia), a dissociative disorder, an eating disorder, an affective disorder (including depression (e.g., postpartum depression), bipolar disorder and dysthymic disorder, suicidality), schizophrenia or other mental disorders (including schizoaffective disorder), a sleep disorder (including insomnia), a substance abuse-related disorder, a personality disorder (including obsessive-compulsive personality disorder), an autism spectrum disorder (including those disorders associated with mutations in Shank family proteins (e.g., Shank3)), a neurodevelopmental disorder (including Rett syndrome, Tuberous Sclerosis Complex, and others). complex), multiple sclerosis, sterol synthesis disorders, pain (including acute and chronic pain), encephalopathy secondary to a medical condition (including hepatic encephalopathy and anti-NMDA receptor encephalitis), epilepsy (including status epilepticus and monogenic forms of epilepsy such as Dravet disease), stroke, traumatic brain injury, movement disorders (including Huntington's disease and Parkinson's disease), visual impairment, hearing loss, and tinnitus.

[0108] In some embodiments, the disorder is a sterol synthesis disorder.

[0109] Other objects and advantages will become apparent to those skilled in the art upon consideration of the detailed description, examples and claims.

[0110] definition

[0111] Chemical Definition

[0112] The definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are defined according to the CAS version of the periodic table of the elements in the Handbook of Chemistry and Physics, 75th edition, and generally specific functional groups are also defined according to the description therein. In addition, the general principles of organic chemistry as well as specific functional groups and reactivity are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[0113] The compounds described herein may contain one or more asymmetric centers and may therefore exist in different isomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of single enantiomers, diastereomers, or geometric isomers, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates, and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (ELEliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present invention also includes the compounds described herein as individual isomers substantially free of other isomers, or as mixtures of different isomers.

[0114] The compounds described herein may also contain one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H (D or deuterium) and 3 H (T or tritium); C can be any isotopic form, including 12 C. 13 C and 14 C; O can be in any isotopic form, including 16 O and 18 O; and so on.

[0115] When a numerical range is listed, it is intended to include all values ​​and subranges within that range. For example, "C 1-6 "Alkyl" is intended to cover C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 alkyl.

[0116] The following terms are intended to have the following meanings as shown, and to help understand the specification of the present invention and the expected scope. When describing the present invention including compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions, unless otherwise stated, the following terms (if present) have the following meanings. It should also be understood that when described herein, any part defined below can be substituted by a variety of substituents, and each definition is intended to include these substituted parts within the scope defined below. Unless otherwise stated, the term "substituted" is defined as follows. It should be further understood that the terms "group" and "atomic radical" can be considered interchangeable when used herein. The articles "a" and "an" can be used herein to refer to one grammatical object or more than one (i.e., at least one) grammatical object of the article. For example, "an analog" refers to one or more than one analog.

[0117] "Aliphatic" refers to an alkyl, alkenyl, alkynyl or carbocyclyl group, as defined herein.

[0118] "Alkyl" refers to a straight or branched chain saturated hydrocarbon group having 1 to 20 carbon atoms ("C 1-20 In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C 1-12 In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1–8 In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1–7 In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1–6 In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1–5 In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1–4 In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1–3 In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1–2 In some embodiments, an alkyl group has 1 carbon atom ("C1 alkyl"). In some embodiments, an alkyl group has 2 to 6 carbon atoms ("C 2–6 C 1–6 Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). Other examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each alkyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkyl") or substituted ("substituted alkyl") with one or more substituents; for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In some embodiments, the alkyl group is an unsubstituted C 1–10 In some embodiments, the alkyl group is a substituted C 1–10Alkyl. Commonly used alkyl abbreviations include Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3), or i-Bu(-CH2CH(CH3)2).

[0119] As used herein, "alkylene", "alkenylene" and "alkynylene" refer to divalent radicals of alkyl, alkenyl and alkynyl groups, respectively. When a carbon atom number or range is provided for a specific "alkylene", "alkenylene" and "alkynylene" group, it is understood that the range or number refers to the range or number of carbon atoms in a linear carbon divalent chain. "Alkylene", "alkenylene" and "alkynylene" groups may be substituted or unsubstituted with one or more substituents as defined herein.

[0120] "Alkylene" refers to an alkyl group in which two hydrogens are removed to provide a divalent radical, and may be substituted or unsubstituted. Unsubstituted alkylene groups include, but are not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), etc. Exemplary substituted alkylene groups, such as those substituted with one or more alkyl(methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, (-C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3)2-), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-), and the like.

[0121] "Alkenyl" refers to a straight or branched hydrocarbon radical ("C-carbon") having 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3 or 4 carbon-carbon double bonds) and optionally one or more carbon-carbon triple bonds (e.g., 1, 2, 3 or 4 carbon-carbon triple bonds). 2–20 In some embodiments, the alkenyl group does not contain any triple bonds. In some embodiments, the alkenyl group has 2 to 10 carbon atoms ("C 2–10 In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2–9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2–8In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2–7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2–6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2–5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2–4 In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2–3 In some embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds may be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). C 2–4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), etc. 2–6 Examples of the alkenyl group include the aforementioned C 2–4 In some embodiments, the alkenyl group is an unsubstituted C 1-4-alkenyl group, an octenyl group, an octenyl group, an octatrienyl group, an octa ... 2–10 In some embodiments, the alkenyl group is a substituted C 2–10 Alkenyl.

[0122] "Alkenylene" refers to an alkenyl group in which two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted. Exemplary unsubstituted divalent alkenylene groups include, but are not limited to, vinylene (-CH=CH-) and propenylene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenylene groups, such as substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted vinylene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylene (e.g., -C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), and the like.

[0123] "Alkynyl" refers to a straight or branched chain hydrocarbon radical having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3 or 4 carbon-carbon triple bonds) and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3 or 4 carbon-carbon double bonds). 2–20 In some embodiments, the alkynyl group does not contain any double bonds. In some embodiments, the alkynyl group has 2 to 10 carbon atoms ("C 2–10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2–9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C 2–8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2–7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C 2–6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2–5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2–4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2–3 In some embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). C 2–4 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), etc. 2–6 Examples of the alkynyl group include the aforementioned C 2–4 Alkynyl groups include pentynyl (C5), hexynyl (C6), and the like. Other examples of alkynyl groups include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each alkynyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkynyl") or substituted ("substituted alkynyl") with one or more substituents; such as 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. In some embodiments, an alkynyl group is an unsubstituted C 2–10 In some embodiments, the alkynyl group is substituted C 2–10 Alkynyl.

[0124] "Alkynylidene" refers to a linear alkynyl group in which two hydrogens are removed to provide a divalent radical, and which may be substituted or unsubstituted. Exemplary divalent alkynylene groups include, but are not limited to, substituted or unsubstituted ethynylene, substituted or unsubstituted propynylene, etc.

[0125] As used herein, the term "heteroalkyl" refers to an alkyl group as defined herein, which further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) in the parent chain, wherein the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain, and / or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In some embodiments, a heteroalkyl group refers to a saturated group ("heteroalkyl") having 1 to 10 carbon atoms and 1, 2, 3, or 4 heteroatoms. 1–10 In some embodiments, a heteroalkyl group is a saturated group having 1 to 9 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroalkyl”). 1–9 In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroalkyl”). 1–8 In some embodiments, a heteroalkyl group is a saturated group having 1 to 7 carbon atoms and 1, 2, 3, or 4 heteroatoms (“heteroalkyl”). 1–7 In some embodiments, a heteroalkyl group is a group having 1 to 6 carbon atoms and 1, 2, or 3 heteroatoms (“heteroC 1–6 In some embodiments, a heteroalkyl group is a saturated group having 1 to 5 carbon atoms and 1 or 2 heteroatoms (“heteroalkyl”). 1–5 In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms (“heteroalkyl”). 1–4 In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom (“heteroalkyl”). 1–3 In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom (“heteroalkyl”). 1–2 In some embodiments, a heteroalkyl group is a saturated group having 1 carbon atom and 1 heteroatom ("heteroC1 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 2 to 6 carbon atoms and 1 or 2 heteroatoms ("heteroC1 alkyl"). 2–6 Unless otherwise specified, each heteroalkyl group is independently unsubstituted (an “unsubstituted heteroalkyl”) or substituted (a “substituted heteroalkyl”) with one or more substituents. In some embodiments, the heteroalkyl group is an unsubstituted heteroalkyl. 1–10 In some embodiments, the heteroalkyl group is a substituted heteroC 1–10 alkyl.

[0126] As used herein, the term "heteroalkenyl" refers to an alkenyl group as defined herein, further comprising one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus), wherein the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain, and / or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In some embodiments, a heteroalkenyl group refers to a group having 2 to 10 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms ("heteroalkenyl"). 2–10 In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–9 In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–8 In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–7 In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1, 2, or 3 heteroatoms (“heteroC 2–6 In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“heteroC 2–5 In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“heteroC 2–4 In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom (“heteroC 2–3 In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms (“heteroC 2–6 Unless otherwise specified, each heteroalkenyl group is independently unsubstituted (an “unsubstituted heteroalkenyl”) or substituted (a “substituted heteroalkenyl”) with one or more substituents. In some embodiments, the heteroalkenyl group is an unsubstituted heteroC 2–10 In some embodiments, the heteroalkenyl group is a substituted heteroC 2–10 Alkenyl.

[0127] The term "heteroalkynyl" as used herein refers to an alkynyl group as defined herein, further comprising one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus), wherein the one or more heteroatoms are inserted between adjacent carbon atoms in the parent carbon chain, and / or one or more heteroatoms are inserted between a carbon atom and the parent molecule, i.e., between the points of attachment. In some embodiments, a heteroalkynyl group refers to a group having 2 to 10 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms ("heteroalkynyl"). 2–10 In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–9 In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–8 In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1, 2, 3, or 4 heteroatoms (“heteroC 2–7 In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1, 2, or 3 heteroatoms (“heteroC 2–6 In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“heteroC 2–5 In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“heteroC 2–4 In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1 heteroatom (“heteroC 2–3 In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms (“heteroC 2–6 Unless otherwise specified, each heteroalkynyl group is independently unsubstituted (an “unsubstituted heteroalkynyl”) or substituted (a “substituted heteroalkynyl”) with one or more substituents. In some embodiments, a heteroalkynyl group is an unsubstituted heteroalkynyl. 2–10 In some embodiments, the heteroalkynyl group is a substituted heteroC 2–10 Alkynyl.

[0128] As used herein, "alkylene", "alkenylene", "alkynylene", "heteroalkylene", "heteroalkenylene" and "heteroalkynylene" refer to divalent radicals of alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl and heteroalkynyl groups, respectively. When the number of carbon atoms or range is provided for a specific "alkylene", "alkenylene", "alkynylene", "heteroalkylene", "heteroalkenylene" and "heteroalkynylene" group, it is understood that the range or number refers to the range or number of carbon atoms in a linear carbon divalent chain. "Alkylene", "alkenylene", "alkynylene", "heteroalkylene", "heteroalkenylene" and "heteroalkynylene" groups may be substituted with one or more substituents as described herein, or may be unsubstituted.

[0129] "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a ring arrangement) having 6-14 ring carbon atoms and 0 heteroatoms in the aromatic ring system ("C 6–14 In some embodiments, an aryl group has six ring carbon atoms ("C6 aryl"; such as phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C 10 In some embodiments, an aryl group has fourteen ring carbon atoms ("C 14 "Aryl" also includes ring systems in which an aryl ring, as defined above, is fused to one or more carbocyclyl or heterocyclyl groups, wherein the radical or point of attachment is on the aryl ring, and in that case the number of carbon atoms continues to be specified as the number of carbon atoms in the aryl ring system. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubidene, triphenylene, and trinaphthalene. Specific aryl groups include phenyl, naphthyl, indenyl and tetrahydronaphthyl. Unless otherwise specified, each aryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted with one or more substituents ("substituted aryl"). In some embodiments, the aryl group is an unsubstituted C 6-14 In some embodiments, the aryl group is substituted C 6-14 Aryl.

[0130] In some embodiments, the aryl group is substituted with one or more groups selected from halogen, C1-C8 alkyl, C1-C8 haloalkyl, cyano, hydroxy, C1-C8 alkoxy, and amino.

[0131] Representative examples of substituted aryl groups include:

[0132]

[0133] Where R 56 and R 57 One of them may be hydrogen and R 56 and R 57 At least one of them is independently selected from C1-C8 alkyl, C1-C8 haloalkyl, 4-10 membered heterocyclyl, alkanoyl, C1-C8 alkoxy, heteroaryloxy, alkylamino, arylamino, heteroarylamino, NR 58 COR 59 NR 58 SOR 59 NR 58 S02R 59 、COO alkyl、COO aryl、CONR 58 R 59 ,CONR 58 OR59 NR 58 R 59 、SO2NR 58 R 59 , S-alkyl, SOalkyl, SO2alkyl, Saryl, SOaryl, SO2aryl; or R 56 and R 57 may combine to form a cyclic ring (saturated or unsaturated) of 5 to 8 atoms, optionally containing one or more heteroatoms selected from N, O or S. R 60 and R 61 are independently hydrogen, C1-C8 alkyl, C1-C4 haloalkyl, C3-C 10 Cycloalkyl, 4- to 10-membered heterocyclic group, C6-C 10 Aryl, substituted C6-C 10 aryl, 5- to 10-membered heteroaryl, or substituted 5- to 10-membered heteroaryl.

[0134] "Fused aryl" refers to an aryl group having two carbons among the ring carbon atoms shared with a second aryl or heteroaryl ring or with a carbocyclyl or heterocyclyl ring.

[0135] "Aralkyl" is a subset of alkyl and aryl as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group.

[0136] "Heteroaryl" refers to a 5- to 10-membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a ring arrangement) having ring carbon atoms and 1 to 4 ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5- to 10-membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom as long as the valence permits. Heteroaryl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems in which a heteroaryl ring as defined above is fused to one or more carbocyclyl or heterocyclyl groups, wherein the point of attachment is on the heteroaryl ring, and in this case, the number of ring members continues to be specified as the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more aryl groups, wherein the point of attachment is on the aryl or heteroaryl ring, and in this case, the number of ring members continues to be specified as the number of ring members in the fused (aryl / heteroaryl) ring system. In bicyclic heteroaryl groups, one ring does not contain heteroatoms (e.g., indolyl, quinolyl, carbazolyl, etc.), and the point of attachment can be on one of the two rings, i.e., on the ring with heteroatoms (e.g., 2-indolyl) or on the ring without heteroatoms (e.g., 5-indolyl).

[0137] In some embodiments, the heteroaryl group is a 5- to 10-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 10-membered heteroaryl”). In some embodiments, the heteroaryl group is a 5- to 8-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 8-membered heteroaryl”). In some embodiments, the heteroaryl group is a 5- to 6-membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5- to 6-membered heteroaryl”). In some embodiments, the 5- to 6-membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5- to 6-membered heteroaryl group has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each heteroaryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl") with one or more substituents. In some embodiments, the heteroaryl group is an unsubstituted 5- to 14-membered heteroaryl group. In some embodiments, the heteroaryl group is a substituted 5- to 14-membered heteroaryl group.

[0138] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl, and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0139] Examples of representative heteroaryl groups include the following:

[0140]

[0141] wherein each Z is selected from carbonyl, N, NR 65 , O and S; and R 65 are independently hydrogen, C1-C8 alkyl, C3-C 10 Cycloalkyl, 4-10 membered heterocyclic group, C6-C 10 aryl and 5- to 10-membered heteroaryl.

[0142] "Heteroaralkyl" is a subset of alkyl and heteroaryl as defined herein, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.

[0143] "Carbocyclyl" or "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical having 3 to 10 ring carbon atoms and 0 heteroatoms in the non-aromatic ring system ("Carbocyclyl" or "Carbocycle"). 3-10 In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms (“C 3-8 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3–6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5–10 Carbocyclyl”). Exemplary C 3–6 Carbocyclyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C 3–8 Carbocyclic groups include but are not limited to the aforementioned C 3–6 Carbocyclyl groups and cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), etc. Exemplary C 3–10 Carbocyclic groups include but are not limited to the aforementioned C 3–8 Carbocyclic groups and cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10) and the like. As described in the previous examples, in some embodiments, the carbocyclyl group is a monocyclic ring ("monocyclic carbocyclyl") or contains a fused, bridged or spiro ring system (such as a bicyclic system ("bicyclic carbocyclyl")), and may be saturated or partially unsaturated. "Carbocyclyl" also includes ring systems in which the carbocyclyl ring as described above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is located on the carbocyclyl ring, and in this case, the number of carbons continues to be specified as the number of carbons in the carbocyclyl ring system. Unless otherwise specified, each carbocyclyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted carbocyclyl") or substituted ("substituted carbocyclyl") by one or more substituents. In some embodiments, the carbocyclyl group is an unsubstituted C 3–10 In some embodiments, the carbocyclyl group is substituted C 3–10 Carbocyclic group.

[0144] In some embodiments, "carbocyclyl" is a monocyclic saturated carbocyclyl group ("C 3–10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3–8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3–6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5–6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5–10 (cycloalkyl) 5–6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). 3–6 Examples of the cycloalkyl group include the aforementioned C 5–6 Cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). 3–8 Examples of the cycloalkyl group include the aforementioned C 3–6 Cycloalkyl groups and cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each cycloalkyl group is independently unsubstituted ("unsubstituted cycloalkyl") or substituted ("substituted cycloalkyl") with one or more substituents. In some embodiments, the cycloalkyl group is an unsubstituted C 3–10 In some embodiments, the cycloalkyl group is substituted C 3–10 Cycloalkyl.

[0145] "Heterocyclyl" or "heterocycle" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3- to 10-membered heterocyclyl"). In heterocyclyl radicals containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valence permits. Heterocyclyl radicals may be monocyclic ("monocyclic heterocyclyl") or fused, bridged or spiro ring systems such as bicyclic systems ("bicyclic heterocyclyl"), and may be saturated or may be partially unsaturated. Heterocyclyl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocyclyl ring, as defined above, is fused to one or more carbocyclyl groups, wherein the point of attachment is located on the carbocyclyl or heterocyclyl ring, or includes ring systems in which a heterocyclyl ring, as defined above, is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is located on the heterocyclyl ring, and in this case, the number of ring members continues to be specified as the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl") with one or more substituents. In some embodiments, heterocyclyl groups are unsubstituted 3 to 10 membered heterocyclyls. In some embodiments, heterocyclyl groups are substituted 3 to 10 membered heterocyclyls.

[0146] In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon (“5-10 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-8 membered heterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-6 membered heterocyclyl”). In some embodiments, a 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, a 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5- to 6-membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0147] Exemplary 3-membered heterocyclyl groups containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiirane. Exemplary 4-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azetidinyl, oxetane, and thiidine. Exemplary 5-membered heterocyclyl groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thiohexyl. Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiohexyl, and dioxane. Exemplary 6-membered heterocyclyl groups containing three heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azepanyl, oxepane, and thioheptanyl. Exemplary 8-membered heterocyclyl groups containing one heteroatom include, but are not limited to, azocyclooctanyl, oxoctanyl, and thiooctanyl. Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocycles) include, but are not limited to, dihydroindole, isoindole, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.

[0148] When used to describe a compound or a group present on a compound, "hetero" means that one or more carbon atoms in the compound or group are replaced by nitrogen, oxygen or sulfur heteroatoms. Hetero can be used to describe any of the above hydrocarbon groups, such as alkyl (such as heteroalkyl), cycloalkyl (such as heterocyclyl), aryl (such as heteroaryl), cycloalkenyl (such as cycloheteroalkenyl), etc., which have 1 to 5, especially 1 to 3 heteroatoms.

[0149] "Acyl" refers to -C(O)R 20 Group, where R 20 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, as defined herein. "Alkanoyl" is an acyl group in which R20 is a group other than hydrogen. Representative acyl groups include, but are not limited to, formyl (-CHO), acetyl (-C(=O)CH3), cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl (-C(=O)Ph), benzylcarbonyl (-C(=O)CH2Ph), -C(O)-C1-C8 alkyl, -C(O)-(CH2) t (C6-C 10 Aryl), –C(O)-(CH2) t (5- to 10-membered heteroaryl), –C(O)-(CH2) t (C3-C 10 Cycloalkyl) and –C(O)-(CH2) t (4- to 10-membered heterocyclyl), wherein t is an integer from 0 to 4. In some embodiments, R 21 is a C1-C8 alkyl group substituted by halogen or hydroxy; or a C3-C 10 Cycloalkyl, 4- to 10-membered heterocyclic group, C6-C 10 Aryl, arylalkyl, 5- to 10-membered heteroaryl or heteroarylalkyl, each of which is substituted with unsubstituted C1-C4 alkyl, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy.

[0150] "Alkoxy" refers to the group -OR 29 , where R 29 is a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. Specific alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy. Specific alkoxy groups are lower alkoxy groups, i.e., having 1 to 6 carbon atoms. Further specific alkoxy groups have 1 to 4 carbon atoms.

[0151] In some embodiments, R 29 is a group having one or more substituents, for example 1 to 5 substituents, and specifically 1 to 3 substituents, especially 1 substituent, which is selected from amino, substituted amino, C6-C 10 Aryl, aryloxy, carboxyl, cyano, C3-C 10Cycloalkyl, 4- to 10-membered heterocyclyl, halogen, 5- to 10-membered heteroaryl, hydroxy, nitro, thioalkoxy, thioaryloxy, mercapto, alkyl-S(O)-, aryl-S(O)-, alkyl-S(O)2- and aryl-S(O)2-. Exemplary 'substituted alkoxy' include, but are not limited to, -O-(CH2) t (C6-C 10 Aryl), –O-(CH2) t (5- to 10-membered heteroaryl), –O-(CH2) t (C3-C 10 Cycloalkyl) and –O-(CH2) t (4 to 10 membered heterocyclyl), wherein t is an integer from 0 to 4, and any aryl, heteroaryl, cycloalkyl or heterocyclyl groups present may themselves be substituted by unsubstituted C1-C4 alkyl, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy. Specific exemplary 'substituted alkoxy' are -OCF3, -OCH2CF3, -OCH2Ph, -OCH2-cyclopropyl, -OCH2CH2OH and -OCH2CH2NMe2.

[0152] "Amino" refers to the -NH2 group.

[0153] "Substituted amino" refers to a group of the formula -N(R 38 )2 amino group, wherein R 38 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclic group, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl group, substituted or unsubstituted heteroaryl group or amino protecting group, wherein at least one R 38 is not hydrogen. In some embodiments, each R 38 independently selected from hydrogen, C1-C8 alkyl, C3-C8 alkenyl, C3-C8 alkynyl, C6-C 10 aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclic group or C3-C 10 Cycloalkyl; or C1-C8 alkyl substituted by halogen or hydroxy; C3-C8 alkenyl substituted by halogen or hydroxy; C3-C8 alkynyl substituted by halogen or hydroxy; or -(CH2) t (C6-C 10 Aryl), -(CH2) t (5- to 10-membered heteroaryl), -(CH2) t (C3-C 10 Cycloalkyl) or -(CH2) t(4- to 10-membered heterocyclyl), wherein t is an integer from 0 to 8, each of which is substituted with unsubstituted C1-C4 alkyl, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy; or two R 38 The groups combine to form an alkylene group.

[0154] Exemplary "substituted amino" include, but are not limited to -NR 39 -C1-C8 alkyl, –NR 39 -(CH2) t (C6-C 10 Aryl), –NR 39 -(CH2) t (5- to 10-membered heteroaryl), –NR 39 -(CH2) t (C3-C 10 Cycloalkyl) and –NR 39 -(CH2) t (4- to 10-membered heterocyclic group), wherein t is an integer from 0 to 4, such as 1 or 2, and each R 39 independently represents H or C1-C8 alkyl; and any alkyl group present may itself be substituted by halogen, substituted or unsubstituted amino or hydroxy; and any aryl, heteroaryl, cycloalkyl or heterocyclyl group present may itself be substituted by unsubstituted C1-C4 alkyl, halogen, unsubstituted C1-C4 alkoxy, unsubstituted C1-C4 haloalkyl, unsubstituted C1-C4 hydroxyalkyl or unsubstituted C1-C4 haloalkoxy or hydroxy. For the avoidance of doubt, the term 'substituted amino' includes the following groups: alkylamino, substituted alkylamino, alkylarylamino, substituted alkylarylamino, arylamino, substituted arylamino, dialkylamino and substituted dialkylamino as defined below. Substituted amino includes monosubstituted amino and disubstituted amino groups.

[0155] "Carboxy" refers to a -C(O)OH group.

[0156] "Cyano" refers to a -CN group.

[0157] "Halo" or "halogen" refers to fluoro (F), chloro (Cl), bromo (Br) and iodo (I). In some embodiments, the halo group is fluoro or chloro.

[0158] "Hydroxy" refers to an -OH group.

[0159] "Nitro" refers to the -NO2 group.

[0160] "Cycloalkylalkyl" refers to an alkyl group in which the alkyl group is substituted by a cycloalkyl group. Common cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, cyclooctylmethyl, cyclopropylethyl, cyclobutylethyl, cyclopentylethyl, cyclohexylethyl, cycloheptylethyl, and cyclooctylethyl.

[0161] "Heterocyclylalkyl" refers to an alkyl group in which the alkyl group is substituted with a heterocyclyl group. Common heterocyclylalkyl groups include, but are not limited to, pyrrolidinylmethyl, piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyrrolidinylethyl, piperidinylethyl, piperazinylethyl, morpholinylethyl, and the like.

[0162] "Nitrogen-containing heterocyclic group" refers to a 4-7 membered non-aromatic cyclic group containing at least one nitrogen atom, such as, but not limited to, morpholine, piperidine (such as 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (such as 2-pyrrolidinyl and 3-pyrrolidinyl), azetidine, pyrrolone, imidazoline, imidazolinone, 2-pyrazoline, pyrazolidine, piperazine and N-alkylpiperazine (such as N-methylpiperazine). Specific examples include azetidine, piperidone and piperazinone.

[0163] "Thioketo" refers to a =S group.

[0164] As defined herein, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl groups are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl or "substituted" or "unsubstituted" heteroaryl groups). In general, the term "substituted", whether preceded by the term "optionally" or not, means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, such as a substituent whose substitution results in a stable compound, such as a compound that does not spontaneously undergo a transformation, such as a rearrangement, cyclization, elimination or other reaction. Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent at each position may be the same or different. The term "substituted" is considered to include substitution with all permissible substituents of organic compounds, any of which described herein results in the formation of stable compounds. The present invention contemplates any and all such combinations to obtain stable compounds. For purposes herein, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituents as described herein which satisfy the valence of the heteroatoms and result in the formation of a stable moiety.

[0165] Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa ,–ON(R bb )2. –N(R bb )2. –N(R bb )3 + X – 、–N(OR cc )R bb , –SH, –SR aa , –SSR cc , –C(=O)R aa , –CO2H, –CHO, –C(OR cc 2. –CO2R aa 、–OC(=O)R aa , –OCO2R aa , –C(=O)N(R bb )2. –OC(=O)N(R bb )2. –NR bb C(=O)R aa ,–NR bb CO2R aa ,–NR bb C(=O)N(R bb )2, –C(=NR bb )R aa , –C(=NR bb )OR aa 、–OC(=NR bb )R aa 、–OC(=NR bb )OR aa , –C(=NR bb )N(R bb )2. –OC(=NR bb )N(R bb )2. –NR bb C(=NR bb )N(R bb )2, –C(=O)NR bb S02R aa ,–NR bb S02R aa 、–SO2N(R bb 2. –SO2R aa , –SO2OR aa 、–OSO2R aa , –S(=O)R aa 、–OS(=O)R aa , –Si(R aa)3. –OSi(R aa )3–C(=S)N(R bb )2, –C(=O)SR aa , –C(=S)SR aa , –SC(=S)SR aa , –SC(=O)SR aa 、–OC(=O)SR aa , –SC(=O)OR aa , –SC(=O)R aa 、–P(=O)2R aa 、–OP(=O)2R aa , –P(=O)(R aa )2. –OP(=O)(R aa )2. –OP(=O)(OR cc )2, –P(=O)2N(R bb )2, –OP(=O)2N(R bb )2, –P(=O)(NR bb )2. –OP(=O)(NR bb )2. –NR bb P(=O)(OR cc )2. –NR bb P(=O)(NR bb )2. –P(R cc )2. –P(R cc )3. –OP(R cc )2. –OP(R cc )3. –B(R aa )2. –B(OR cc 2. –BR aa (OR cc ), C 1–10 Alkyl, C 1–10 Perhaloalkyl, C 2–10 Alkenyl, C 2–10 Alkynyl, C 3–10 Carbocyclic group, 3 to 14 membered heterocyclic group, C 6–14 aryl and 5 to 14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0166] Or the two geminal hydrogens on the carbon atom are replaced by groups =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa, =NNR bb S(=O)2R aa , =NR bb or = NOR cc replace;

[0167] R aa Each occurrence is independently selected from C 1–10 Alkyl, C 1–10 Perhaloalkyl, C 2–10 Alkenyl, C 2–10 Alkynyl, C 3–10 Carbocyclic group, 3 to 14 membered heterocyclic group, C 6–14 aryl and 5- to 14-membered heteroaryl, or two R aa to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0168] R bb Each occurrence is independently selected from hydrogen, -OH, -OR aa , –N(R cc )2, –CN, –C(=O)R aa , –C(=O)N(R cc 2. –CO2R aa , –SO2R aa , –C(=NR cc )OR aa , –C(=NR cc )N(R cc )2. –SO2N(R cc 2. –SO2R cc , –SO2OR cc , –SOR aa , –C(=S)N(R cc )2, –C(=O)SR cc , –C(=S)SR cc 、–P(=O)2R aa , –P(=O)(R aa )2, –P(=O)2N(R cc )2, –P(=O)(NR cc 2. C 1–10 Alkyl, C 1–10 Perhaloalkyl, C 2–10 Alkenyl, C 2–10 Alkynyl, C 3–10 Carbocyclic group, 3 to 14 membered heterocyclic group, C 6–14 aryl and 5- to 14-membered heteroaryl, or two R bbThe groups are combined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0169] R cc Each occurrence is independently selected from hydrogen, C 1–10 Alkyl, C 1–10 Perhaloalkyl, C 2–10 Alkenyl, C 2–10 Alkynyl, C 3–10 Carbocyclic group, 3 to 14 membered heterocyclic group, C 6–14 aryl and 5- to 14-membered heteroaryl, or two R cc The groups are combined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;

[0170] R dd Each occurrence is independently selected from halogen, –CN, –NO2, –N3, –SO2H, –SO3H, –OH, –OR ee ,–ON(R ff )2. –N(R ff )2. –N(R ff )3 + X – 、–N(OR ee )R ff , –SH, –SR ee , –SSR ee , –C(=O)R ee , –CO2H, –CO2R ee 、–OC(=O)R ee , –OCO2R ee , –C(=O)N(R ff )2. –OC(=O)N(R ff )2. –NR ff C(=O)R ee ,–NR ff CO2R ee ,–NR ff C(=O)N(R ff )2, –C(=NR ff )OR ee 、–OC(=NR ff )R ee 、–OC(=NR ff )OR ee , –C(=NRff )N(R ff )2. –OC(=NR ff )N(R ff )2. –NR ff C(=NR ff )N(R ff )2. –NR ff S02R ee 、–SO2N(R ff 2. –SO2R ee , –SO2OR ee 、–OSO2R ee , –S(=O)R ee , –Si(R ee )3. –OSi(R ee )3. –C(=S)N(R ff )2, –C(=O)SR ee , –C(=S)SR ee , –SC(=S)SR ee 、–P(=O)2R ee , –P(=O)(R ee )2. –OP(=O)(R ee )2. –OP(=O)(OR ee 2. C 1–6 Alkyl, C 1–6 Perhaloalkyl, C 2–6 Alkenyl, C 2–6 Alkynyl, C 3–10 Carbocyclyl, 3- to 10-membered heterocyclyl, C6- 10 aryl, 5- to 10-membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution, or two geminal R dd Substituents may combine to form =O or =S;

[0171] R ee Each occurrence is independently selected from C 1–6 Alkyl, C 1–6 Perhaloalkyl, C 2–6 Alkenyl, C 2–6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 aryl, 3 to 10 membered heterocyclyl and 3 to 10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution;

[0172] R ffEach occurrence is independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3 to 10 membered heterocyclic group, C 6-10 aryl and 5- to 10-membered heteroaryl, or two R ff The groups are combined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution; and

[0173] R gg Each occurrence is independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C1-6 alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 Alkyl)3, -OSi(C 1-6 alkyl)3-C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 Alkyl)2, -OP(=O)(C 1-6 Alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 aryl, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl; or two geminal R gg Substituents may combine to form =O or =S; where X - For the counter ion.

[0174] "Counter ions" or "anionic counter ions" are negatively charged groups that associate with cationic quaternary amino groups to maintain electrical neutrality. Exemplary counter ions include halides (such as F - , Cl - Br - , I-), NO3 - 、ClO4 - OH - 、H2PO4 - 、HSO4 - 、SO4 -2 , sulfonate ions (such as methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethane-1-sulfonic acid-2-sulfonate, etc.) and carboxylate ions (such as acetate, acetate, propionate, benzoate, glycerate, lactate, tartrate, glycolate, etc.).

[0175] The nitrogen atoms may be substituted or unsubstituted as the valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR aa , –N(R cc )2, –CN, –C(=O)R aa , –C(=O)N(R cc 2. –CO2R aa , –SO2R aa , –C(=NR bb )R aa , –C(=NR cc )OR aa , –C(=NR cc )N(R cc )2. –SO2N(R cc 2. –SO2R cc , –SO2OR cc , –SOR aa , –C(=S)N(R cc )2, –C(=O)SR cc , –C(=S)SR cc 、–P(=O)2R aa , –P(=O)(R aa )2, –P(=O)2N(R cc )2, –P(=O)(NR cc 2. C 1–10 Alkyl, C 1–10 Perhaloalkyl, C 2–10 Alkenyl, C 2–10 Alkynyl, C 3–10Carbocyclic group, 3 to 14 membered heterocyclic group, C 6–14 aryl and 5- to 14-membered heteroaryl, or two R cc The groups are combined to form a 3- to 14-membered heterocyclyl or 5- to 14-membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution, where R aa , R bb , R cc and R dd As mentioned above.

[0176] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims.It is not intended that the invention be limited in any way to the exemplary substituents listed above.

[0177] Other definitions

[0178] The term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with human and lower animal tissues without toxicity, irritation, allergic reaction, etc. within the scope of health medical judgment, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and inorganic and organic bases. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts formed of amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid) or salts formed by using other methods in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Representative alkali metal or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. When appropriate, pharmaceutically acceptable salts also include non-toxic ammonium salts, quaternary ammonium salts and amine cation salts formed using counterions (such as halogens, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates).

[0179] "Subjects" intended for administration include, but are not limited to, humans (i.e., males or females of any age group, such as child subjects (e.g., infants, children, teenagers) or adult subjects (e.g., young adults, middle-aged adults, or elderly people)) and / or non-human animals, such as mammals (e.g., primates (e.g., macaques, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs). In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0180] Disease, disorder and condition are used interchangeably herein.

[0181] As used herein and unless otherwise indicated, the terms "treat," "treating," and "treatment" refer to actions that occur while a subject has a particular disease, disorder, or condition that reduces the severity of the disease, disorder, or condition, or slows or arrests the progression of the disease, disorder, or condition ("therapeutic treatment"), as well as actions before a subject begins to have a particular disease, disorder, or condition ("prophylactic treatment").

[0182] Generally, an "effective amount" of a compound refers to an amount sufficient to elicit a desired biological response. Those skilled in the art will appreciate that the effective amount of a compound of the invention may vary depending on the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject. An effective amount encompasses both therapeutic and prophylactic treatments.

[0183] As used herein and unless otherwise specified, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic effect in the treatment of a disease, disorder, or condition, or sufficient to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount that provides a therapeutic effect in the treatment of a disease, disorder, or condition when the therapeutic agent is used alone or in combination with other therapies. The term "therapeutically effective amount" can include an amount that generally improves treatment, reduces or avoids symptoms or causes of a disease or condition, or increases the efficacy of another therapeutic agent.

[0184] As used herein and unless otherwise specified, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease, disorder, or condition, or one or more symptoms associated with a disease, disorder, or condition, or to avoid its recurrence. A prophylactically effective amount of a compound refers to an amount that provides a prophylactic effect in the prevention of a disease, disorder, or condition when the therapeutic agent is used alone or in combination with other agents. The term "prophylactically effective amount" may include an amount that generally improves prevention or increases the prophylactic effect of another prophylactic agent.

[0185] DETAILED DESCRIPTION OF SOME EMBODIMENTS OF THE INVENTION

[0186] As generally described herein, the present invention provides oxysterols for preventing and / or treating a wide range of disorders, including but not limited to NMDA-mediated disorders. These compounds are expected to have improvements over other oxysterols in terms of in vivo efficacy, pharmacokinetic (PK) properties, oral bioavailability, formulation, stability and / or safety.

[0187] Compound

[0188] In one aspect, the present invention relates to compounds of formula (I):

[0189]

[0190] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen or C 1-6 Alkyl; R 2 C 1-6 Alkyl, carbocyclic or heterocyclic; R 5 is absent or is hydrogen; and represents a single bond or a double bond, where For a double bond, the other is a single bond, and R 5 Does not exist.

[0191] In some embodiments, R 1 In some embodiments, the compound of formula (I) is a compound of formula (X):

[0192]

[0193] or a pharmaceutically acceptable salt thereof, wherein: R 2 C 1-6 Alkyl, carbocyclic or heterocyclic; R 5 is absent or is hydrogen; and represents a single bond or a double bond, where For a double bond, the other is a single bond and R 5 Does not exist.

[0194] In some embodiments, R 1 C 1-6 In some embodiments, R 1 To replace C 1-6 In some embodiments, R 1 For unsubstituted C 1-6 In some embodiments, R 1 is methyl (e.g., -CH3, -CF3 or -CH2OCH3), ethyl or isopropyl.

[0195] In some embodiments, R 1 is methyl (eg, -CH3) or ethyl (eg, -CH2CH3).

[0196] In some embodiments, R 2 C 1-6 In some embodiments, R 2 To replace C 1-6 In some embodiments, R 2 For unsubstituted C 1-6 In some embodiments, R 2 is methyl (e.g., -CH3), ethyl (e.g., -CH2CH3, -CH2CF3, -CH(CH3)(CF3)), isopropyl, tert-butyl or cyclopropyl. In some embodiments, R 2 In some embodiments, R 2 is -CH2CF3 or -CH(CH3)(CF3). In some embodiments, R 1 and R 2 C 1-6 In some embodiments, R 1 C 1-6 Alkyl and R 2 C 1-6 In some embodiments, R 1 is methyl or ethyl and R 2 is unsubstituted or substituted C 1-6 In some embodiments, R 1 is methyl or ethyl, and R 2 It is a carbocyclic group or a heterocyclic group.

[0197] In some embodiments, Represents a single bond.

[0198] In some embodiments, the compound of formula (I) is a compound of formula (IA) or formula (IB):

[0199]

[0200] In some embodiments, the compound of formula (I) is a compound of formula (IBi) or formula (IB-ii):

[0201]

[0202] In some embodiments, the compound of formula (I) is a compound of formula (IC):

[0203]

[0204] In some embodiments, the compound of formula (IC) is a compound of formula (ICi) or (IC-ii):

[0205]

[0206] In some embodiments, the compound of formula (ICi) is a compound of formula (ICia) or (ICib):

[0207]

[0208] In some embodiments, the compound of formula (IC-ii) is a compound of formula (IC-ii-a) or (IC-ii-b):

[0209]

[0210] In some embodiments, R 2 C 1-6 In some embodiments, R 2 To replace C 1-6 In some embodiments, the compound of formula (I) is a compound of formula (II):

[0211]

[0212] or a pharmaceutically acceptable salt thereof.

[0213] In some embodiments, the compound of formula (II) is a compound of formula (II-A) or formula (II-B):

[0214]

[0215] In some embodiments, the compound of formula (II) is a compound of formula (II-C) or formula (II-D):

[0216]

[0217] In some embodiments, the compound of formula (II) is a compound of formula (II-E):

[0218]

[0219] In some embodiments, the compound of formula (II-E) is a compound of formula (II-Ei) or formula (II-E-ii):

[0220]

[0221] In some embodiments, the compound of formula (II-Ei) is a compound of formula (II-Eia) or formula (II-Eib):

[0222]

[0223] In some embodiments, the compound of formula (II-E-ii) is a compound of formula (II-E-ii-a) or formula (II-E-ii-b):

[0224]

[0225] In some embodiments, the compound of formula (I) is a compound of formula (VII):

[0226]

[0227] or a pharmaceutically acceptable salt thereof.

[0228] In some embodiments, the compound of formula (VII) is a compound of formula (VII-A) or formula (VII-B):

[0229]

[0230] In some embodiments, the compound of formula (VII) is a compound of formula (VII-C) or formula (VII-D):

[0231]

[0232] In some embodiments, the compound of formula (VII) is a compound of formula (VII-E):

[0233]

[0234] In some embodiments, the compound of formula (VII-E) is a compound of formula (VII-Ei) or formula (VII-E-ii):

[0235]

[0236] In some embodiments, the compound of formula (VII-Ei) is a compound of formula (VII-Eia) or formula (VII-Eib):

[0237]

[0238] In some embodiments, the compound of formula (VII-E-ii) is a compound of formula (VII-E-ii-a) or formula (VII-E-ii-b):

[0239]

[0240] In some embodiments, the compound of formula (I) is a compound of formula (III):

[0241]

[0242] or a pharmaceutically acceptable salt thereof.

[0243] In some embodiments, the compound of formula (III) is a compound of formula (III-A) or formula (III-B):

[0244]

[0245] In some embodiments, the compound of formula (I) is a compound of formula (IV):

[0246]

[0247] or a pharmaceutically acceptable salt thereof.

[0248] In some embodiments, the compound of formula (IV) is a compound of formula (IV-A) or formula (IV-B):

[0249]

[0250] or a pharmaceutically acceptable salt thereof.

[0251] In some embodiments, R 2 In some embodiments, R 2 is a carbocyclic group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl).

[0252] In some embodiments, R 2 In some embodiments, R 2 is an oxygen-containing heterocycle (eg, tetrahydropyran).

[0253] In some embodiments, the compound of formula (I) is a compound of formula (V):

[0254]

[0255] or a pharmaceutically acceptable salt thereof, wherein X is -CH2-, -O-, -S- or -NR A -, and m is an integer selected from 0, 1, 2, 3, 4 or 5; wherein R A is hydrogen, alkyl, -C(O)R C 、-C(O)N(R C )2 or -SO2N(R C )2; and each R Cis independently hydrogen, alkyl, aryl or heteroaryl. In some embodiments, X is -CH2-, -O-, -S- or -NH-.

[0256] In some embodiments, the compound of Formula (V) is a compound of Formula (VAi) or Formula (VA-ii):

[0257]

[0258] In some embodiments, the compound of formula (V) is a compound of formula (VB):

[0259]

[0260] In some embodiments, X is -CH2-.

[0261] In some embodiments, X is -O-.

[0262] In some embodiments, m is 0, 1, 2, or 3.

[0263] In some embodiments, the compound of formula (V) is a compound of formula (VBi):

[0264]

[0265] or a pharmaceutically acceptable salt thereof.

[0266] In some embodiments, the compound of formula (V) is a compound of formula (VC):

[0267]

[0268] In some embodiments, the compound of formula (I) is a compound of formula (VI):

[0269]

[0270] or a pharmaceutically acceptable salt thereof.

[0271] In some embodiments, the compound of formula (VI) is a compound of formula (VI-A) or formula (VI-B):

[0272]

[0273] or a pharmaceutically acceptable salt thereof.

[0274] In some embodiments, R 1 C 1-6 In some embodiments, R 1 is methyl (e.g., -CH3, -CF3 or -CH2OCH3), ethyl or isopropyl.

[0275] In some embodiments, R 1 It is methyl, ethyl or isopropyl.

[0276] In some embodiments, the compound of formula (I) is selected from:

[0277]

[0278]

[0279]

[0280]

[0281]

[0282]

[0283]

[0284]

[0285] or a pharmaceutically acceptable salt thereof.

[0286] In some embodiments, the compound of formula (I) is selected from:

[0287]

[0288]

[0289]

[0290] or a pharmaceutically acceptable salt thereof.

[0291] Pharmaceutical composition

[0292] In another aspect, the invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of the invention (eg, a compound of formula (I)).

[0293] When used as a medicine, the compounds provided herein are generally administered in the form of a pharmaceutical composition. The composition can be prepared in a manner known in the pharmaceutical field and comprises at least one active compound.

[0294] In one embodiment, with respect to pharmaceutical compositions, the carrier is a parenteral carrier, oral or topical carrier.

[0295] The present invention also relates to a compound of the present invention (eg, a compound of formula (I) or a pharmaceutical composition thereof) for use as a medicine or drug.

[0296] Typically, the compounds provided herein are administered in a therapeutically effective amount. The amount of the compound actually administered is typically determined by a physician based on relevant circumstances (including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of each patient, the severity of the patient's symptoms, etc.).

[0297] The pharmaceutical compositions provided herein can be administered by various routes, including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular and intranasal. Depending on the desired delivery route, the compounds provided herein are preferably formulated as injectable compositions or oral compositions, or are formulated as saline, lotions or patches for transdermal administration.

[0298] Compositions for oral administration can take the form of bulk liquid solutions or suspensions or bulk powders. However, more commonly, the composition exists in unit dosage form to help accurate administration. The term "unit dosage form" refers to physically dispersed units suitable for single doses of human subjects and other mammals, each unit containing a predetermined amount of active substances and suitable pharmaceutical excipients, wherein the amount of active substances is calculated to produce the desired therapeutic effect. Typical unit dosage forms include ampules or syringes of pre-filled, pre-measured liquid compositions, or pills, tablets, or capsules in the case of solid compositions. In the composition, the compound is usually a small amount of component (about 0.1 to 50% by weight or preferably about 1 to about 40% by weight), and the remainder is various vehicles or carriers, and processing aids that help form the desired dosage form.

[0299] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle, as well as buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following ingredients or compounds having similar properties, binders such as microcrystalline cellulose, tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, Primogel, or corn starch; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavoring agents such as mint, methyl salicylate, or orange flavoring.

[0300] Injectable compositions are usually based on injectable sterile saline or phosphate buffered saline or other injectable carriers known in the art. As mentioned above, the active compound in the composition is usually a minority component, usually about 0.05 to 10% by weight, and the rest is an injectable carrier, etc.

[0301] Transdermal compositions are usually formulated as topical ointments or creams containing active ingredients, the amount of which is usually about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight. When formulated as an ointment, the active ingredient is usually combined with paraffin or a water-miscible ointment base. Alternatively, the active ingredient can be formulated as an emulsion together with, for example, an oil-in-water cream base. The transdermal preparations are known in the art and usually include other ingredients to increase the transdermal penetration stability of the active ingredient or preparation. All of these known transdermal preparations and ingredients are included in the scope described herein.

[0302] The compounds provided herein may also be administered by transdermal devices. Thus, transdermal administration may be accomplished by use of patches of the reservoir or porous membrane type or by use of solid matrix types.

[0303] The above ingredients for orally administrable, injectable or topically administrable compositions are representative only. Other materials and processing techniques are listed in Section 8 of Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[0304] The above ingredients for orally administrable, injectable or topically administrable compositions are representative only. Other materials and processing techniques are listed in Section 8 of Remington's The Science and Practice of Pharmacy, 21st Edition, 2005, Publisher: Lippincott Williams & Wilkins, which is incorporated herein by reference.

[0305] The compounds of the present invention can be administered in a sustained release form or by a sustained release drug delivery system. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0306] The present invention also relates to pharmaceutically acceptable formulations of compounds of the present invention (e.g., compounds of formula (I)). In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β-, and γ-cyclodextrins, which are composed of 6, 7, and 8 α-l,4-linked glucose units, respectively, optionally containing one or more substitutions on the linked sugar moieties, the substitution agents including, but not limited to, methylation, hydroxyalkylation, acylation, and sulfoalkyl ether substituents. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, such as, for example, sulfobutyl ether β-cyclodextrin, also known as See, for example, US 5,376,645. In some embodiments, the formulation comprises hexapropyl-β-cyclodextrin. In more specific embodiments, the formulation comprises hexapropyl-β-cyclodextrin (10-50% in water).

[0307] The present invention also relates to pharmaceutically acceptable acid addition salts of the compounds of the present invention (e.g., compounds of formula (I)). Acids that can be used to prepare pharmaceutically acceptable salts are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as hydrochlorides, hydroiodides, hydrobromides, nitrates, sulfates, bisulfates, phosphates, acetates, lactates, citrates, tartrates, succinates, maleates, fumarates, benzoates, p-toluenesulfonates, etc.

[0308] The following formulation examples illustrate representative pharmaceutical compositions that can be prepared according to the present invention. However, the present invention is not limited to the following pharmaceutical compositions.

[0309] Exemplary Formulation 1 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) may be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate may be added as a lubricant. The mixture is formed into 240 to 270 mg tablets (each having 80 to 90 mg of active compound) in a tablet press.

[0310] Exemplary Formulation 2 - Capsules: A compound of the invention (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) can be mixed as a dry powder with a starch diluent in a weight ratio of about 1: 1. The mixture is filled into 250 mg capsules (each capsule having 125 mg of active compound).

[0311] Exemplary Formulation 3 - Liquid: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) (125 mg) may be mixed with sucrose (1.75 g) and xanthan gum (4 mg), and the resulting mixture may be blended, sieved with a 10 mesh US sieve, and then mixed with an aqueous solution of previously prepared microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg). Sodium benzoate (10 mg), flavoring agents, and coloring agents are diluted with water and added under stirring. Sufficient water may then be added to produce a total volume of 5 mL.

[0312] Exemplary Formulation 4 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) may be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate may be added as a lubricant. The mixture is formed into 450 to 900 mg tablets (150 to 300 mg of active compound) in a tablet press.

[0313] Exemplary Formulation 5 - Injection: A compound of the invention (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) can be dissolved in a buffered sterile saline injectable aqueous medium or suspended in a buffered sterile saline injectable aqueous medium at a concentration of about 5 mg / mL.

[0314] Exemplary Formulation 6 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) can be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture is formed into 90 to 150 mg tablets (30 to 50 mg of active compound) in a tablet press.

[0315] Exemplary Formulation 7 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) can be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture is formed into 30 to 90 mg tablets (10 to 30 mg of active compound per tablet) in a tablet press.

[0316] Exemplary Formulation 8 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) can be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture is formed into 0.3 to 30 mg tablets (0.1 to 10 mg of active compound per tablet) in a tablet press.

[0317] Exemplary Formulation 9 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) can be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate can be added as a lubricant. The mixture is formed into 150 to 240 mg tablets (50 to 80 mg of active compound per tablet) in a tablet press.

[0318] Exemplary Formulation 10 - Tablets: A compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) may be mixed as a dry powder with a dry gelatin binder in a weight ratio of about 1:2. A small amount of magnesium stearate may be added as a lubricant. The mixture is formed into 270 to 450 mg tablets (90 to 150 mg of active compound per tablet) in a tablet press.

[0319] The injected dose levels are in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour over a period of about 1 hour to 120 hours, particularly over a period of 24 to 96 hours. A preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be applied to achieve adequate steady-state levels. For a 40 to 80 kg human patient, the total maximum dose is not expected to exceed about 2 g / day.

[0320] In order to prevent and / or treat long-term conditions, treatment regimens are usually extended to many months or many years, so oral administration is preferred in view of the convenience and tolerance of the patient. For oral administration, 1 to 5 times a day, especially 2 to 4 times a day and typically 3 times a day are representative regimens. Using these dosage regimens, each dose provides about 0.01 to about 20 mg / kg of the compound of the present invention, preferably each dose provides about 0.1 to about 10 mg / kg, and especially about 1 to about 5 mg / kg.

[0321] Transdermal doses are generally selected to provide similar or lower blood levels than those used with injected doses.

[0322] When used to avoid CNS disorders, the compounds provided herein are administered at the above-mentioned dosage levels to subjects at risk of developing the disorder, usually under the advice and supervision of a physician. Subjects at risk of developing a specific disorder typically include those with a family history of the disorder or those identified as being particularly susceptible to developing the disorder by genetic testing or screening.

[0323] Methods of treatment and use

[0324] As described herein, the compounds of the present invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) are generally designed to regulate NMDA function, and therefore act as oxysterols for treating and preventing, for example, CNS-related disorders of a subject. In some embodiments, the compounds of the present invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) are generally designed to pass through the blood-brain barrier (e.g., designed to be transported across the blood-brain barrier). Regulation, as used herein, refers to, for example, an inhibitory or enhancing effect on NMDA receptor function. In some embodiments, the compounds of the present invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) may act as a negative allosteric modulator (NAM) of NMDA and inhibit NMDA receptor function. In some embodiments, the compounds of the present invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) may act as a positive allosteric modulator (PAM) of NMDA and enhance NMDA receptor function. In some embodiments, compounds of the invention (eg, compounds of Formula (I) and pharmaceutically acceptable salts thereof) modulate NMDA function but do not act as negative allosteric modulators (NAMs) or positive allosteric modulators (PAMs) of NMDA.

[0325] In some embodiments, the disorder is cancer. In some embodiments, the disorder is diabetes. In some embodiments, the disorder is a sterol synthesis disorder. In some embodiments, the disorder is a gastrointestinal (GI) disorder, for example, constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) (e.g., ulcerative colitis, Crohn's disease), structural disorders affecting the gastrointestinal tract, anal disorders (e.g., hemorrhoids, internal hemorrhoids, external hemorrhoids, anal fissures, perianal abscesses, anal fistulas), colon polyps, cancer, colitis. In some embodiments, the disorder is inflammatory bowel disease.

[0326] In some embodiments, the disorder is S-Lewis syndrome (SLOS). In some embodiments, the disorder is desmosterolosis. In some embodiments, the disorder is sitosterolemia. In some embodiments, the disorder is cerebrotendinous xanthomatosis (CTX). In some embodiments, the disorder is mevalonate kinase deficiency (MKD). In some embodiments, the disorder is SC4MOL gene mutation (SMO deficiency). In some embodiments, the disorder is Nieto-Schmidt disease. In some embodiments, the disorder is autism spectrum disorder (ASD). In some embodiments, the disorder is associated with phenylketonuria.

[0327] Exemplary disorders associated with NMDA-modulation include, but are not limited to, gastrointestinal (GI) disorders, e.g., constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) (e.g., ulcerative colitis, Crohn's disease), structural disorders affecting the GI tract, anal disorders (e.g., hemorrhoids, internal hemorrhoids, external hemorrhoids, anal fissures, perianal abscesses, anal fistulas), colon polyps, cancer, colitis, and CNS disorders, e.g., those described herein.

[0328] Exemplary CNS disorders associated with NMDA-modulation include, but are not limited to, adjustment disorders, anxiety disorders (including obsessive-compulsive disorder, post-traumatic stress disorder, social phobia, and generalized anxiety disorder), cognitive disorders (including Alzheimer's disease and other forms of dementia (frontotemporal dementia)), dissociative disorders, eating disorders, affective disorders (including depression (e.g., postpartum depression), bipolar disorder, dysthymic disorder, suicidality), schizophrenia or other psychotic disorders (including schizoaffective disorder), sleep disorders (including insomnia), substance abuse-related disorders, Disorders, personality disorders (including obsessive-compulsive personality disorder), autism spectrum disorders (including those associated with mutations in Shank family proteins (e.g., Shank3)), neurodevelopmental disorders (including Rett syndrome), multiple sclerosis, sterol synthesis disorders, pain (including acute and chronic pain; headaches, such as migraines), epilepsy (including status epilepticus and monogenic forms of epilepsy, such as Dravet disease and tuberous sclerosis complex (TSC)), stroke, traumatic brain injury, movement disorders (including Huntington's disease and Parkinson's disease) and tinnitus. In some embodiments, the compounds of the present invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) can be used to induce sedation or anesthesia. In some embodiments, the compounds of the invention (e.g., compounds of formula (I) and pharmaceutically acceptable salts thereof) are used to treat or prevent adjustment disorders, anxiety disorders, cognitive disorders, dissociative disorders, eating disorders, affective disorders, schizophrenia or other mental disorders, sleep disorders, substance abuse-related disorders, personality disorders, autism spectrum disorders, neurodevelopmental disorders, sterol synthesis disorders, pain, epilepsy, stroke, traumatic brain injury, movement disorders and visual disorders, hearing loss and tinnitus. In some embodiments, the disorder is Huntington's disease. In some embodiments, the disorder is Parkinson's disease. In some embodiments, the disorder is an inflammatory disease (e.g., lupus).

[0329] In another aspect, provided herein is a method for treating or preventing brain excitation in a subject susceptible to or suffering from a brain excitation-related disorder, comprising administering to the subject an effective amount of a compound of the present invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof).

[0330] In another aspect, provided herein is a combination of a compound of the invention (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) and another pharmaceutically active agent. The compounds provided herein can be administered as the sole active agent, or they can be administered in combination with other agents. The combination can be administered by any technique known to those skilled in the art, including separate administration, sequential administration, simultaneous administration, and alternating administration.

[0331] Diseases and disorders

[0332] Described herein are methods for treating sterol synthesis disorders. Exemplary disorders are as described herein. The methods include administering to a subject (e.g., a subject suffering from a sterol synthesis disorder (e.g., SLOS)) a compound that modulates NMDA receptors. Exemplary compounds are as described herein.

[0333] Sterol synthesis disorders

[0334] In one aspect, described herein is a method for treating sterol synthesis disorders. Cholesterol plays an important role in growth and development. It is a membrane lipid and a precursor of various molecules, which play an important role in cell growth and differentiation, protein glycosylation and signal transduction pathways. The biosynthesis of cholesterol involves various enzymes and intermediates. Obstacles caused by defects in any of the enzymes involved in cholesterol biosynthesis can bring about intermediate accumulation and biomolecule imbalance, thereby causing obstacles including congenital skeletal deformities, malformed facial features, psychomotor retardation and developmental stagnation. In one embodiment, sterol synthesis disorders or symptoms of sterol synthesis disorders can be treated by administering compounds of the present invention, such as compounds regulating NMDA receptors as described herein, to subjects suffering from sterol synthesis disorders. Other obstacles are described as follows.

[0335] S-L-O syndrome

[0336] In one aspect, described herein is a method for treating S-L-O syndrome (or SLOS, or 7-dehydrocholesterol reductase deficiency). SLOS is a congenital disorder of cholesterol synthesis. In addition to microcephaly, moderate to severe intellectual disability, hypersensitivity, stereotyped behavior, dysmorphic facial features, and syndactyly of the second / third toes, one of the characteristics of the disease is reduced brain sterol (24 (S) -hydroxycholesterol) levels. SLOS is an autosomal recessive genetic disorder caused by a defect in the terminal enzyme of the cholesterol synthesis pathway, and causes low or low-normal plasma cholesterol levels and increased 7- and 8-dehydrocholesterol (DHC; 7DHC and 8DHC) levels. Common therapies currently used include dietary cholesterol supplementation, treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG CoA reductase inhibitors, also known as statins) and treatment with drugs that enhance cholesterol production and / or growth; and reduce the accumulation of 7DHC and 8DHC, which are potential toxic precursors of cholesterol.

[0337] Streptosterol disease

[0338] Streptosterolosis is a deficiency of the enzyme streptosterol reductase and has a phenotype similar to SLOS. In one aspect, described herein are methods of treating streptosterolosis with the compounds described herein.

[0339] Sitosterolemia

[0340] Sitosterolemia is a rare autosomal recessive disorder caused by mutations in two ATP-binding cassette (ABC) transporter genes (ABCG5 and ABCG8). Sitosterolemia increases the absorption of plant sterols and cholesterol from the intestine. Patients often present with tendinous and nodular xanthomas and premature coronary heart disease. In one aspect, methods of treating sitosterolemia with compounds described herein are described herein.

[0341] Cerebrotendinous xanthomatosis (CTX)

[0342] In one aspect, methods of treating cerebrotendinous xanthomas (also known as cerebral cholesterol deposition disease or Van Bogaert-Scherer-Epstein syndrome) with the compounds described herein are described herein. CTX can be caused by mutations in the CYP27A1 gene, which produces sterol 27-hydroxylase. Sterol 27-hydroxylase metabolizes cholesterol into bile acids (e.g., chenodeoxycholic acid), which are important for the absorption of fat in the intestine. Dysfunction of the enzyme can lead to cholesterol accumulation in tissues. CTX is characterized by childhood diarrhea, cataracts, tendinous xanthomas, decreased mental power, and involuntary movements in adults.

[0343] Mevalonate kinase deficiency syndrome (MKD)

[0344] Mevalonate kinase deficiency, also known as mevalonic aciduria (a more severe form of MKD) or hyper-IgD syndrome (HIDS, or hyperimmunoglobulinemia D) with periodic fever syndrome (a more benign form of MKD), results in the accumulation of mevalonic acid in the urine due to insufficient mevalonate kinase activity. MKD can lead to developmental delay, dystonia, anemia, hepatosplenomegaly, dysmorphic features, mental retardation, and overall failure to thrive. Mevalonic aciduria is characterized by physical and mental developmental delay, failure to thrive, recurrent episodes of fever with vomiting and diarrhea, enlargement of the liver, spleen, and lymph nodes, microcephaly (small head size), cataracts, low muscle tone, short stature, distinctive facial features, ataxia, and anemia. HIDS is characterized by recurrent episodes of fever associated with lymphadenopathy, joint pain, gastrointestinal problems, and rash. In one aspect, methods of treating MKD with the compounds described herein are described herein.

[0345] SC4MOL gene mutation (SMO deficiency)

[0346] SC4MOL gene deficiency is a genetic disorder in cholesterol biosynthesis (e.g., a mutation in the SC4MOL gene encoding the enzyme neosterol oxidase). SC$MOL deficiency is characterized by the accumulation of dimethyl- and monomethylsterols that can be detected in blood, skin scrapings, or primary skin fibroblasts. In one aspect, described herein are methods of treating SMO deficiency with the compounds described herein.

[0347] Nieto-Pitt disease

[0348] Nieto-Pinus disease is a lysosomal storage disease caused by a genetic mutation that affects metabolism. Nieto-Pinus disease results in an abnormal accumulation of cholesterol and other fatty substances (lipids) due to the body's inability to transport them. The accumulation destroys the affected area.

[0349] Autism

[0350] In one aspect, the method for treating autism spectrum disorder or autism is described herein. Autism spectrum disorder (ASD) and autism refer to a group of complex brain development disorders. Autism is usually characterized by social interaction difficulties, such as language and non-verbal communication. Repetitive behavior is also common in individuals with autism. Autism can be related to intellectual disability, motor coordination and attention difficulties and physical health problems, such as sleep and gastrointestinal disorders. Individuals with autism can also be outstanding in visual skills, music, mathematics and art. Autism can refer to autism, childhood disintegrative disorder, general developmental delay (PDD-NOS) and Asperger syndrome when not otherwise specified. Autism also refers to autism of single genetic cause such as synaptic disease, such as Rett syndrome, fragile X syndrome, Angelman syndrome.

[0351] Disorders associated with phenylketonuria

[0352] In one aspect, methods for treating disorders associated with phenylketonuria (e.g., cognitive impairment) with the compounds of the present invention are described herein. Phenylketonuria can lead to hypercholesterolemia and low vitamin D status. It has been found that, compared with subjects without phenylketonuria, total and low-density cholesterol and 25-hydroxyvitamin D are reduced in subjects with phenylketonuria (Clin.Chim.Acta 2013,416:54-59). In subjects with phenylketonuria, 24S-hydroxycholesterol and 27S-hydroxycholesterol and 7α-hydroxycholesterol (e.g., representing peripheral and liver cholesterol elimination, respectively) have been shown to be significantly reduced, while in subjects with phenylketonuria, 7β-hydroxycholesterol (e.g., reflecting oxidative stress) is significantly increased. In subjects with phenylketonuria, changes in 24S-OHC and 7β-hydroxycholesterol levels are associated with phenylalanine levels, and 27S-hydroxycholesterol levels can be associated with 25-hydroxyvitamin D levels. Example

[0353] In order to make the invention described herein fully understood, the following examples are set forth. Synthetic methods or intermediates can be found in, for example, WO2014 / 160480*. The synthetic examples and biological examples described herein are used to illustrate the compounds, pharmaceutical compositions and methods provided herein, and should not be construed as limiting their scope in any form.

[0354] The stereochemistry specified herein (e.g., the steroid C24 position is specified as "R" or "S") can be an assumed (e.g., random) assignment. For example, when the absolute configuration is "S.", the C24 position can be depicted as the "R" configuration. When the absolute configuration is "R.", the C24 position can also be depicted as the "S" configuration.

[0355] List of abbreviations

[0356] Me: methyl; Ac: acetyl; Bu: butyl; t-Bu: tert-butyl; Ph: phenyl; THF: tetrahydrofuran; Na2SO4: sodium sulfate; NaHCO3: sodium bicarbonate; Na2S2O3: sodium thiosulfate; PE: petroleum ether; DCM: dichloromethane; DMF: N,N-dimethylformamide; Et: ethyl; EtOAc: ethyl acetate; EtOH: ethanol; MeOH: methanol; t-BuLi: tert-butyl lithium; MTBE: tert-butyl methyl ether; HMPA: hexamethylphosphorus triamide; n-BuLi: n-butyl lithium; TsCl: 4-methylbenzene-1-sulfonyl chloride; Ph3PMeBr: methyltriphenylphosphorane bromide onium; PCC: pyridinium chlorochromate; t-BuOK: potassium tert-butoxide; TBAF: tetra-n-butylammonium fluoride; TBSCl: tert-butyl(chloro)dimethylsilane; AlMe3: trimethylaluminum; DMP: Dess-Martin periodinane; (i-PrO)4Ti: titanium tetraisopropoxide; LAH: lithium aluminum hydride; LDA: lithium diisopropylamide; MAD: methyl di(2,6-di-tert-butyl-4-methylphenolaluminum); n-BuLi: n-butyllithium; BHT: 2,6-di-tert-butyl-p-cresol (butylated hydroxytoluene); DIEA: diisopropylethylamine; NCS: N-chlorosuccinimide; iPrMgBr: isopropylmagnesium bromide.

[0357] Synthesis method

[0358] Example 1. Synthesis of compound 1.

[0359]

[0360] Step 1. Synthesis of intermediate A-1. At 20 ° C, t-BuOK (688 g, 6.14 mol) was added to a suspension of PPh3MeBr (2.13 kg, 5.97 mol) in THF (3000 mL). The color of the suspension changed to yellow. After stirring at 50 ° C for 1 h, pregnenolone (630 g, 2.05 mol) was added at 50 ° C. The reaction mixture was stirred at 50 ° C for 2 h. After cooling to 20 ° C, the mixture was treated with NH4Cl (10% aqueous solution, 5 L) and heptane (3.5 L) and stirred for 15 minutes. The organic layer was separated and concentrated in vacuo to give a crude product, which was a thick oil, which was poured into MTBE (10 L) under vigorous stirring and the mixture was stirred at room temperature for 16 hours. An off-white solid was formed and collected by filtration and washed with MTBE (3 L). The combined filtrate was mixed with MeOH (10 L) and concentrated to 6 L in vacuo. A gray-white solid is formed, which is collected by filtration, washed with MeOH (3L), and air-dried to obtain 700g of wet gray-white solid. The combined MeOH filtrate is concentrated in vacuo to obtain a thick oil. The oil is poured into MTBE (3L) under vigorous stirring and the mixture is stirred for 3 hours. A gray-white solid is formed and collected by filtration, washed with MTBE (1L). The combined filtrate is mixed with MeOH (3L) and concentrated in vacuo to 1.5L. A gray-white solid is formed, which is collected by filtration, washed with MeOH (500mL), and air-dried to obtain 150g of wet gray-white solid. The previous 700g and 150g batches are combined and vacuum dried to obtain A-1 (552g, 88%), which is a gray-white solid. 1 H NMR (400MHz, CDCl3) δ5.40-5.30(m,1H),4.85(s,1H),4.71(s,1H),3.60-3.50(m,1H),2.36-2.18(m,2H),2.08-1.96(m, 2H),1.92-1.78(m,3H),1.76(s,3H),1.73-1.48(m,9H),1.38-1.03(m,4H),1.01(s,3H),1.00-0.91(m,1H),0.58(s,3H).

[0361] Step 2. Synthesis of intermediate A-2. At 25 ° C, DMP (496 g, 1.17 mol) was added portionwise to a solution of A-1 (184 g, 585 mmol) in DCM (2000 mL), and then water (42 mL) was added. The mixture was stirred at 25 ° C for 30 minutes. Water (1500 mL) and NaHCO3 (750 g) were added portionwise, and gas was released. The mixture was then filtered with a diatomaceous earth pad and the solid was washed with DCM (500 mL). The organic layer of the filtrate was separated, washed with Na2S2O3 (1000 mL, saturated), dried with Na2SO4, filtered and concentrated in vacuo at less than 30 ° C to obtain A-2 (250 g, crude), which was a light yellow jelly. The crude material was used directly in the next step.

[0362] Step 3. Synthesis of intermediate A-3. To a solution of BHT (769 g, 3.49 mol) in toluene (1500 mL) was added AlMe3 (870 mL, 2 M in toluene, 1.74 mol) at 0°C. After stirring at 0°C for 1 h, the reaction mixture was cooled to -78°C and a solution of A-2 (250 g crude, theoretical mass: 182 g, 582 mmol) in toluene (1000 mL) was added. After stirring at -78°C for 1 h, MeMgBr (580 mL, 3 M in ether, 1.74 mmol) was added at -78°C and the mixture was stirred at -78°C for another 1 h. The mixture was quenched by pouring it portionwise into citric acid (4000 mL, 20% aqueous solution) with gas release. Two more batches were performed and combined. The mixture was extracted with EtOAc (10 L). The organic layer is separated, washed with brine (5L, 10%), NaHCO3 (5L, saturated aqueous solution), brine (5L, saturated), dried over Na2SO4 and concentrated in vacuo. The crude product is purified by silica gel column (eluted with PE→EtOAc) to give crude A-3 (440g), which is a light yellow solid. DMAP (24.4g) and Ac2O (51g) are added to a solution of crude A-3 (440g) in DCM (6L). The mixture is stirred at 20 ° C for 1h. NaHCO3 (1L, saturated aqueous solution) is added to the mixture and stirred for 10min. The organic layer is separated, concentrated in vacuo and the residue is ground with PE (2L). The solid is washed with PE (3x500mL) and dried in vacuo to give A-3 (262g), which is an off-white solid. The combined filtrate was concentrated, purified by silica gel column (PE / EtOAc=50 / 1 to 8 / 1) and triturated with PE (1 L) to give A-3 (30 g). 1H NMR (400MHz, CDCl3) δ5.35-5.28(m,1H),4.85(s,1H),4.71(s,1H),2.48-2.37(m,1H),2.08-1.94(m,3H) ,1.92-1.85(m,1H),1.82-1.33(m,14H),1.29-1.08(m,7H),1.02(s,3H),1.00-0.93(m,1H),0.59(s,3H).

[0363] Step 4. Synthesis of intermediate A-4. A-3 (100 g, 304 mmol) was dissolved in 9-BBN (1.21 L, 0.5 M in THF, 608 mmol) at 0 ° C and nitrogen. The solution was stirred at 65 ° C for 1 hour and cooled to 10 ° C again. A gray solid precipitated. Ethanol (279 g, 6080 mmol) and NaOH aqueous solution (304 mL, 5 M, 1520 mmol) were added dropwise to the mixture below 10 ° C to obtain a clear solution. Then, hydrogen peroxide (343 g, 30% in water, 3040 mmol) was added dropwise below 10 ° C. The reaction mixture was stirred at 75 ° C for 1 hour. After cooling to 20 ° C, a white solid precipitated and was collected by filtration. The filter cake was washed with water (3 x 500 mL) and dried in vacuo to give a white solid, which was triturated in ethanol (1.5 L) at reflux to give A-4 (92 g, 88%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.31-5.29(m,1H),3.65-3.63(m,1H),3.38-3.37(m,1H),2.42(d,J=12.4, 1H),2.05-1.92(m,3H),1.88-1.63(m,4H),1.63-1.40(m,8H),1.40-0.90(m,16H),0.70(s,3H).

[0364] Step 5. Synthesis of intermediate A-5. At 15 ° C, TsCl (204 g, 1071 mmol) was added to a solution of A-4 (124.5 g, 357 mmol) in chloroform (1 L) and pyridine (700 mL). The mixture was stirred at 15 ° C for 2 hours. The mixture was concentrated in vacuo to remove most of the chloroform. The pyridine mixture was added to water (6 L). An off-white solid was produced and collected by filtration and washed with water (6x1 L). The off-white solid was dissolved in DCM (3.5 L), dried with Na2SO4, filtered and concentrated in vacuo to give A-5 (163 g, 92%), which was an off-white solid. 1H NMR (400MHz, CDCl3) δ7.78(d,J=8.0Hz,2H),7.34(d,J=8.4Hz,2H),5.29-5.28(m,1H),3.96(dd,J=3.2,9.6Hz,1H),3.79(dd,J= 6.4, 9.2Hz, 1H), 2.45 (s, 3H), 2.41 (d, J = 13.6Hz, 1H), 1.99-1.91 (m, 3H), 1.77-1.39 (m, 11H), 1.26-0.86 (m, 16H), 0.64 (s, 3H).

[0365] Step 6. Synthesis of compound A-6. At 15 ° C, KI (258 g, 1560 mmol) was added to a solution of A-5 (163 g, 325 mmol) in DMF (1.7 L), and the mixture was stirred at 60 ° C for 2 hours. Sodium benzenesulfinate (195 g, 975 mmol) was added and the mixture was stirred at 60 ° C for 2 hours. The reaction mixture was cooled to 25 ° C and combined with another batch using 83 g A-5. The combined mixture was poured into water (20 L) to produce some yellow solids. The mixture was filtered and the filter cake was washed with water (3x2 L). The resulting filter cake was dissolved in DCM (5 L), washed with water (2x1 L), brine (2x1 L), dried with Na2SO4, filtered and concentrated in vacuo to give a crude product as a yellow solid, which was recrystallized in toluene (2.5 L) to give A-6 (150 g, 65%) as a light yellow solid. The filtrate from the recrystallization was concentrated in vacuo to give additional crude A-6 (30 g) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ7.91(d,J=7.2Hz,2H),7.69-7.61(m,1H),7.60-7.50(m,2H),5.28-5.27(m,1H),3.14(d,J=14.0Hz,1H),2.85(dd,J=9.6,14 .0Hz,1H),2.41(d,J=12.8Hz,1H),2.17-2.03(m,1H),2.02-1.87(m,3H) ,1.81-1.65(m,3H),1.60-1.32(m,8H),1.25-0.85(m,15H),0.65(s,3H). LCMS Rt = 2.057 min in 3.0 min chromatogram, 30-90AB, MS ESI C 29 H 41 O2S[M+H-H2O] + The calculated value is 453 and the measured value is 453.

[0366] Step 7. Synthesis of compound 1-2. At -70 ° C and nitrogen, n-BuLi (1.69 mL, 4.24 mmol) was added to THF (2 mL), and a suspension of A-6 (500 mg, 1.06 mmol) in THF (5 mL) was added dropwise to obtain a light yellow suspension. After stirring at -70 ° C for 30 minutes, a solution of compound 1-1 (212 mg, 2.12 mmol) in THF (2 mL) was added. The reaction mixture was stirred at -70 ° C for 10 minutes and stirred at 25 ° C for 16 hours. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3x50 mL). The combined organic phase was washed with brine (100 mL), dried with Na2SO4, filtered and concentrated in vacuo to obtain a crude product, which was purified by silica gel column (PE / EtOAc=10 / 1) to obtain compound 1-2 (500 mg, crude), which was a yellow solid and was used directly.

[0367] Step 8. Synthesis of compound 1. At 60 ° C, Mg powder (630 mg, 26.3 mmol) was added to a solution of compound 1-2 (500 mg, 0.876 mmol) in MeOH (10 mL). The mixture was stirred at 60 ° C for 2 hours and another batch of Mg powder (630 mg, 26.3 mmol) was added. The reaction mixture was stirred at 60 ° C for another 16 hours. After cooling, the mixture was quenched with HCl (100 mL, 1 M) until the reaction mixture became clear and extracted with DCM (2x30 mL). The combined organic phase was dried with Na2SO4, filtered, concentrated and purified by silica gel column (PE / EtOAc=10 / 1 to 8 / 1) to obtain compound 1 (104 mg, 28%) as an off-white solid.

[0368] Compound 1: 1 H NMR (400MHz,CDCl3)δ5.31-5.30(m,1H),3.19-3.05(m,1H),2.44-2.40(m,1H),2.08-1.91(m,3H),1.91-1.57(m,6H),1.52-1.35(m,11H),1.74-1.12(m,10H),1.11-1.01(m,5H),0.90(s,9H),0.68(s,3H). LCMS Rt=1.564min in 2min chromatogram,10-80AB,MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0369] Step 9. Compound 1 (0.83 g) was purified by SFC (column: AD (250 mm*30 mm, 5 um), 0.1% NH3H2OETOH, gradient: from 30% to 100%, flow rate (ml / min): 60 mL / min, 25°C) to give compound 1-A (379 mg, 46%) and compound 1-B (338 mg, 41%) as an off-white solid.

[0370] Compound 1-A: 1H NMR (400 MHz, CDCl3) δ 5.33-5.28 (m, 1H), 3.12-3.06 (m, 1H), 2.45-2.40 (m, 1H), 2.05-1.92 (m, 3H), 1.91-1.64 (m, 5H), 1.63-1.57 (m, 3H), 1.52-1.38 (m, 6H), 1.37-1.24 (m, 3H), 1.21-1.09 (m, 5H), 1.09-1.03 (m, 2H), 1.02-1.00 (m, 4H), 0.99-0.96 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.90 (s, 9H), 0.68 (s, 3H). LCMS Rt = 1.361 min in 2.0 min chromatography, 30-90 AB, MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0371] Compound 1-B: 1 H NMR (400 MHz, CDCl3) δ 5.32-5.30 (m, 1H), 3.16-3.14 (m, 1H), 2.45-2.40 (m, 1H), 2.05-1.92 (m, 3H), 1.90-1.66 (m, 4H), 1.63-1.57 (m, 2H), 1.52-1.38 (m, 6H), 1.37-1.24 (m, 5H), 1.21-1.09 (m, 5H), 1.09-0.95 (m, 5H), 0.94 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 0.69 (s, 3H). LCMS Rt = 1.361 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0372] Example 2. Synthesis of Compound 2.

[0373]

[0374] Synthesis of compound 2-2. At -70 ° C and nitrogen, n-BuLi (2.5M, 2.65mmol, 1.05mL, 2.5eq) was added to THF (6mL), and a suspension of A-6 (1.06mmol, 500mg, 1.0eq.) in THF (3mL) was added dropwise to obtain a light yellow suspension. After stirring at -70 ° C for 30 minutes, a solution of compound 2-1 (1.27mmol, 127mg, 1.2eq.) in THF (1mL) was added dropwise. The reaction mixture was stirred at 15 ° C for 12 hours. The reaction was quenched with saturated NH4Cl (30mL) and extracted with EtOAc (3x10mL). The combined organic layer was dried with Na2SO4, filtered and concentrated to give compound 2-2 (560mg, crude), which was a light yellow foam, which was used directly in the next step.

[0375] Synthesis of compound 2. NiCl2 (127 mg, 0.980 mmol) was added to a solution of compound 2-2 (560 mg, 0.98 mmol) in MeOH (10 mL). After heating to 55 ° C, Mg shavings (938 mg) were added and the mixture was stirred at 55 ° C for 30 minutes. After that, another batch of Mg shavings (938 mg) was added and the reaction mixture was stirred at 55 ° C for 16 hours. After cooling, the mixture was quenched with HCl (100 mL, 1 N) until the reaction mixture became clear and extracted with DCM (2x30 mL). The combined organic phases were dried with Na2SO4, filtered and concentrated. The crude residue was purified by flash column purification (0-10% EtOAc in PE / DCM (v / v=2 / 1)) to give compound 2 (26 mg, 6%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 5.30-5.29 (m, 1H), 3.54-3.52 (m, 1H), 2.44-2.40 (m, 1H), 2.05-1.90 (m, 3H), 1.85-1.58 (m, 4H), 1.56-1.24 (m, 18H), 1.23-0.92 (m, 19H), 0.68 (s, 3H). LCMS Rt = 1.359 min in 2.0 min chromatography, 30-90 AB_ELSD, MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0376] Example 3. Synthesis of compounds 3 and 4.

[0377]

[0378] Synthesis of compound 3-2. At 0 ° C and nitrogen, ethyl magnesium bromide (26.9 mL, 80.9 mmol, 3M in Et2O) was added dropwise to a solution of compound 3-1* (7.0 g, 16.2 mmol) in THF (70 mL). The reaction mixture was stirred at 25 ° C for 12 h. The mixture was quenched with saturated NH4Cl aqueous solution (100 mL) and extracted with EtOAc (2x200 mL). The combined organic phases were washed with brine (200 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1) to give compound 3-2 (500 mg, 8%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.30-5.28(m,1H),2.42-2.39(m,5H),1.98-1.63(m,8H),1.53-0.84(m,27H),0.66(s,3H).

[0379] Synthesis of compound 3-3. NaBH4 (93.8 mg, 2.48 mmol) was added portionwise to a solution of compound 3-2 (500 mg, 1.24 mmol) in MeOH (10 mL). The reaction mixture was stirred at 25 ° C for 2 h. The reaction mixture was quenched with saturated aqueous NH4Cl (10 mL) and extracted with EtOAc (2x30 mL). The combined organic phase was washed with brine (30 mL) and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1) to give compound 3-3 (500 mg, crude), which was purified by preparative HPLC to give compound 3-3 (60 mg, 12%), which was an off-white solid. 1 HNMR (400MHz, CDCl3) δ5.33-5.28(m,1H),3.48-3.47(m,1H),2.45-2.38(m,1H),2.02-1.57(m,14H),1.57-0.92(m,26H),0.67(s,3H).

[0380] Synthesis of compounds 3 and 4. Compound 3-3 (60 mg, 149 μmol) / MeOH (5 mL) was separated by SFC (column: AD (250 mm*30 mm, 5 um); condition: alkali-EtOH) to obtain peak 1, which is compound 3 (33.6 mg, 56%) and peak 2, which is compound 4 (18.3 mg, 31%), which is an off-white solid. Compound 3: 1H NMR (400MHz,CDCl3)δ5.32-5.28(m,1H),3.48-3.46(m,1H),2.46-2.39(m,1H),2.02-1.57(m,11H),1.54-0.92(m,29H),0.67(s,3H). LCMS Rt=1.443min in 2.0min chromatogram,10-80AB,,MS ESI C 27 H 45 O[M-H2O+H] + The calculated value is 385, and the found value is 385. Compound 4: 1 H NMR (400MHz,CDCl3)δ5.33-.28(m,1H),3.48-3.46(m,1H),2.45-2.41(m,1H),2.02-1.57(m,11H),1.54-0.92(m,29H),0.68(s,3H). LCMS Rt=1.446min in 2.0min chromatogram,10-80AB,MS ESI C 27 H 45 O[M-H2O+H] + The calculated value is 385 and the measured value is 385.

[0381] Example 4. Synthesis of compounds 6 and 7.

[0382]

[0383] Pd / C (100 mg, 10%, anhydrous) was added to a solution of compound 3 (90 mg, 223 μmol) in EtOAc (10 mL), and the mixture was stirred at 50 ° C in hydrogen (50 psi) for 12 h. The mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1 to 10 / 1) to give compound 6 (4.8 mg, 5%) and compound 7 (44.5 mg, 49%) as off-white solids. Compound 6: 1 H NMR (400MHz,CDCl3)δ3.47-3.46(m,1H),2.05-1.82(m,4H),1.79-1.57(m,2H),1.55-0.90(m,38H),0.64(s,3H). LCMS Rt=1.484min in 2.0min chromatogram,10-80AB,,MS ESI C 27 H 45 [M-2H2O+H] + The calculated value is 369, and the found value is 369. Compound 7: 1H NMR (400 MHz, CDCl3) δ 3.49-3.46 (m, 1H), 1.97-1.90 (m, 1H), 1.90-1.55 (m, 1H), 1.55-1.62 (m, 4H), 1.53-1.24 (m, 19H), 1.23-0.82 (m, 15H), 0.80 (s, 3H), 0.64-0.63 (m, 4H). LCMS Rt = 1.474 min in 2.0 min chromatography, 10-80 AB, MS ESI C 27 H 45 [M-2H2O+H] + The calculated value is 369 and the measured value is 369.

[0384] Example 5. Synthesis of compounds 8 and 9.

[0385]

[0386] Pd / C (100 mg, 10%, anhydrous) was added to a solution of compound 4 (90 mg, 223 umol) in EtOAc (10 mL), and the mixture was stirred at 50 ° C in hydrogen (50 psi) for 12 h. The mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1 to 10 / 1) to give compound 8 (5.5 mg, 6%) and compound 9 (64.7 mg, 72%), which were off-white solids. Compound 8: 1 H NMR (400 MHz, CDCl3) δ 3.47-3.46 (m, 1H), 1.86-1.75 (m, 4H), 1.65-0.90 (m, 40H), 0.64 (s, 3H). LCMS Rt = 1.484 min in 2.0 min chromatography, 10-80 AB, MS ESI C 27 H 45 [M-2H2O+H] + The calculated value is 369 and the measured value is 369.

[0387] Compound 9: 1 H NMR (400 MHz, CDCl3) δ 3.47-3.46 (m, 1H), 1.97-1.90 (m, 1H), 1.90-1.78 (m, 1H), 1.70-1.58 (m, 6H), 1.50-0.90 (m, 35H), 0.64-0.63 (m, 4H). LCMS Rt = 1.472 min in 2.0 min chromatography, 10-80 AB, MS ESI C 27 H 45 [M-2H2O+H]+ The calculated value is 369 and the measured value is 369.

[0388] Example 6. Synthesis of compounds 10 and 11.

[0389]

[0390] Synthesis of compound 6-2. At 0 ° C and nitrogen, isopropylmagnesium bromide (16.1 mL, 32.2 mmol, 2M in THF) was added dropwise to a solution of compound 6-1* (3.6 g, 8.07 mmol) in THF (50 mL). The reaction mixture was stirred at 25 ° C for 12 h. The mixture was quenched with saturated NH4Cl aqueous solution (50 mL) and extracted with EtOAc (2x100 mL). The combined organic phases were washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1) to give compound 6-2 (600 mg, 17%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.30-5.26(m,1H),2.61-2.51(m,1H),2.38-2.34(m,3 H),2.01-1.59(m,8H),1.55-1.25(m,11H),1.23-0.83(m,21H),0.67(s,3H).

[0391] Synthesis of compound 6-3. To a suspension of compound 6-2 (500 mg, 1.16 mmol) in MeOH (8 mL) was added NaBH4 (87.7 mg, 2.32 mmol) in portions. The reaction mixture was stirred at 25 ° C for 2 h. The reaction mixture was quenched with saturated NH4Cl aqueous solution (10 mL) and H2O (30 mL) was added. An off-white solid precipitated, which was filtered, collected and dried in vacuo to give compound 6-3 (500 mg, 100%), which was an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.30-5.26(m,1H),3.31-3.30(m,1H),2.40-2.30(m,1 H),2.04-1.63(m,7H),1.55-1.25(m,15H),1.23-0.84(m,22H),0.67(s,3H).

[0392] Synthesis of compounds 10 and 11. Compound 6-3 (500 mg, 1.16 mmol) / MeOH (10 mL) was separated by SFC under alkaline conditions (column: AD (250 mm*30 mm, 5 um); condition: alkali-MeOH) to obtain peak 1, which is compound 10 and peak 2, which is compound 11 (230 mg, 46%), which is an off-white solid. Compound 10: 1 H NMR (400 MHz, CDCl3) δ 5.30-5.24 (m, 1H), 3.32-3.31 (m, 1H), 2.40-2.34 (m, 1H), 2.04-1.90 (m, 3H), 1.90-1.57 (m, 10H), 1.55-1.25 (m, 9H), 1.23-0.82 (m, 22H), 0.67 (s, 3H). LCMS Rt = 1.648 min in 2.0 min chromatogram, 10-80 AB, MS ESI C 29 H 49 O[M-H2O+H] + The calculated value is 413, and the found value is 413. Compound 11: 1 H NMR (400 MHz, CDCl3) δ 5.29-5.25 (m, 1H), 3.32-3.31 (m, 1H), 2.40-2.32 (m, 1H), 2.04-1.57 (m, 6H), 1.54-1.25 (m, 17H), 1.23-0.84 (m, 21H), 0.68 (s, 3H) LCMS Rt = 1.641 min in 2.0 min chromatography, 10-80 AB, MS ESI C 29 H 49 O[M-H2O+H] + The calculated value is 413 and the measured value is 413.

[0393] Example 7. Synthesis of compounds 12 and 13.

[0394]

[0395] Pd / C (200 mg, 10%, anhydrous) was added to a solution of compound 10 (150 mg, 348 μmol) in EtOAc (15 mL), and the mixture was stirred at 50 ° C in hydrogen (50 psi) for 12 h. The mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (PE / EtOAc=30 / 1 to 20 / 1) to give compound 12 (10.8 mg, 7%) and compound 13 (82.7 mg, 55%) as off-white solids. Compound 12: 1H NMR (400 MHz, CDCl3) δ 3.31-3.30 (m, 1H), 1.95-1.58 (m, 5H), 1.50-1.10 (m, 22H), 1.10-0.88 (m, 21H), 0.64 (s, 3H). LCMS Rt = 1.680 min in 2.0 min chromatography, 10-80 AB, MS ESI C 29 H 49 [M-2H2O+H] + The calculated value is 397, and the found value is 397. Compound 13: 1 H NMR (400 MHz, CDCl3) δ 3.31-3.30 (m, 1H), 1.97-1.80 (m, 1H), 1.80-1.75 (m, 1H), 1.75-1.58 (m, 4H), 1.58-1.25 (m, 17H), 1.25-0.82 (m, 24H), 0.64-0.63 (m, 4H). LCMS Rt = 1.682 min in 2.0 min chromatography, 10-80 AB, MS ESI C 29 H 49 [M-2H2O+H] + The calculated value is 397 and the measured value is 397.

[0396] Example 8. Synthesis of compounds 14 and 15.

[0397]

[0398] Pd / C (200 mg, 10%, anhydrous) was added to a solution of compound 11 (150 mg, 348 μmol) in EtOAc (15 mL), and the mixture was stirred at 50 ° C in hydrogen (50 psi) for 12 h. The mixture was filtered through a celite pad and the filtrate was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (PE / EtOAc=30 / 1 to 20 / 1) to give compound 14 (10.1 mg, 7%) and compound 15 (65.8 mg, 44%) as off-white solids. Compound 14: 1 H NMR (400MHz, CDCl3) δ3.31-3.30(m,1H),1.95-1.57(m,7H),1.50-1.10(m,22H),1.10-0.90(m,19H),0.65(s,3H).

[0399] LCMS Rt=1.702min 2.0min Chromatography, 10-80AB, MS ESI C 29 H 49

[0400] [M-2H2O+H] + The calculated value is 397, and the found value is 397. Compound 15: 1 H NMR (400 MHz, CDCl3) δ 3.31-3.30 (m, 1H), 1.95-1.90 (m, 1H), 1.90-1.76 (m, 1H), 1.76-1.57 (m, 4H), 1.5.57-1.25 (m, 18H), 1.25-0.70 (m, 23H), 0.64-0.63 (m, 4H). LCMS Rt = 1.686 min in 2.0 min chromatography, 10-80 AB, MS ESI C 29 H 49 [M-2H2O+H] + The calculated value is 397 and the measured value is 397.

[0401] Example 9. Synthesis of compounds 16 and 17.

[0402]

[0403] Synthesis of compound 9-2. To a solution of 2,6-di-tert-butyl-4-methylphenol (220 g, 1.0 mol) in toluene (250 mL) was added AlMe3 (250 mL, 501 mmol, 2 M in toluene) at below 25 °C. The solution was stirred at 25 °C for 1 h. A solution of compound 9-1 (50 g, 167 mmol) in DCM (400 mL) was then added dropwise at -78 °C. Stirred at -78 °C for 1 h, and EtMgBr (167 mL, 501 mmol, 3 M in ether) was added dropwise at -78 °C. The resulting solution was stirred at -78 °C to -50 °C for 3 h. At -78 °C, the reaction was quenched by saturated citric acid (100 mL). Stirred at 25 °C for 0.5 h, the resulting mixture was filtered and the filtrate was extracted with DCM (3 x 100 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The reaction was carried out twice in parallel. The crude products were combined and purified by silica gel column (PE / EtOAc=5 / 1) to give 38 g of crude product as a white solid, which was recrystallized with PE to give compound 9-2 as an off-white solid (13.5 g, 13%). 1 H NMR(CDCl3)400MHzδ5.33-5.26(m,1H),5.23-5.10(m,1H),2.45-1.90(m,6H),1.78-0.70(m,28H).

[0404] Synthesis of compound 9-3. At 0 ° C and nitrogen, diethylaluminum chloride (1M in hexane, 158 mL, 158 mmol) was added dropwise to a solution of compound 9-2 (13 g, 39.5 mmol) and methyl propionate (8.29 g, 98.7 mmol) in anhydrous DCM (100 mL). The mixture was stirred at 20 ° C for 16 hours. The reaction mixture was poured into ice water and extracted with DCM (3x300 mL). The extract was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc=5 / 1) to obtain compound 9-3 (14 g, 86%) to obtain an off-white solid. 1 H NMR(CDCl3)400MHzδ6.93(dd,J=15.6Hz,8.0Hz,1H),5.81(d,J=8.0Hz,1H),5.42-5.38(m,1H),5.33-5.24(m,1H),3.73(s,3H),3.05-2.95(m,1H),2.4 0-2.30(m,1H),2.10-1.95(m,3H),1.90-1.65(m,4H),1.60-1.25(m,9H),1. 88(d,J=7.2Hz,3H),1.15-0.95(m,6H),0.84(t,J=7.6Hz,3H),0.78(s,3H).

[0405] Synthesis of compound 9-4. Pd / C (2 g, wet 10%) was added to a solution of compound 9-3 (9 g, 21.8 mmol) in THF (100 mL) at 15 °C. After degassing and backfilling with hydrogen three times, the reaction mixture was stirred under a hydrogen balloon at 15 °C for 16 h. The mixture was filtered through a celite pad. The filtrate was concentrated in vacuo to give a crude compound 9-4 (8.7 g, crude) to give an off-white solid. 1 H NMR(CDCl3)400MHzδ5.35-5.25(m,1H),3.69(s,3H),2.40-2.15(m,4H),2.10-1.40(m,17H),2.15-0.80(m,16H),0.70(s,3H).

[0406] Synthesis of compound 9-5. Lithium aluminum hydride (1.13 g, 30.0 mmol) was added to a solution of compound 9-4 (5 g, 12.0 mmol) in THF (100 mL) at 0 ° C. The reaction mixture was then stirred at 25 ° C for 5 min. The reaction was then quenched with aqueous NH4Cl solution (50 mL) and citric acid solution (30 mL) to pH = 4-5. The reaction solution was then extracted with EtOAc (3x100 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give a crude product compound 9-5 (4 g, 80%) to give an off-white solid. 1 H NMR(CDCl3)400MHzδ5.35-5.25(m,1H),3.18-3.05(m,2H),2.40-2.32(m,1H),2.08-1.80(m,18H),1.80-0.80(m,19H),0.68(s,3H).

[0407] Synthesis of compound 9-6. PCC (1.10 g, 5.14 mmol) was added to a solution of compound 9-5 (1 g, 2.57 mmol) in DCM (15 mL) and THF (15 mL). The resulting reaction mixture was stirred at 25 ° C for 2 hours. The combined organic phase was dried, concentrated and purified by Combi-flash (0-15% EtOAc / PE) to give compound 9-6 (700 mg, 70%) as an off-white solid. 1 H NMR(CDCl3)400MHzδ9.77(s,1H),5.30-5.26(m,1H),2.46-2.35(m,2H),2.04-1.57(m,12H),1.50-0.83(m,23H),0.68(m,3H).

[0408] Synthesis of compound 9-7. Under nitrogen, methylmagnesium bromide (0.513ml, 1.54mmol) was added to a solution of compound 9-6 (100mg, 0.258mmol) in THF (5mL). The resulting reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was quenched with saturated NH4Cl solution (10mL) and then concentrated to give a residue, which was extracted with EtOAc (3x10mL). The combined organic phase was dried, concentrated and purified by Combi-flash (0-15% EtOAc / PE) to give compound 9-7 (10mg, 10%) as an off-white solid. 1H NMR(CDCl3)400MHzδ5.30-5.24(m,1H),3.80-3.74(m,1H),2.38-2.35(m,1H),2.05-0.83(m,40H),0.68(m,3H). LCMS MS ESI C 27 H 45 O[M-H2O+H] + The calculated value is 385 and the measured value is 385.

[0409] Synthesis of Compounds 16 and 17. Compound 9-7 (150 mg, 0.372 mmol) was purified by SFC (column: AD (250 mm*30 mm, 10 um), condition: base-MEOH) to obtain Compound 16 (10.6 mg, 7%) and Compound 17 (25.2 mg, 17%) as off-white solids. Compound 16: 1 H NMR (400MHz, CDCl3) δ5.29-5.27(m,1H),3.75-3.71(m,1H),2.38-2.34(m,1H),2.05-0.80(m,40H),0.67(s,3H). LCMSt R = 1.221min in 2min chromatogram, 30-90AB_ELSD, MS ESI C 27 H 45 O[M-H2O+H] + The calculated value is 385, and the found value is 385. Compound 17: 1 H NMR (400MHz, CDCl3) δ5.29-5.27(m,1H),3.75-3.71(m,1H),2.38-2.34(m,1H),2.05-0.80(m,40H),0.67(s,3H). LCMSt R = 1.216min in 2min chromatography, 30-90AB_ELSD, MS ESI C 27 H 45 O[M-H2O+H] + The calculated value is 385 and the measured value is 385.

[0410] Example 10. Synthesis of compounds 18 and 19.

[0411]

[0412] Synthesis of compound 10-2. A solution of compound 10-1* (2 g, 5.01 mmol) and Pd / C (200 mg, 10%) in THF (30 mL) was hydrogenated under 15 psi hydrogen at 25° C. for 3 h. The mixture was filtered through a celite pad, and the filtrate was concentrated quickly to give compound 10-2 (1.8 g, crude) as an off-white solid.

[0413] Synthesis of compound 10-3. At less than 15 ° C, a solution of compound 10-2 (1.8 g, 4.47 mmol) in THF (25 mL) was added dropwise with a solution of LiAlH4 (339 mg, 8.94 mmol) in THF (5 mL). The solution was stirred at 15 ° C for 2 h. The reaction was quenched by adding a saturated NH4Cl aqueous solution (20 mL) at 0 ° C. The resulting mixture was extracted with EtOAc (2x50 mL). The combined organic layer was washed with brine (2x30 mL) and concentrated in vacuo to give compound 10-3 (1.6 g, crude), which was a light yellow solid.

[0414] Synthesis of compound 10-4. At 25 ° C, a mixture of compound 10-3 (1.6 g, 4.27 mmol) in DCM (10 mL) and THF (10 mL) was added to PCC (2.27 g, 10.6 mmol). The reaction mixture was stirred at 25 ° C for 3 hours. The solution was filtered and the filter cake was washed with DCM (25 mL). The combined filtrate was concentrated in vacuo. The residue was purified by silica gel column and eluted with PE / EtOAc=8 / 1 to give compound 10-4 (0.9 g, 54%) as an off-white solid.

[0415] Synthesis of compound 10-5. At -78 ° C, isopropylmagnesium chloride (3.61 mL, 7.23 mmol, 2M in THF) was added dropwise to a solution of compound 10-4 (0.9 g, 2.41 mmol) in THF (30 mL). The mixture was stirred at -78 ° C for 2 hours. Then, the mixture was warmed to 25 ° C and stirred for 3 hours. The reaction was poured into water (100 mL) and extracted with EtOAc (2x30 mL). The combined organic layer was washed with brine (50 mL), dried with Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column and eluted with PE / EtOAc=5 / 1 to give compound 10-5 (0.6 g, 57%) as an off-white solid.

[0416] Synthesis of compounds 18 and 19. Compound 10-5 (0.6 g) was purified by SFC under alkaline conditions (column: AD (250 mm*30 mm, 5 um); condition: alkaline-MEOH) to obtain peak 1, compound 18 (140 mg, 23%), which was an off-white solid and peak 2, compound 19 (220 mg, 37%), which was a light yellow solid. Compound 18: 1 H NMR (400MHz, CDCl3) δ5.35-5.27(m,1H),3.38-3.26(m,1H),2.52-2.37(m,1H),2.07-1.92(m,3H),1.90-1.59(m,6 H),1.56-1.35(m,7H),1.33-1.21(m,3H),1.18-1.10(m,7H),1.03-1.00(m,6H),0.97-0.87(m,10H),0.68(s,3H). LCMS R t = 1.298min in 2min chromatogram, 30-90AB, MS ESI C 28 H 47 O[M-H2O+H] + The calculated value is 399 and the measured value is 399.

[0417] Compound 19: 1 H NMR (400MHz, CDCl3) δ5.33-5.25(m,1H),3.30(br.s.,1H),2.41(d,J=13.2Hz,1H),2.05-1.90(m, 3H),1.90-1.55(m,6H),1.51-1.04(m,19H),1.03-0.96(m,4H),0.95-0.85(m,10H),0.67(s,3H). LCMS R t = 1.294min in 2min chromatogram, 30-90AB, MS ESIC 28 H 47 O[M-H2O+H] + The calculated value is 399 and the measured value is 399.

[0418] Example 11. Synthesis of Compound 20.

[0419]

[0420] To a mixture of compound 18 (50 mg, 119 μmol) and Pd / C (50 mg, 10%) in EtOH (10 mL) was hydrogenated at 50 ° C in hydrogen (50 psi) for 12 h. The reaction mixture was filtered through a celite pad and the pad was washed with EtOAc (2x20 mL). The combined filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1 to 10 / 1) to give compound 20 (38.5 mg, 76%) as an off-white powder. 1 H NMR (400 MHz, CDCl3) δ 3.31-3.30 (m, 1H), 1.96-1.90 (m, 1H), 1.90-1.75 (m, 1H), 1.75-1.57 (m, 4H), 1.54-0.80 (m, 39H), 0.65-064 (m, 4H). LCMS Rt = 1.578 min in 2.0 min chromatography, 10-80 AB, MS ESI C 28 H 47 [M-2H2O+H] + The calculated value is 383 and the measured value is 383.

[0421] Example 12. Synthesis of Compound 21.

[0422]

[0423] A mixture of compound 19 (50 mg, 119 μmol) and Pd / C (50 mg, 10%) in EtOH (10 mL) was hydrogenated at 50 ° C in hydrogen (50 psi) for 12 h. The reaction mixture was filtered through a celite pad and the pad was washed with EtOAc (20 mLx2). The combined filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1 to 10 / 1) to give compound 21 (9.8 mg, 20%) as an off-white powder. 1 H NMR (400MHz,CDCl3)δ3.31-3.30(m,1H),1.97-1.92(m,1H),1.92-1.75(m,1H),1.75-1.57(m,27H),1.54-0.80(m,16H),0.65-064(m,4H). LCMS Rt=1.535min in 2.0min chromatogram,10-80AB,,MS ESI C 28 H 47 [M-2H2O+H] + The calculated value is 383 and the measured value is 383.

[0424] Example 13. Synthesis of compounds 22 and 23.

[0425]

[0426] Synthesis of compounds 22 and 23. At 0 ° C, ethylmagnesium bromide (876 μL, 3.0M, 2.63mmol) was added to a solution of compound 9-6 (340mg, 879 μmol) in THF (20mL). The reaction mixture was stirred at 15 ° C for 2 hours, then quenched with saturated NH4Cl (10mL) and extracted with ethyl acetate (3x50mL). The combined organic phase was washed with brine (60mL), dried and filtered with Na2SO4 and concentrated in vacuo to give compound 13-1, which was an off-white solid (240mg). The solid was purified by SFC (column: AD (250mm*30mm, 5um); condition: alkali-MeOH) to give peak 1, which was an off-white solid compound 22 (13mg, 4%), and peak 2, which was an off-white solid compound 23 (54.0mg, impure). Compound 22: 1 H NMR (400MHz, CDCl3) δ5.31(d,J=5.0Hz,1H),3.49(br.s.,1H),2.39(d,J=11.0Hz,1H),2.09-1.94(m,3H),1.92-1.80(m, 1H),1.78-1.71(m,1H),1.69-1.37(m,16H),1.35-1.23(m,4H),1.22-0.92(m,14H),0.87(t,J=7.5Hz,3H),0.70(s,3H). LCMS R t = 2.334min in 4min chromatography, 50-100AB, MSESI C 28 H 47 O[[M-H2O+H] + The calculated value is 399 and the measured value is 399.

[0427] Further purification of compound 23. Compound 23 (54 mg, 129 μmol, impure) was purified by SFC (column: AD (250 mm*30 mm, 5 um); condition: base-MEOH) to give a light yellow solid (34 mg), which was purified by trituration with n-hexane to give compound 23 (8.5 mg, 16%) as an off-white solid. 1H NMR(400MHz, CDCl3)δ5.32(br.s.,1H),3.51(br.s.,1H),2.39(d,J=13.1Hz,1H),2.11-1.95(m,3H),1.93-1.82(m,1H), 1.75(d,J=13.3Hz,1H),1.69-1.35(m,18H),1.33-1.24(m,3H),1.23-0.91(m,13H),0.87(t,J=7.4Hz,3H),0.70(s,3H). LCMS R t = 2.340 min in 4 min chromatography, 50-100 AB, MS ESI C 28 H 47 O[[M-H2O+H] + The calculated value is 399 and the measured value is 399.

[0428] Example 14. Synthesis of compounds 24, 25 and 26.

[0429]

[0430] Synthesis of compound 24: Cyclopropylmagnesium bromide (180 mL, 90 mmol, 0.5 M in THF) was added portionwise to a solution of compound 9-6 (0.7 g, 1.80 mmol) in THF (10 mL). The mixture was stirred at 15 ° C for 16 hours. The mixture was quenched with saturated NH4Cl solution (100 mL) and then extracted with EtOAc (2x30 mL). The combined organic phase was dried, concentrated and purified by preparative HPLC to give compound 24 (50 mg, 6%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.29-5.27 (m, 1H), 2.81 (s, 1H), 2.38-2.34 (m, 1H), 2.05-0.85 (m, 38H), 0.67 (s, 3H), 0.60-0.45 (m, 2H), 0.30-0.15 (m, 2H). LCMS Rt = 1.284 min in 2 min chromatography, 30-90 AB_ELSD, MS ESIC 29 H 45 [M-2H2O+H] + The calculated value is 393 and the measured value is 393.

[0431] Synthesis of Compounds 25 and 26: 90 mg of Compound 24 (90 mg, 0.209 mmol) was purified by SFC (column: AD (250 mm*30 mm, 5 um); condition: base-MEOH) to obtain Peak 1, which is Compound 25 (24.0 mg, 27%) and Peak 2, which is an off-white solid Compound 26 (11.1 mg, 12%). Compound 25: 1 H NMR (400MHz, CDCl3) δ5.29-5.27(m,1H),2.82-2.79(m,1H),2.43-2.40(m,1 H),2.05-0.80(m,38H),0.67(s,3H),0.55-0.40(m,2H),0.30-0.15(m,2H). LCMSt R = 1.280min in 2min chromatography, 30-90AB_ELSD, MS ESI C 29 H 45 [M-2H2O+H] + The calculated value is 393, and the found value is 393. Compound 26: 1 HNMR(400MHz, CDCl3)δ5.29-5.27(m,1H),2.82-2.79(m,1H),2.43-2.40(m, 1H),2.05-0.80(m,38H),0.67(s,3H),0.55-0.40(m,2H),0.30-0.15(m,2H). LCMS R t = 1.282min in 2min chromatography, 30-90AB_ELSD, MS ESI C 29 H 45 [M-2H2O+H] + The calculated value is 393 and the measured value is 393.

[0432] Example 15. Synthesis of compounds 27, 28 and 29.

[0433]

[0434] To a solution of compound 10-4 (4 g, 10.7 mmol) in THF (50 mL) was added cyclopropylmagnesium bromide (428 mL, 214 mmol, 0.5 M in THF) in portions. The mixture was stirred at 15 ° C for 16 hours. The mixture was quenched with saturated NH4Cl solution (500 mL) and then extracted with EtOAc (2x100 mL). The combined organic phases were dried, concentrated and purified by combi-flash (0-20% EtOAc / PE) to give compound 27 (2 g, 45%) as an off-white solid. Compound 27: 1H NMR (400 MHz, CDCl3) δ 5.30-5.29 (m, 1H), 2.80 (s, 1H), 2.43-2.40 (m, 1H), 2.02-1.43 (m, 16H), 1.40-0.80 (m, 20H), 0.67 (s, 3H), 0.55-0.40 (m, 2H), 0.30-0.15 (m, 2H). LCMS Rt = 1.231 min in 2 min chromatography, 30-90 AB_ELSD, MS ESI C 28 H 43 [M-2H2O+H] + The calculated value is 379 and the measured value is 379.

[0435] Synthesis of Compounds 28 and 29. 0.17 g of Compound 27 (170 mg, 0.409 mmol) was purified by SFC (column: AY (250 mm*30 mm, 10 um); condition: alkali-IPA) to obtain Peak 1, which is Compound 28 (37 mg, 22%) and Peak 2, which is an off-white solid Compound 29 (50 mg, 30%). Compound 28: 1 H NMR (400MHz,CDCl3)δ5.30-5.29(m,1H),2.82-2.79(m,1H),2.43-2.40(m,1H),2.05-0.80(m,36H),0.67(s,3H),0.55-0.40(m,2H),0.30-0.15(m,2H).LCMS Rt=1.217min in 2min chromatogram,30-90AB_ELSD,MS ESI C 28 H 43 [M-2H2O+H] + The calculated value is 379, and the found value is 379. Compound 29: 1 H NMR (400MHz,CDCl3)δ5.30-5.29(m,1H),2.82-2.79(m,1H),2.43-2.40(m,1H),2.05-0.80(m,36H),0.68(s,3H),0.55-0.40(m,2H),0.30-0.15(m,2H).LCMS Rt=1.218min in 2min chromatogram,30-90AB_ELSD,MS ESI C 28 H 43 [M-2H2O+H] + The calculated value is 379 and the measured value is 379.

[0436] Example 16. Synthesis of Compound 30.

[0437]

[0438] Synthesis of compound 16-2. Pd / C (anhydrous, 10% on carbon, 1 g) was added to a solution of compound 16-1 (5 g, 12.8 mmol) in ethanol (100 mL). The mixture was degassed and purged with hydrogen 3 times and stirred at 50 ° C at 50 psi for 16 hours. The reaction mixture was filtered through a celite pad and the filter cake was washed with DCM (100 mL). The filtrate was concentrated to give compound 16-2 (5 g, 100%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ3.66(s,3H),3.63-3.53(m,1H),2.41-2.29(m,1H),2.26-2.16(m,1H),1.98-1.89(m,1H) ,1.86-1.55(m,6H),1.51-1.17(m,12H),1.15-0.95(m,5H),0.94-0.82(m,5H),0.79(s,3H),0.67-0.56(m,4H).

[0439] Synthesis of compound 16-3. To a solution of compound 16-2 (11 g, 28.1 mmol) in DCM (200 mL) was added silica gel (9 g) and PCC (9.07 g, 42.1 mmol). The mixture became dark and was stirred at 15 ° C for 16 hours. The reaction mixture was filtered and the filtrate was concentrated. The dark residue was purified by column chromatography on silica gel (PE / EtOAc / DCM=15 / 1 / 1) to give compound 16-3 (10.5 g, 96%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 3.66 (s, 3H), 2.43-2.16 (m, 5H), 2.10-1.94 (m, 3H), 1.91-1.74 (m, 2H), 1.73-1.65 (m, 1H), 1.58-1.46 (m, 3H), 1.43-1.23 (m, 8H), 1.18-0.98 (m, 7H), 0.94-0.83 (m, 4H), 0.76-0.65 (m, 4H). LCMS Rt = 1.257 min in 2 min chromatogram, 30-90 AB, MS ESI C 25 H 41 O3[M+H] + The calculated value is 389 and the measured value is 389.

[0440] Synthesis of compound 16-4. Trimethylaluminum (2M in toluene, 23.1 mL, 46.2 mmol) was added dropwise to a solution of 2,6-di-tert-butyl-4-methylphenol (20.41 g, 92.5 mmol) in anhydrous toluene (70 mL) at 0°C in nitrogen. The mixture was stirred at 0°C for 1 hour and cooled to -70°C. A solution of compound 16-3 (6 g, 15.4 mmol) in anhydrous toluene (100 mL) was added dropwise to the above solution. The mixture was stirred at -70°C for 1 hour, and then methylmagnesium bromide (3M in diethyl ether, 15.4 mL, 46.2 mmol) was added dropwise. The resulting mixture was stirred at -70°C for 2 hours. The reaction mixture was quenched with aqueous citric acid solution (200 mL) and extracted three times with EtOAc and THF (200 mL / 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc / THF=20 / 1 / 1) to give compound 16-4 (6 g, 96%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 3.66 (s, 3H), 2.40-2.16 (m, 2H), 1.99-1.90 (m, 1H), 1.89-1.73 (m, 2H), 1.68-0.83 (m, 29H), 0.80 (s, 3H), 0.70-0.60 (m, 4H). LCMS Rt = 1.273 min in 2 min chromatography, 30-90 AB, MS ESI C 26 H 43 O2[M-H2O+H] + The calculated value is 387 and the measured value is 387.

[0441] Synthesis of compound 16-5. At 0 ° C, LiAlH4 (421 mg, 11.1 mmol) was added to a solution of compound 16-4 (3 g, 7.41 mmol) in anhydrous THF (50 mL) in portions. The mixture was stirred at 0 ° C for 30 minutes. The reaction mixture was quenched with water (5 mL), and an aqueous NaOH solution (10%, 5 mL) was added dropwise, and then filtered through a diatomaceous earth pad. The filter cake was washed with THF (5x20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered and concentrated to give compound 16-5 (2.5 g, 90% yield), which was an off-white solid. 1HNMR (400MHz,CDCl3)δ3.61(s,2H),1.97-1.94(m,1H),1.89-1.75(m,1H),1.68-1.52(m,6H),1.50-1.18(m,16H),1.17-0.84(m,11H),0.80(s,3H),0.70-0.60(m,4H). LCMS Rt=1.137min in 2min chromatogram,30-90AB,MS ESI C 25 H 43 O[M-H2O+H] + The calculated value is 359 and the measured value is 359.

[0442] Synthesis of compound 16-6. To a solution of compound 16-5 (2 g, 5.31 mmol) in anhydrous DCM (30 mL) was added silica gel (2.5 g) and PCC (2.28 g, 10.6 mmol). The mixture was stirred at 15 ° C for 16 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc / THF=20 / 1 / 1) to give compound 16-6 (1.3 g, 66%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 2.51-2.26 (m, 2H), 1.99-1.73 (m, 3H), 1.69-1.18 (m, 19H), 1.17-0.83 (m, 10H), 0.80 (s, 3H), 0.72-0.59 (m, 4H). LCMS Rt = 1.212 min in 2 min chromatography, 30-90 AB, MS ESI C 25 H 39 [M-2H2O+H-] + The calculated value is 339 and the measured value is 339.

[0443] Synthesis of compound 30. At 25 ° C and nitrogen, compound 16-6 (200 mg, 0.533 mmol) was added to a solution of cyclopropylmagnesium bromide (0.5 M in THF, 21.2 mL, 10.6 mmol). The mixture was stirred at 50 ° C for 16 hours. The reaction mixture was quenched with NH4Cl aqueous solution (50 mL), extracted with EtOAc (3x50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE / EtOAc=20 / 1) to give compound 30 (100 mg, 45%) as an off-white solid. 1H NMR (400 MHz, CDCl3) 2.85-2.75 (m, 1H), 2.00-1.93 (m, 1H), 1.93-1.73 (m, 1H), 1.73-0.83 (m, 34H), 0.80 (s, 3H), 0.70-0.59 (m, 4H), 0.57-0.43 (m, 2H), 0.30-0.16 (m, 2H) LCMS Rt = 1.443 min in 2 min chromatogram, 10-80 AB,, MS ESI C 28 H 45 [M-2H2O+H] + The calculated value is 381 and the measured value is 381.

[0444] Example 17. Synthesis of compounds 31 and 32.

[0445]

[0446] Synthesis of compound 17-2. Benzoyl chloride (295 mg, 2.10 mmol) was added to a solution of compound 30 (440 mg, 1.05 mmol) in pyridine (10 mL) at 25 ° C. The reaction was then stirred at 50 ° C for 16 h. The reaction was quenched by adding water (10 mL) and extracted with EtOAc (2x10 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column (PE / EtOAC=40 / 1) to give compound 17-2 (420 mg, 64%) as a yellow oil.

[0447] Synthesis of compounds 17-3 and 17-4. The mixture of compound 17-2 was purified and separated by SFC (column: AD (250mm*30mm, 10um) gradient: B in A (A=NH3.H2O, B=EtOH), flow rate: 30mL / min) to obtain peak 1, which is compound 17-3 (170mg, 41%), which is an off-white solid and peak 2, which is an off-white solid compound 17-4 (160mg, 38%). Compound 17-3: 1 H NMR (400MHz, CDCl3) δ8.06 (d, J = 8.8Hz, 2H), 7.99 (d, J = 8.4Hz, 2H), 7.58-7.48 (m, 2H), 7.48-7.38 (m, 4H), 4.55-4.45 (m, 1H), 2.11-0.77 (m, 37H), 0.73-0.55 (m, 5H), 0.52-0.45 (m, 2H), 0.39-0.31 (m, 1H). Compound 17-3: 1H NMR(400MHz, CDCl3)δ8.06(d,J=8.8Hz,2H),7.99(d,J=8.4Hz,2H),7.58-7.48(m,2H),7.48-7.38(m, 4H),4.55-4.45(m,1H),2.11-0.77(m,37H),0.73-0.55(m,5H),0.52-0.45(m,2H),0.39-0.31(m,1H).

[0448] Synthesis of compound 31. At 25 ° C, NaOH (63.5 mg, 1.59 mmol) and H2O (1 mL) were added to a solution of compound 17-3 (50 mg, 0.08 mmol) in THF (1 mL) and MeOH (1 mL). The solution was stirred at 50 ° C for 16 h. The reaction solution was extracted with EtOAc (2x5 mL). The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column (PE / EtOAc=3 / 1) to obtain the desired product compound 31 (4.0 mg, 12%), which was an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 2.85-2.75 (m, 1H), 1.98-1.93 (m, 1H), 1.93-1.76 (m, 1H), 1.76-0.75 (m, 37H), 0.70-0.60 (m, 4H), 0.58-0.45 (m, 2H), 0.30-0.15 (m, 2H). LCMS Rt = 1.437 min in 2 min chromatography, 10-80 AB, MS ESI C 28 H 45 The calculated value of is 381 ([M-2H2O+H] + ), the measured value is 381.

[0449] Synthesis of compound 32. At 25 ° C, NaOH (63.5 mg, 1.59 mmol) and H2O (1 mL) were added to a solution of compound 17-4 (50 mg, 0.08 mmol) in THF (1 mL) and MeOH (1 mL). The reaction solution was extracted with EtOAc (5 mLx2). The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column (PE / EtOAc=3 / 1) to obtain the desired product compound 32 (8.0 mg, 24%), which was an off-white solid. 1H NMR (400MHz,CDCl3)δ2.84-2.76(m,1H),1.96-1.92(m,1H),1.90-1.73(m,1H),1.73-0.83(m,34H),0.81(s,3H),0.70-0.61(m,4H),0.58-0.44(m,2H),0.29-0.19(m,2H). LCMS Rt=1.436min in 2min chromatogram,10-80AB,MS ESI C 28 H 45 The calculated value of is 381 ([M-2H2O+H] + ), the measured value is 381.

[0450] Example 18. Synthesis of Compound 33.

[0451]

[0452] Synthesis of compound 18-2. At 10 ° C, trimethylaluminum (19.2 mL, 2M in toluene) was added to a solution of 2,6-di-tert-butyl-4-methylphenol (17 g, 77.1 mmol) in toluene (50 mL). The mixture was stirred at 20 ° C for 1 h. At -70 ° C and nitrogen, a solution of compound 16-3 (5 g, 12.8 mmol) in toluene (20 mL) was added dropwise. The mixture was stirred at -70 ° C for 1 hour. At -70 ° C, EtMgBr solution (12.7 mL, 3M) was added dropwise. The mixture was stirred at -70 ° C for another 3 hours, and then the reaction mixture was quenched with citric acid (150 mL, saturated aqueous solution). The reaction was warmed to 25 ° C. The organic layer was separated and concentrated in vacuo. The crude product was purified by column chromatography on silica gel (PE / EtOAc=200 / 1 to 10 / 1) to give compound 18-2 (3.8 g) as an off-white solid.

[0453] 1 H NMR (400MHz, CDCl3) δ3.66 (s, 3H), 2.41-2.30 (m, 1H), 2.26-2.15 (m, 1H), 1.94 (td, J = 3.3, 12. 5Hz,1H),1.90-1.73(m,2H),1.69-1.58(m,3H),1.56-0.84(m,28H),0.82(s,3H),0.64(s,4H).

[0454] Synthesis of compound 18-3. LiAlH4 (500 mg, 13.17 mmol) was added to THF (50 mL) at 0 ° C and nitrogen. A solution of compound 18-2 (1.5 g, 3.58 mmol) in THF (15 mL) was added to the mixture at 0 ° C. The mixture was stirred at 0 ° C for 20 min. Water (1 mL) / THF (1 mL) was added to form an off-white solid from the solution. The mixture was filtered and concentrated in vacuo to give compound 18-3 (700 mg, crude), which was an off-white solid. 1 H NMR (400MHz, CDCl3) δ3.70-3.55(brs,2H),1.98-1.90(m,1H),1.90-1.72(m,1H),1.72-0.72(m,39H),0.64(s,3H).

[0455] Synthesis of compound 18-4. At 0 ° C and nitrogen, a solution of compound 18-3 (100 mg, crude) in DCM (5 mL) was added with Dess-Martin reagent (215 mg). The mixture was stirred at 20 ° C for 2 h. A solution of NaHCO (215 mg) and Na2S2O3 (348 mg) in water (10 mL) was added. The mixture was extracted with petroleum ether (3x10 mL). The organic layer was separated, washed with water (20 mL), dried with Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 8 / 1) to give compound 18-4 (52 mg), which was an off-white solid.

[0456] 1 H NMR (400MHz, CDCl3) δ9.76(s,1H),2.51-2.24(m,2H),1.98-1.90(m,1H),1.89-1.73(m,2H),1.68-1.59(m,3H),1.54-0.77(m,30H),0.65(s,5H).

[0457] Synthesis of compound 33. At -70 ° C and nitrogen, methylmagnesium bromide (0.5 mL, 1.5 mmol, 3M in ether) was added to a solution of compound 18-4 (52 mg, 0.134 mmol) in THF (1 mL). The mixture was stirred at 20 ° C for 20 min, and then saturated NH4Cl (4 mL), EtOAc (5 mL) and H2O (3 mL) were added. The mixture was extracted with EtOAc (3x6 mL), washed with saturated NaCl (2x15 mL), dried with Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 12 / 1) to give compound 33 (18.4 mg, 30%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ3.78-3.70(m,1H),1.99-1.91(m,1H),1.89-1.76(m,1H),1.68-0.80(m,41H),0.65(s,4H). LCMS R t = 1.448min in 2min chromatogram, 10-80AB_E, MS ESI C 27 H 45 [M-2H2O+H] + The calculated value is 369 and the measured value is 369.

[0458] Example 19. Synthesis of Compound 34.

[0459]

[0460] Synthesis of compound 34. At -70 ° C and nitrogen, ethylmagnesium bromide (2.2 mL, 6.6 mmol, 3M in ether) was added to a solution of compound 18-4 (250 mg, crude) in THF (20 mL). The mixture was stirred at 20 ° C for 1 h, and then saturated NH4Cl (20 mL), EtOAc (20 mL) and H2O (10 mL) were added. The mixture was extracted with EtOAc (20 mLx3), washed with saturated NaCl (60 mLx2), dried with Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 12 / 1) to give compound 34 (80 mg), which was an off-white solid. 1H NMR (400MHz, CDCl3) δ3.53-3.42(m,1H),2.00-1.92(m,1H),1.89-1.75(m,1 H),1.69-1.58(m,3H),1.56-0.84(m,37H),0.82(s,3H),0.68-0.59(m,4H). LCMS R t = 1.526min in 2min chromatogram, 10-80AB_E, MS ESI C 28 H 47 [M-2H2O+H] + The calculated value is 383 and the measured value is 383.

[0461] Example 20. Synthesis of compounds 35 and 36.

[0462]

[0463] Synthesis of compound 20-2. To a solution of compound 34 (64 mg, 0.153 mmol) in pyridine (3 mL) was added benzoyl chloride (32.2 mg, 0.229 mmol) and triethylamine (23.1 mg, 0.229 mmol). The mixture was stirred at 25 ° C for 5 h, and then the reaction mixture was quenched with saturated NH4Cl (6 mL). The mixture was extracted with EtOAc (3x6 mL), washed with saturated NaCl (2x15 mL), dried with Na2SO4, filtered, and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=50 / 1 to 10 / 1) to give compound 20-2 (70 mg, crude). LCMS R t = 1.257min in 1.5min chromatogram, 5-95AB, MS ESI C 28 H 47 [M-BzOH-H2O+H] + The calculated value is 383 and the measured value is 383.

[0464] Synthesis of compounds 20-3 and 20-4. (SFC) Compound 20-2 (70 mg, crude) was separated by SFC (column: IC (250 mm*30 mm, 10 um); conditions: base-IPA; gradient: 35% B; flow rate: 80 mL / min) to give compound 20-3 (18 mg, Rt=5.988 min) and compound 20-4 (30 mg, Rt=6.229 min).

[0465] Synthesis of compound 35. To a solution of compound 20-3 (18 mg, 0.03442 mmol) in THF (1 mL) and MeOH (1 mL) was added an aqueous solution of NaOH (1 mL, 20%). The mixture was stirred at 20 ° C for 20 h. The mixture was concentrated in vacuo, extracted with EtOAc (2x2 mL), washed with NaHCO3 (3x4 mL) and brine (2x3 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give compound 35 (8.5 mg, 59%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ3.55-3.40(m,1H),2.00-1.90(m,1H),1.85-1.75(m,1 H),1.65-1.55(m,4H),1.50-0.85(m,36H),0.82(s,3H),0.65-0.60(m,4H). LCMSt R = 1.322min in 2min chromatogram, 30-90AB_E, MS ESI C 28 H 47 [M-2H2O+H] + The calculated value is 383 and the measured value is 383.

[0466] Synthesis of compound 36. To a solution of compound 20-4 (30 mg, 0.057 mmol) in THF (1 mL) and MeOH (1 mL) was added an aqueous solution of NaOH (1 mL, 20%). The mixture was stirred at 20 ° C for 20 h. The mixture was concentrated in vacuo, extracted with EtOAc (2x2 mL), washed with NaHCO3 (3x4 mL) and brine (2x3 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give compound 36 (5.2 mg, 22%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ3.55-3.40(m,1H),2.00-1.90(m,1H),1.85-1.75(m,1H) ),1.65-1.55(m,4H),1.50-0.85(m,36H),0.82(s,3H),0.65-0.60(m,4H)LCMS t R = 1.507min in 2min chromatogram, 30-90AB_E, MS ESI C 28 H 47 [M-2H2O+H] + The calculated value is 383 and the measured value is 383.

[0467] Example 21. Synthesis of compound 37.

[0468]

[0469] Isopropylmagnesium bromide (3.2 mL, 6.4 mmol, 2M in THF) was added to a solution of compound 18-4 (50 mg, crude) in THF (20 mL) at -70 ° C under nitrogen. The mixture was stirred at 20 ° C for 1 h. Saturated NH4Cl (20 mL), EtOAc (20 mL) and H2O (10 mL) were added to the mixture. The mixture was extracted with EtOAc (3x20 mL), washed with saturated NaCl (2x60 mL), dried with Na2SO4, filtered and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 12 / 1) to give compound 37 (5.3 mg) as an off-white solid. 1 H NMR(400MHz, CDCl3) δ3.35-3.27(m.,1H),1.96(d,J=12.8Hz,1H),1.88-1.76( m,1H),1.73-1.58(m,5H),1.53-0.84(m,37H),0.82(s,3H),0.68-0.59(m,4H). LCMSt R =1.371min in 2min chromatogram, 30-90AB_E, MS ESI C 29 H 49 [M-2H2O+H] + The calculated value is 397 and the measured value is 397.

[0470] Example 22. Synthesis of Compound 38.

[0471]

[0472] Cyclopropylmagnesium bromide (12.8 mL, 6.4 mmol, 0.5 M in THF) was added to a solution of compound 18-4 (250 mg, crude) in THF (20 mL) at -70 ° C under nitrogen. The mixture was stirred at 20 ° C for 1 h. Saturated NH4Cl (20 mL), EtOAc (20 mL) and H2O (10 mL) were added to the mixture. The mixture was extracted with EtOAc (3x20 mL), washed with saturated NaCl (2x60 mL), dried with Na2SO4, filtered, and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 12 / 1) to give compound 38 (110 mg, 40%) as an off-white solid. 1H NMR (400MHz, CDCl3) δ2.85-2.75(m,1H),2.00-1.92(m,1H),1.89-1.76(m,1H),1.69-1.59( m,4H),1.55-0.85(m,32H),0.82(s,3H),0.65(s,4H),0.56-0.43(m,2H),0.29-0.16(m,2H). LCMSt R = 1.518min in 2min chromatogram, 10-80AB_E, MS ESI C 29 H 47 [M-2H2O+H] + The calculated value is 395 and the measured value is 395.

[0473] Example 23. Synthesis of compounds 39 and 40.

[0474]

[0475] Synthesis of compound 23-2. To a solution of compound 38 (80 mg, 0.186 mmol) in pyridine (3 mL) was added benzoyl chloride (39.1 mg, 0.279 mmol) and triethylamine (28.1 mg, 0.279 mmol). The mixture was stirred at 25 ° C for 5 h. The reaction mixture was quenched with saturated NH4Cl (6 mL). The mixture was extracted with EtOAc (3x6 mL), washed with saturated NaCl (2x15 mL), dried with Na2SO4, filtered, and concentrated in vacuo to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc=50 / 1 to 10 / 1) to give compound 23-2 (80 mg, crude). LCMS t R = 1.247min in 1.5min chromatogram, 5-95AB_E, MS ESI C 29 H 47 [M-BzOH-H2O+H] + The calculated value is 395 and the measured value is 395.

[0476] Synthesis of compounds 23-3 and 23-4. Compound 23-2 (80 mg, crude) was separated by SFC (column: IC (250 mm*30 mm, 10 um); conditions: base-IPA; gradient: 30% B; flow rate: 50 mL / min) to give compound 23-3 (23 mg, Rt=6.153) and compound 23-4 (35 mg, Rt=6.357).

[0477] Synthesis of compound 39. To a solution of compound 23-3 (23 mg, 0.04 mmol) in THF (1 mL) and MeOH (1 mL) was added an aqueous NaOH solution (2 mL, 20%). The mixture was stirred at 20 ° C for 20 h. The mixture was concentrated in vacuo, extracted with EtOAc (2x2 mL), washed with NaHCO3 (3x4 mL) and brine (2x3 mL), dried with Na2SO4, filtered and concentrated in vacuo to give a solid, which was purified by column chromatography on silica gel (PE / EtOAc=100 / 1 to 8 / 1) to give compound 39 (9 mg, 49%), which was an off-white solid. 1 H NMR (400MHz, CDCl3) δ2.85-2.75(m,1H),2.00-1.92(m,1H),1.89-1.76(m,1H),1.75-1.59(m,6H ),1.55-0.89(m,30H),0.82(s,3H),0.70-0.60(m,4H),0.56-0.43(m,2H),0.29-0.16(m,2H)LCMS t R =1.484min in 2min chromatogram, 30-90AB_E, MS ESIC 29 H 47 [M-2H2O+H] + The calculated value is 395 and the measured value is 395.

[0478] Synthesis of compound 40. To a solution of compound 23-4 (35 mg, 0.065 mmol) in THF (1 mL) and MeOH (1 mL) was added an aqueous solution of NaOH (2 mL, 20%). The mixture was stirred at 20 ° C for 20 hours. The mixture was concentrated in vacuo, extracted with EtOAc (2x2 mL), washed with NaHCO3 (3x4 mL) and brine (2x3 mL), dried over Na2SO4, filtered and concentrated in vacuo to give compound 40 (14 mg, 50%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ2.85-2.75(m,1H),2.00-1.92(m,1H),1.89-1.76(m,1H),1.69-1.59(m, 2H),1.55-0.85(m,34H),0.82(s,3H),0.65(m,4H),0.56-0.43(m,2H),0.29-0.16(m,2H)LCMS t R =1.510min in 2min chromatogram, 30-90AB_E, MS ESI C 29 H 47 [M-2H2O+H] +The calculated value is 395 and the measured value is 395.

[0479] Example 24. Synthesis of Compound 41.

[0480]

[0481] Step 1. To a solution of G1a-1 (1 g, 7.4 mmol) in THF (7 mL) was added t-BuLi (9.25 mL, 1.6 M in pentane, 14.8 mmol) dropwise at -60 °C under nitrogen. After addition, the mixture was slowly warmed to -40 °C for 0.5 h to give a solution of G1a in THF, which was used directly in the next step.

[0482] Step 2. G1a (0.87 mL, 0.46 M in THF and pentane, 0.402 mmol) was added to THF (2 mL) at -70 ° C under nitrogen. Stir at -70 ° C for 5 min and add a solution of compound 10-4 (50 mg, 0.314 mmol) in THF (3 mL). The reaction mixture was gradually warmed to 15 ° C for 10 hours. The mixture was quenched with 10 mL of saturated NH4Cl and extracted with 50 mL EtOAc. The separated organic phase was washed with 10 mL of brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography and eluted with PE / EtOAc=10 / 1~2 / 1 to give compound 41 (7.3 mg, 13%) as an off-white solid.

[0483] 1 H NMR (400MHz,CDCl3)δ.5.35-5.25(m,1H),3.49-3.32(m,1H),2.48-2.38(m,1H),2.38-2.25(m,1H),2.05-1.71(m,12H),1.50-0.86(m,29H),0.72-0.63(m,3H). LCMS Rt=1.300min in 2min chromatogram,30-90AB_E.M,MS ESI C 29 H 45 [M-2H2O+H] + The calculated value is 393 and the measured value is 393.

[0484] Step 3. Compound 41 (800 mg, 1.86 mmol) was separated by SFC (column: AD (250 mm*30 mm, 5 um). Conditions: 0.1% NH3H2O ​​ETOH. Gradient: 40% B. Flow rate: 40 mL / min) to give compound 41-A (123 mg, 15%) as an off-white solid and compound 41-B (109 mg, 14%) as an off-white solid.

[0485] Compound 41-A: 1 H NMR (400MHz, CDCl3) δ 5.32-5.28 (m, 1H), 3.46-3.38 (m, 1H), 2.46-2.27 (m, 2H), 2.02-1.67 (m, 13H), 1.55-1.36 (m, 8H), 1.31-1.22 (m, 2H), 1.19-1.06 (m, 8H), 1.05-0.89 (m, 10H), 0.67 (s, 3H). LCMS Rt = 1.321 min in 2.0 min chromatogram, 30-90AB, MS ESIC 29 H 45 [M+H-2H2O] + The calculated value is 393 and the measured value is 393.

[0486] Compound 41-B: 1 H NMR (400 MHz, CDCl3) δ 5.33-5.28 (m, 1H), 3.49-3.42 (m, 1H), 2.45-2.39 (m, 1H), 2.36-2.28 (m, 1H), 2.04-1.66 (m, 12H), 1.53-1.22 (m, 10H), 1.20-0.98 (m, 12H), 0.96-0.77 (m, 7H), 0.68 (s, 3H). LCMS Rt = 1.316 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 29 H 45 [M+H-2H2O] + The calculated value is 393 and the measured value is 393.

[0487] Example 25. Synthesis of Compound 42.

[0488]

[0489] Cyclopentylmagnesium chloride (0.402 mL, 1.0 M in THF, 0.402 mmol) was added to THF (1 mL) at -70 ° C under nitrogen. Stir at -70 ° C for 5 min, and a solution of compound 10-4 (50 mg, 0.134 mmol) in THF (4 mL) was added. The reaction mixture was gradually warmed to 15 ° C for 18 hours. The mixture was quenched with 10 mL of saturated NH4Cl and extracted with 50 mL of EtOAc. The separated organic phase was washed with 10 mL of brine, dried over Na2SO4, filtered and concentrated. The residue was purified by flash column and eluted with PE / EtOAc=10 / 1~2 / 1 to give compound 42 (4.1 mg, 7%) as an off-white solid.

[0490] 1 H NMR (400MHz,CDCl3)δ.5.35-5.25(m,1H),3.40-3.29(m,1H),2.46-2.37(m,1H),2.05-1.60(m,12H),1.55-0.82(m,32H),0.72-0.61(m,3H). LCMS Rt=1.389min in 2min chromatogram,30-90AB_E.M,MS ESI C 30 H 47 [M-2H2O+H] + The calculated value is 407 and the measured value is 407.

[0491] Example 26. Synthesis of Compound 43.

[0492]

[0493] Cyclohexylmagnesium chloride (0.402 mL, 2.0 M in THF, 0.804 mmol) was added to THF (1 mL) at -70 ° C under nitrogen. Stirring for 5 min at -70 ° C, a solution of compound 10-4 (100 mg, 0.268 mmol) in THF (1 mL) was added. The reaction mixture was gradually warmed to 15 ° C and kept for 18 hours. The mixture was quenched with 10 mL of saturated NH4Cl and extracted with 50 mL of EtOAc. The separated organic phase was washed with 10 mL of brine, dried with Na2SO4, filtered and concentrated. The residue was purified by flash column and eluted with PE / EtOAc (10 / 1 to 2 / 1) to give compound 43 (20 mg, 16%) as an off-white solid.

[0494] 1 H NMR (400MHz,CDCl3)δ.5.40-5.25(m,1H),3.40-3.26(m,1H),2.51-2.30(m,1H),2.09-1.91(m,3H),1.90-1.59(m,10H),1.55-0.85(m,33H),0.68(s,3H). LCMS Rt=1.490min in 2min chromatogram,30-90AB_E.M,MS ESI C 31 H 49 [M-2H2O+H] + The calculated value is 421 and the measured value is 421.

[0495] Example 27. Synthesis of Compound 44.

[0496]

[0497] Step 1. G5-1 (0.15 g, 1.24 mmol) was added to a vigorously stirred suspension of Mg shavings (602 mg, 24.8 mmol) and iodine (31.3 mg, 0.124 mmol) in THF (5 mL) under nitrogen. The mixture was heated to 60°C. After the reaction started, a solution of G5-1 (1.35 g, 11.16 mmol) in THF (6 mL) was slowly added. After the addition, the mixture was stirred at 60°C for 2 hours to obtain a gray suspension of G5 in THF, which was used directly in the next step.

[0498] Step 2. G5 (0.402 mL, 1.0 M in THF, 0.402 mmol) was added to THF (2 mL) at -70 ° C under nitrogen. After stirring at -70 ° C for 5 minutes, a solution of compound 10-4 (50 mg, 0.314 mmol) in THF (3 mL) was added. The reaction mixture was gradually warmed to 15 ° C and stirred for 18 hours. The mixture was quenched with 10 mL of saturated NH4Cl and extracted with 50 mL EtOAc. The separated organic phase was washed with 10 mL of brine, dried over Na2SO4 and concentrated. The residue was purified by flash column and eluted with PE / EtOAc=10 / 1 to 2 / 1 to give compound 44 (10 mg, 16%) as an off-white solid.

[0499] 1 H NMR (400MHz,CDCl3)δ5.38-5.25(m,1H),4.11-3.89(m,2H),3.42-3.24(m,3H),2.47-2.36(m,1H),2.04-1.91(m,3H),1.90-1.59(m,6H),1.53-1.45(m,14H),1.40-0.86(m,17H),0.68(s,3H).LCMS Rt=1.187min in 2min chromatogram,30-90AB_E.M,MS ESI C 30 H 49 O2[M-H2O+H] + The calculated value is 441 and the measured value is 441.

[0500] Step 3. The product compound 44 (830 mg, 1.80 mmol) was purified by SFC (column: AD (250 mm*30 mm, 5 um); condition: 0.1% NH3H2O ​​IPA; gradient: 40% B; gradient time (min): 30; flow rate (ml / min): 60.) to give compound 44-A (142 mg, 17%) as a white solid and compound 44-B (220 mg, 27%) as a white solid.

[0501] Compound 44-A: 1 H NMR (400MHz,CDCl3)δ5.33-5.28(m,1H),4.05-3.96(m,2H),3.43-3.30(m,3H),2.46-2.38(m,1H),2.05-1.92(m,3H),1.91-1.66(m,4H),1.65-1.57(m,2H),1.54-1.41(m,10H),1.40-1.20(m,5H),1.19-1.06(m,7H),1.05-0.88(m,9H),0.68(s,3H).LCMS Rt=1.167min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 30 H 49 O2[M+H-H2O] + The calculated value is 441 and the measured value is 441.

[0502] Compound 44-B: 1 H NMR (400MHz,CDCl3)δ5.34-5.27(m,1H),4.06-3.97(m,2H),3.43-3.28(m,3H),2.47-2.38(m,1H),2.04-1.92(m,3H),1.89-1.66(m,4H),1.64-1.57(m,5H),1.53-1.35(m,9H),1.33-1.21(m,3H),1.21-1.07(m,7H),1.06-0.90(m,9H),0.68(s,3H).LCMS Rt=1.163min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 30 H 49 O2[M+H-H2O] + The calculated value is 441 and the measured value is 441.

[0503] Example 28. Synthesis of compounds 45 and 46.

[0504]

[0505] Synthesis of compound 28-1. At -70 ° C and nitrogen, n-BuLi (2.96 mL, 2.5M in hexane, 7.42 mmol) was added to THF (5 mL). After that, a suspension of A-6 (1 g, 2.12 mmol) in THF (8 mL) was added dropwise to give a light yellow suspension. After stirring at -70 ° C for 30 minutes, a solution of 2-(2,2,2-trifluoroethyl)oxirane (320 mg, 2.52 mmol) in THF (5 mL) was added. The reaction mixture was stirred at -70 ° C for 10 minutes, warmed to 15 ° C and stirred for 16 hours. The reaction was quenched with saturated NH4Cl (40 mL) and extracted with EtOAc (100 mLx3). The combined organic layer was dried with Na2SO4, filtered and concentrated to give compound 28-1 (1.15 g, crude), which was a light yellow solid, which was used directly in the next step.

[0506] Synthesis of compounds 45 and 46. Under stirring, at 50°C and nitrogen, magnesium shavings (0.2 g, 8.22 mmol) (activated with 0.5% aqueous HCl, water, anhydrous EtOH and MTBE) and NiCl2 (49.7 mg, 0.384 mmol) were added to a solution of compound 28-1 (1.15 g, 1.92 mmol) in 25 mL of anhydrous MeOH to induce continuous hydrogen generation. After adding 10 batches of 0.2 g of magnesium shavings, the reaction mixture was quenched by 2M HCl (250 mL) at 10°C until the solid dissolved. The mixture was extracted with EtOAc (400 mL). The organic layer was washed with saturated NaHCO3 (50 mL), brine (50 mL), dried with Na2SO4, filtered and concentrated. The residue was purified by flash column, eluted with PE:EtOAc=20:1-5:1 to give 300 mg of impure product as an off-white solid. The impure product was further purified by SFC (column: Chiralpak AD-3 150×4.6 mm ID, 3 um mobile phase: A: CO2 B: methanol (0.05% DEA) gradient: from 5% to 40% B over 5 min, keep at 40% for 2.5 min, then keep at 5% B for 2.5 min flow rate: 2.5 mL / min column temperature: 35°C) to give compound 45 (99.9 mg, 11%) and compound 46 (84 mg, 10%).

[0507] Compound 45: 1H NMR (400MHz,CDCl3)δ5.38-5.25(m,1H),4.06-3.88(m,1H),2.48-2.35(m,1H),2.32-2.18(m,2H),2.08-1.90(m,3H),1.87-1.63(m,4H),1.60-1.45(m,12H),1.40-0.83(m,16H),0.68(s,3H).LCMS Rt=1.203min in 2min chromatogram,30-90AB_2MIN_E.M,MSESI C 27 H 42 F3O[M+H-H2O] + The calculated value is 439, the found value is 439. SFC Rt = 4.933min in 10min chromatogram, AD_3_MeOH_DEA_5_40_25ML.

[0508] Compound 46: 1 H NMR (400 MHz, CDCl3) δ 5.35-5.25 (m, 1H), 4.01-3.88 (m, 1H), 2.45-2.35 (m, 1H), 2.32-2.18 (m, 2H), 2.05-1.91 (m, 3H), 1.90-1.60 (m, 4H), 1.60-1.45 (m, 12H), 1.40-0.83 (m, 16H), 0.69 (s, 3H). LCMS Rt = 1.205 min in 2 min chromatogram, 30-90 AB_2MIN_E.M, MS ESI C 27 H 42 F3O[M+H-H2O] + The calculated value is 439, the found value is 439. SFC Rt = 5.640min in 10min chromatogram, AD_3_MeOH_DEA_5_40_25ML.

[0509] Example 29. Synthesis of Compound 47.

[0510]

[0511] Pd / C (anhydrous, 10%, 350 mg) was added to a solution of compound 45 (140 mg, 0.307 mmol) in MeOH / THF (10 mL / 1 mL) under argon. After degassing with nitrogen three times, the reaction mixture was degassed with hydrogen three times. The reaction mixture was stirred at 55 ° C in hydrogen (50 Psi) for 16 hours. The catalyst was removed by suction filtration, and the filtrate was concentrated to give a crude product, which was purified by silica gel column (EtOAc in PE, 10%-15%) to give compound 47 (30 mg, 21%) as a white solid.

[0512] 1 H NMR (400MHz, CDCl3) δ 3.96-3.94 (m, 1H), 2.30-2.21 (m, 2H), 1.97-1.93 (m, 1H), 1.92-1.81 (m, 2H), 1.80-1.58 (m, 4H), 1.55-1.26 (m, 6H), 1.24-1.20 (m, 11H), 1.19-0.93 (m, 11H), 0.80 (s, 3H), 0.66-0.62 (m, 4H). LCMS Rt = 1.220 min in 2 min chromatogram, 30-90AB, MS ESIC 27 H 44 F3O[M+H-H2O] + The calculated value is 441 and the measured value is 441.

[0513] Example 30. Synthesis of Compound 48.

[0514]

[0515] Pd / C (anhydrous, 10%, 350 mg) was added to a solution of compound 46 (102 mg, 0.223 mmol) in MeOH / THF (10 mL / 1 mL) in argon. After degassing with nitrogen 3 times, the reaction mixture was degassed with hydrogen 3 times. The reaction mixture was stirred at 55 ° C and hydrogen (50 Psi) for 16 hours. The catalyst was removed by suction filtration, and the filtrate was concentrated to give a crude product, which was purified by silica gel column (EtOAc in PE, 10%-15%) to give compound 48 (25 mg, 24%) as a white solid.

[0516] 1H NMR (400 MHz, CDCl3) δ 4.00-3.95 (m, 1H), 2.29-2.26 (m, 2H), 1.97-1.93 (m, 1H), 1.92-1.81 (m, 2H), 1.80-1.58 (m, 4H), 1.55-1.26 (m, 6H), 1.24-1.20 (m, 11H), 1.19-0.93 (m, 11H), 0.80 (s, 3H), 0.66-0.64 (m, 4H). LCMS Rt = 1.218 min in 2 min chromatogram, 30-90AB, MS ESIC 27 H 44 F3O[M+H-H2O] + The calculated value is 441, and the measured value is 441.

[0517] Example 31. Synthesis of compounds 49, 50 and 51.

[0518]

[0519] Synthesis of K2. MoO3 (3 g, 208 mmol) was added to 150 mL of 30% H2O2 in water. The mixture was stirred at 40°C for 5 hours to form a yellow solution containing a suspended white solid. After cooling to 20°C, the suspension was filtered through a 1-cm diatomaceous earth pad. The yellow filtrate was cooled to 10°C (with an ice bath and magnetic stirring) and HMPA (37.2 g, 208 mmol) was added dropwise. A yellow crystalline precipitate was produced. After filtration, the yellow product was recrystallized from 100 mL of EtOH at -20°C to obtain 52 g of crude K2 as a yellow solid.

[0520] Synthesis of K3. K2 (52 g, 138 mmol) was dried in vacuo over P2O5 for 6 hours to give 50 g of a yellow solid. The yellow solid was dissolved in 150 mL of THF at 20°C. Pyridine (11.1 g, 140 mmol) was added. Stirring at 20°C for 10 minutes gave a yellow crystalline solid. After filtration, the filter cake was washed with THF (50 mL) and MTBE (200 mL) and dried in vacuo to give 48 g of crude K3 as a yellow solid, which was used directly.

[0521] Synthesize compound 29-2. At -70 ° C and nitrogen, n-BuLi solution (5.15 mL, 12.9 mmol, 2.5 M in hexane) was added dropwise to a solution of diisopropylamine (1.81 mL, 12.9 mmol) in THF (80 mL). After stirring at -70 ° C for 10 minutes, the reaction mixture was gradually warmed to 10 ° C and kept for 0.5 h. After cooling to -70 ° C, a solution of compound 29-1 (2 g, 10.8 mmol) in THF (20 mL) was added. The reaction mixture was stirred for 0.5 h. K3 (7.06 g, 16.2 mmol) was added. After stirring at -20 ° C for 3 hours, the mixture was quenched with 200 mL of saturated Na2SO3 and extracted with MTBE (2x200 mL). The combined organic phase was washed with 100 mL of brine, dried with NaSO4, filtered and concentrated to give 2.1 g of crude product as a brown oil.

[0522] 1 H NMR (400MHz, CDCl3) δ.4.55 (s, 1H), 4.37-4.24 (m, 2H), 3.16-3.03 (m, 1H), 2.78-2.66 (m, 1H), 1.32 (t, J = 6.8Hz, 3H), 1.09 (d, J = 6.8Hz, 3H).

[0523] Synthesis of compound 29-3. At -10 ° C and nitrogen, LiAlH4 (789 mg, 20.8 mmol) was added portionwise to a solution of compound 29-2 (2.1 g, 10.4 mmol) in THF (100 mL). The reaction mixture was stirred at 15 ° C for 2 hours. At 0 ° C, water (1 mL), 15% NaOH aqueous solution (1 mL) and water (3 mL) were added dropwise to quench the reaction. After stirring at 15 ° C for 15 minutes, 2 g MgSO4 was added at 15 ° C. The mixture was stirred at this temperature for 1 h. After vacuum filtration with diatomaceous earth and washing with DCM (2x100 mL), the organic layer was concentrated in vacuo to obtain 2 g of crude product, which was a yellow oil.

[0524] 1 H NMR (400MHz, CDCl3) δ.4.09-4.03 (m, 1H), 3.69-3.61 (m, 2H), 2.39-2.27 (m, 1H), 2.21 (d, J = 4.0Hz, 1H), 1.20 (d, J = 7.2Hz, 3H).

[0525] Synthesis of compound 29-4. At 0 ° C, TsCl (2.87 g, 15.1 mmol) was added to a solution of compound 29-3 (2 g, 12.6 mmol) in pyridine (15 mL) in portions over 5 minutes. The reaction solution was stirred at 15 ° C for 16 hours. At 0 ° C, the reaction mixture was quenched with 2N HCl (95 mL) to pH = 1-2. The internal temperature was maintained below 30 ° C and the mixture was extracted with MTBE (2x250 mL). The combined organic layer was dried with Na2SO4, filtered, concentrated and purified by column (0-20% EtOAc in PE) to give compound 29-4 (2.1 g, 53%), which was a light yellow oil.

[0526] 1 H NMR(400MHz, CDCl3)δ.7.80(d,J=8.4Hz,2H),7.37(d,J=8.4Hz,2H),4.22-4.15(m,1H),4.06 -3.97(m,2H),2.47(s,3H),2.41-2.29(m,1H),2.18(d,J=4.8Hz,1H),1.14(d,J=7.2Hz,3H).

[0527] Synthesis of compound 29-5. Diisopropylamine (2.35 mmol, 237 mg) was added to THF (3.5 mL) at -70 ° C and nitrogen, followed by n-BuLi (2.22 mmol, 0.89 mL, 2.5 M in hexane). The reaction was warmed to 15 ° C and then cooled to -70 ° C. A suspension of A-6 (0.637 mmol, 300 mg) in THF (1.5 mL) was added dropwise to give a light yellow suspension. After stirring at -70 ° C for 30 minutes, a solution of compound 29-4 (700 μmol, 218 mg) in THF (1.5 mL) was added over 5 min (slightly exothermic, keeping the internal temperature <-70 ° C). The reaction was stirred at 15 ° C for 12 hours. The reaction was quenched with saturated NH4Cl (30 mL) and extracted with EtOAc (3x10 mL). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated to give compound 29-5 (400 mg, crude) as a light yellow foam, which was used directly in the next step.

[0528] Synthesis of compound 49. At 55 ° C, Mg powder (940 mg, 39.2 mmol) was added to a solution of compound 29-5 (400 mg, 0.654 mmol) in MeOH (5 mL). The mixture was stirred at 55 ° C for 16 hours. The mixture was quenched with HCl (30 mL, 1 N) until the mixture became clear and extracted with DCM (3x10 mL). The combined organic phase was washed with saturated NaHCO (20 mL), dried with Na2SO4, filtered, concentrated and purified by Combi-flash (0-15% EtOAc in PE) to give compound 49 (80 mg, 26%) as an off-white solid.

[0529] 1 H NMR(400MHz, CDCl3)δ.5.31-5.30(m,1H),3.96-3.95(m,1H),2.43-2.40(m,1H), 2.23-2.15(m,1H),2.05-1.91(m,3H),1.90-1.62(m,4H),1.61-1.58(m,3H),1.56 -1.42 (m, 7H), 1.41-1.36 (m, 1H), 1.33-1.22 (m, 2H), 1.20-1.16 (m, 5H), 1.15-1.10 (m, 4H), 1.09-1.07 (m, 1H), 1.06-1.03 (m, 4H), 1.02-0.93 (m, 4H), 0.68 (s, 3H). LCMS Rt = 1.295 min in 2 min chromatography, 30-90 AB_ELSD, MS ESI C 28 H 44 F3O[M+H-H2O] + The calculated value is 453 and the measured value is 453.

[0530] Synthesis of compounds 50 and 51. Compound 49 (55 mg, 0.116 mmol) was separated by SFC (column: AD (250 mm*30 mm, 5 um), gradient: (A=0.05% NH3 / H2O, B=MeOH) flow rate: 120 mL / min) to give compound 50 (15 mg, 27%) and compound 51 (11 mg, 20%) as off-white solids.

[0531] Compound 50: 1H NMR (400MHz,CDCl3)δ.5.31-5.30(m,1H),3.96-3.95(m,1H),2.43-2.40(m,1H),2.23-2.15(m,1H),2.05-1.91(m,3H),1.90-1.58(m,3H),1.56-1.45(m,7H),1.44-1.35(m,5H),1.34-1.20(m,1H),1.19-1.11(m,10H),1.10-0.85(m,9H),0.68(s,3H).LCMS Rt=1.292min in 2min chromatogram,30-90AB_ELSD,MS ESI C 28 H 44 F3O[M+H-H2O] + The calculated value is 453, the found value is 453. SFC Rt = 5.077 min in 10 min chromatogram, AD_3_MeOH_DEA_5_40_25ML, (UV210nm).

[0532] Compound 51: 1 H NMR (400 MHz, CDCl3) δ.5.31-5.30 (m, 1H), 3.96-3.95 (m, 1H), 2.43-2.40 (m, 1H), 2.23-2.15 (m, 1H), 2.05-1.91 (m, 3H), 1.90-1.58 (m, 6H), 1.56-1.36 (m, 8H), 1.35-1.22 (m, 3H), 1.20-1.11 (m, 9H), 1.10-0.97 (m, 5H), 0.96-0.90 (m, 4H), 0.68 (s, 3H). LCMS Rt = 1.294 min in 2 min chromatography, 30-90 AB_ELSD, MS ESI C 28 H 44 F3O[M+H-H2O] + The calculated value is 453, the found value is 453. SFC Rt = 5.412 min in 10 min chromatogram, AD_3_MeOH_DEA_5_40_25ML, (UV210nm).

[0533] Example 32. Synthesis of compounds 52, 53 and 54.

[0534]

[0535] Step 1. To a solution of diisopropylamine (781 mg, 7.72 mmol) in THF (8 mL) was added n-BuLi solution (2.8 mL, 2.5 M in hexane, 7.10 mmol) dropwise at -78 °C under nitrogen. The mixture was warmed to 0 °C. To a suspension of 32-1 (1.5 g, 3.09 mmol) in THF (15 mL) was added a freshly prepared LDA solution. The mixture was stirred at -78 °C for 30 minutes. A solution of 2-(2,2,2-trifluoroethyl)oxirane (583 mg, 4.63 mmol) in THF (6 mL) was added. The mixture was stirred at -78 °C for 30 minutes and warmed to 25 °C and stirred for 48 hours. At 15 °C, the reaction mixture was quenched by water (100 mL) and HCl (1 M, aqueous solution) until pH = 5. The mixture was extracted with EtOAc (500 mL). The separated organic phase was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash column (10-50% EtOAc in PE) to give 32-2 (1.4 g, 74%) as an off-white solid which was used directly.

[0536] Step 2. At 60 ° C and nitrogen, Mg powder (1.64 g, 68.7 mmol) was added to a solution of 32-2 (1.4 g, 2.29 mmol) in 20 mL of anhydrous MeOH. At 10 ° C, the reaction mixture was quenched by 2M HCl (250 mL) until the solid dissolved. After extraction with EtOAc (400 mL), the organic layer was washed with saturated NaHCO3 (50 mL), brine (50 mL), dried with Na2SO4, filtered and concentrated. The residue was purified by flash column and eluted with PE / EtOAc=20:1-5:1 to give compound 52 (510 mg, 47%) as an off-white solid.

[0537] 1 H NMR (400 MHz, CDCl3) δ 5.30-5.28 (m, 1H), 3.98-3.96 (m, 1H), 2.35-2.25 (m, 3H), 2.05-2.00 (m, 6H), 1.96-1.60 (m, 6H), 1.57-1.04 (m, 11H), 1.03-0.92 (m, 8H), 0.86-0.83 (m, 6H), 0.68 (s, 3H). LCMS Rt = 1.299 min in 2 min chromatography, 30-90 AB, MS ESI C 28 H 44 F3O[M+H-H2O] + The calculated value is 453 and the measured value is 453.

[0538] Step 3. Compound 52 (510 mg, 1.08 mmol) was purified and separated by SFC (column: AD (250 mm*30 mm, 5 um); mobile phase: supercritical CO2 / MeOH+NH3H2O=40 / 40; flow rate: 60 ml / min; wavelength: 220 nm) to obtain compound 53 (208 mg, 41%) as an off-white solid and compound 54 (212 mg, 42%) as an off-white solid.

[0539] Compound 53: 1 H NMR (400MHz, CDCl3) δ5.29-5.27(m,1H),3.96-3.93(m,1H),2.40-2.20(m,3H),2.06-1.92(m,3H),1.88-1.59(m,6H ),1.52-1.34(m,8H),1.33-1.22(m,2H),1.05-1.00(m,10H),0.96-0.93(m,5H),0.85(t,J=7.6Hz,3H),0.68(s,3H)

[0540] LCMS Rt=1.304min in 2min chromatogram, 30-90AB, MS ESI C 28 H 44 F3O

[0541] [M+H-H2O] + The calculated value is 453 and the measured value is 453.

[0542] Compound 54: 1 H NMR (400 MHz, CDCl3) δ 5.29-5.27 (m, 1H), 4.00-3.95 (m, 1H), 2.41-2.16 (m, 3H), 2.08-1.79 (m, 4H), 1.77-1.68 (m, 2H), 1.67-1.56 (m, 4H), 1.52-1.34 (m, 9H), 1.32-1.16 (m, 3H), 1.16-0.96 (m, 8H), 0.94-0.92 (m, 4H), 0.85 (t, J = 7.6 Hz, 3H), 0.68 (s, 3H). LCMS Rt = 1.305 min in 2 min chromatography, 30-90 AB, MS ESI C 28 H 44 F3O[M+H-H2O] + The calculated value is 453 and the measured value is 453.

[0543] Example 33. Synthesis of Compound 55.

[0544]

[0545] Pd / C (anhydrous, 10%, 350 mg) was added to a solution of compound 54 (186 mg, 0.395 mmol) in MeOH (20 mL) under argon. After degassing with nitrogen three times, the reaction mixture was degassed with hydrogen three times. The reaction mixture was stirred at 55 ° C in hydrogen (50 Psi) for 16 hours. The catalyst was removed by suction filtration, and the filtrate was concentrated to give a crude product, which was purified by silica gel column (EtOAc in PE, 10%-15%) to give compound 55 (26 mg, 13%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 4.00-3.94 (m, 1H), 2.33-2.22 (m, 2H), 1.97-1.93 (m, 1H), 1.92-1.81 (m, 2H), 1.80-1.58 (m, 4H), 1.55-1.26 (m, 8H), 1.24-1.20 (m, 11H), 1.19-0.93 (m, 11H), 0.82 (s, 3H), 0.67-0.61 (m, 4H). LCMS Rt = 1.273 min in 2 min chromatogram, 30-90 AB, MS ESI C 28 H 46 F3O[M+H-H2O] + The calculated value is 455 and the measured value is 455.

[0546] Example 34. Synthesis of Compound 56.

[0547]

[0548] Pd / C (anhydrous, 10%, 350 mg) was added to a solution of compound 53 (183 mg, 0.389 mmol) in MeOH (20 mL) under argon. After degassing with nitrogen 3 times, the reaction mixture was degassed with hydrogen 3 times. The reaction mixture was stirred at 55 ° C in hydrogen (50 Psi) for 16 hours. The catalyst was removed by suction filtration, and the filtrate was concentrated to give a crude product, which was purified by silica gel column (EtOAc in PE, 10%-15%) to give compound 56 (20 mg, 10%) as an off-white solid.

[0549] 1H NMR (400MHz, CDCl3) δ 3.96-3.93 (m, 1H), 2.30-2.20 (m, 2H), 1.97-1.93 (m, 1H), 1.92-1.81 (m, 2H), 1.80-1.58 (m, 4H), 1.55-1.26 (m, 8H), 1.24-1.20 (m, 11H), 1.19-0.93 (m, 11H), 0.82 (s, 3H), 0.66-0.64 (m, 4H). LCMS Rt = 1.268 min in 2 min chromatogram, 30-90AB, MS ESIC 28 H 46 F3O[M+H-H2O] + The calculated value is 455 and the measured value is 455.

[0550] Example 35. Synthesis of compounds 57 and 58.

[0551]

[0552] Step 1. At 60 ° C, a solution of bromocyclobutane (2.5 g, 18.5 mmol) in THF (4 mL) was added to a suspension of Mg (1 g, 41.1 mmol) and I2 (10 mg) in THF (1 mL). The mixture was stirred at 60 ° C for 1 h. Then, at 0 ° C, a solution of cyclobutylmagnesium bromide (18.55 mmol in 15 mL THF) was added to a solution of 9-6 (0.5 g, 1.29 mmol) in THF (10 mL). The mixture was stirred at 0 ° C for 1 h and quenched with NH4Cl (10 mL, saturated aqueous solution). The mixture was extracted with EtOAc (30 mL). The organic layer was separated, concentrated in vacuo, and purified by silica gel purification (PE / EtOAc=10 / 1 to 7 / 1) to give a crude product, which was recrystallized from MeCN (50 mL) to give 35-1 (100 mg, 18%, 50 mg sent as a sample) as an off-white solid. 1 H NMR (400MHz,CDCl3)δ5.33-5.21(m,1H),3.50-3.38(m,1H),2.42-2.24(m,2H),2.09-1.61(m,13H),1.55-1.21(m,13H),1.20-0.89(m,14H),0.85(t,J=7.6Hz,3H),0.70-0.64(m,3H).LCMS Rt=1.612min in 2.0min chromatogram,30-90AB_E,weak MS.MS MS ESI C 30 H 49 O[M+H-H2O] +The calculated value is 425.3778 and the measured value is 425.3779.

[0553] Step 2. 440 mg of 35-1 was separated by SFC (equipment: SFC-14; method: column: AD (250 mm * 30 mm, 5 um); condition: 0.1% NH3H2O ​​EtOH; B at the beginning: 40%; B at the end: 40%; gradient time (min): 100% B maintenance time (min): flow rate (ml / min): 60ML / MIN; injection: 160) to give compound 57 (100 mg, 23%, 50 mg sample) and compound 58 (130 mg, SFC impure). Impure compound 57 (130 mg) was purified by SFC (column: AD (250 mm * 30 mm, 5 um); condition: 0.1% NH3H2O ​​ETOH, 40% B; flow rate (ml / min): 60) to give compound 58 (112 mg, 26%), which was an off-white solid.

[0554] Compound 57: 1 H NMR (400MHz, CDCl3) δ5.35-5.22 (m, 1H), 3.480-3.37 (m, 1H), 2.40-2.28 (m, 2H), 2.09-1.61 (m, 13H), 1.55-1.21 (m, 13H), 1.20-0.89 (m, 14H), 0.85 (t, J = 7.6 Hz, 3H), 0.67 (s, 3H). HPLC Rt = 5.51 min in 8.0 min chromatogram, 50-100_AB_E. MS MS ESIC 30 H 49 O[M+H-H2O] + The calculated value is 425.3778 and the measured value is 425.3770.

[0555] Compound 58: 1 H NMR (400MHz,CDCl3)δ5.35-5.22(m,1H),3.480-3.37(m,1H),2.40-2.28(m,2H),2.09-1.61(m,13H),1.55-1.21(m,14H),1.20-0.89(m,13H),0.85(t,J=7.6Hz,3H),0.68(s,3H).LCMS Rt=1.361min in 2.0min chromatogram,30-90AB_E,MS ESI C30H47[M+H-2H2O] + The calculated value is 407 and the measured value is 407.

[0556] Example 36. Synthesis of compounds 36-6, 59, 59-A, 59-B, 60, 60-A and 60-B.

[0557]

[0558]

[0559] Step 1. At 30 ° C, DMP (43.2 g, 102 mmol) was added to a solution of 16-1 (20 g, 51.4 mmol) in DCM (200 mL). The reaction mixture was stirred at 30 ° C for 1 h. The reaction mixture was quenched with saturated NaHCO3 aqueous solution (100 mL). The mixture was filtered. The DCM layer was separated and the aqueous phase was extracted with DCM (100 mL). The combined organic phase was washed with saturated Na2S2O3 aqueous solution (150 mL), brine (150 mL), dried over Na2SO4, filtered and concentrated to give 36-1 (20 g, crude), which was a yellow solid. 1 H NMR (400MHz, CDCl3) δ5.37-5.31(m,1H),3.66(s,3H),3.32-3.24(m,1H),2.86-2.78(m,1H),2.49-2.19(m,5H),2.08-2.02 (m,3H),1.91-1.75(m,2H),1.55-1.39(m,5H),1.38-1.27(m,5H),1.20-1.01(m,5H),0.94-0.91(m,3H),0.73-0.66(m,4H).

[0560] Step 2. Trimethylaluminum (2M in toluene, 77.5 mL, 155 mmol) was added dropwise to a solution of BHT (73.9 g, 336 mmol) in anhydrous toluene (100 mL) at 0°C and nitrogen. The mixture was stirred at 15°C for 1 hour and cooled to -70°C. A solution of 36-1 (20 g, 51.7 mmol) in toluene (50 mL) was added below -60°C. The resulting mixture was stirred at -70°C for 1 hour. Ethylmagnesium bromide (51.6 mL, 3.0 M in ether, 155 mmol) was added dropwise below -60°C. The reaction mixture was stirred at -70°C for another 1 hour. At -70°C, the reaction mixture was quenched by saturated citric acid (400 mL). The mixture was slowly warmed to 15°C and extracted with ethyl acetate (3x400 mL). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by Combi-flash (0% to 20% EtOAc in PE) to give 36-2 (13 g, 60%) as an off-white solid. 1HNMR(400MHz, CDCl3)δ5.31-5.25(m,1H),3.66(s,3H),2.47-2.16(m,4H),2.07-1.69(m,6H),1.66-1 .59(m,3H),1.55-1.38(m,6H),1.36-1.23(m,4H),1.20-1.00(m,7H),0.98-0.81(m,7H),0.67(s,3H).

[0561] Step 3. LiAlH4 (3.41 g, 90.0 mmol) was added portionwise to a solution of 36-2 (25 g, 60.0 mmol) in THF (500 mL) at 0°C under nitrogen. The reaction was stirred at 0°C for 30 min. The reaction was quenched with 1M HCl (300 mL) and extracted with EtOAc (3x300 mL) at 0°C. The combined organic phases were washed with brine (500 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by Combi-flash (0% to 20% EtOAc in PE / DCM (v / v=1 / 1)) to give 36-3 (3 g, pure) and (10 g, impure) as off-white solids. 1 H NMR (400MHz, CDCl3) δ5.34-5.24(m,1H),3.67-3.55(m,2H),2.41-2.30(m,1H),2.07-1.91(m,3H),1.88-1.60(m,5H ),1.55-1.33(m,10H),1.30-1.20(m,3H),1.17-1.01(m,8H),1.00-0.89(m,5H),0.85(t,J=7.4Hz,3H),0.68(s,3H).

[0562] Step 4. At 20 ° C, DMP (6.52 g, 15.4 mmol) was added to a solution of 36-3 (3 g, 7.71 mmol) in DCM (100 mL). The reaction mixture was stirred at 20 ° C for 10 min. At 20 ° C, the reaction mixture was quenched with saturated NaHCO3 aqueous solution (100 mL). The mixture was filtered. The DCM layer was separated and the aqueous phase was extracted with DCM (50 mL). The combined organic phase was washed with saturated Na2S2O3 aqueous solution (150 mL), brine (150 mL), dried over Na2SO4, filtered and concentrated to give 36-4 (3 g, crude), which was an off-white solid. 1H NMR (400MHz, CDCl3) δ9.80-9.73(m,1H),5.32-5.24(m,1H),2.51-2.29(m,3H),2.07-1.93(m,3H),1.88-1.70(m,3 H),1.65-1.57(m,4H),1.50-1.24(m,10H),1.21-1.04(m,5H),1.02-0.96(m,1H),0.98-0.82(m,8H),0.68(s,3H).

[0563] Step 5. To a vigorously stirred suspension of Mg (1.76 g, 72.8 mmol) wood shavings and iodine (46.1 mg, 0.182 mmol) in THF (2 mL) was added 1,2-dibromoethane (68.3 mg, 0.364 mmol) and 10% 4-chlorotetrahydro-2H-pyran (4.4 g, 36.4 mmol) in THF (18 mL) under nitrogen. The mixture was heated to 60°C, the reaction mixture became clear and the Grignard reaction started to occur, and the remaining 4-chlorotetrahydro-2H-pyran in THF was slowly added over 30 minutes. The reaction mixture was stirred at 65°C for 2 h to give a solution of (tetrahydro-2H-pyran-4-yl)magnesium chloride in THF (~2 M). The Grignard solution was used without any further purification. At 15 ° C and nitrogen, a solution of 36-4 (800 mg, 2.06 mmol) in THF (150 mL) was added to the Grignard reagent at one time. After stirring at 15 ° C for 2 min, the mixture was quenched by 200 mL of saturated NH4Cl and extracted with 200 mL of EtOAc. The separated organic phase was washed with 200 mL of brine, dried with Na2SO4, filtered and concentrated. The residue was purified by Combi-flash (0% to 30% of EtOAc in PE / DCM (v / v=1 / 1)) to give 36-5 (550 mg, 56%), which was an off-white solid, and 50 mg of 36-5 was sent for sample. 1H NMR (400MHz,CDCl3)δ5.32-5.25(m,1H),4.06-3.96(m,2H),3.42-3.29(m,3H),2.39-2.33(m,1H),2.07-1.79(m,6H),1.77-1.60(m,7H),1.51-1.38(m,10H),1.35-1.21(m,4H),1.16-1.01(m,8H),0.97-0.90(m,4H),0.85(t,J=7.4Hz,3H),0.71-0.66(m,3H).LCMS Rt=1.212min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 31 H 51 O2[M+H-H2O] + The calculated value is 455 and the measured value is 455.

[0564] Step 5. 36-5 (500 mg, 1.05 mmol) was purified by SFC (column: AD (250 mm*30 mm, 5 um); conditions: 0.1% NH3H2O ​​IPA; gradient 40% B; gradient time (min): 30; flow rate (ml / min): 60.) to give compound 59 (210 mg, 42%, 50 mg for sample delivery) as an off-white solid and compound 60 (200 mg, 40%, 45 mg for sample delivery) as an off-white solid.

[0565] Compound 59 (peak 1): 1 H NMR (400MHz,CDCl3)δ5.32-5.25(m,1H),4.06-3.96(m,2H),3.43-3.29(m,3H),2.40-2.32(m,1H),2.07-1.79(m,4H),1.77-1.60(m,4H),1.55-1.35(m,14H),1.34-1.17(m,5H),1.15-0.90(m,12H),0.85(t,J=7.4Hz,3H),0.68(s,3H).LCMS Rt=1.221min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 31 H 51 O2[M+H-H2O] + The calculated value is 455 and the measured value is 455.

[0566] Compound 60 (peak 2): 1H NMR (400MHz,CDCl3)δ5.31-5.26(m,1H),4.06-3.96(m,2H),3.43-3.29(m,3H),2.40-2.33(m,1H),2.07-1.93(m,4H),1.88-1.61(m,9H),1.54-1.38(m,9H),1.34-1.06(m,8H),1.05-0.90(m,9H),0.85(t,J=7.4Hz,3H),0.68(s,3H).LCMS Rt=1.218min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 31 H 51 O2[M+H-H2O] + The calculated value is 455 and the measured value is 455.

[0567] Step 6. Anhydrous Pd / C (300 mg) was added to a solution of compound 59 (150 mg, 0.317 mmol) in MeOH (5 mL) and THF (5 mL) at 15 ° C. The mixture was degassed and purged with hydrogen several times, then stirred at 55 ° C for 72 hours in 50 psi hydrogen. The reaction mixture was filtered through a celite pad and washed with THF (2x5 mL). The filtrate was concentrated. The residue was purified by Combi-flash (0-30% EtOAc in PE / DCM (v / v=1 / 1)) to give compound 59-A (20 mg, 13%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 4.06-3.94 (m, 2H), 3.43-3.27 (m, 3H), 2.00-1.67 (m, 6H), 1.55-1.48 (m, 4H), 1.45-1.32 (m, 13H), 1.29-1.12 (m, 11H), 1.07-0.89 (m, 12H), 0.65 (s, 3H). LCMS Rt = 1.261 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 31 H 51 O[M+H-2H2O] + The calculated value is 439 and the measured value is 439.

[0568] Step 7. Anhydrous Pd(OH)2 (300 mg) was added to a solution of compound 59 (50 mg, 0.105 mmol) in MeOH (5 mL) and THF (5 mL) at 15 ° C. The mixture was degassed and purged with hydrogen several times, then stirred at 55 ° C for 72 hours in 50 psi hydrogen. The reaction mixture was filtered through a celite pad and washed with THF (2x5 mL). The filtrate was concentrated. The residue was purified by Combi-flash (0% to 30% EtOAc in PE / DCM (v / v=1 / 1)) to give compound 59-B (10 mg, 20%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 4.05-3.95 (m, 2H), 3.42-3.29 (m, 3H), 1.99-1.91 (m, 1H), 1.89-1.58 (m, 6H), 1.56-1.35 (m, 14H), 1.33-1.16 (m, 8H), 1.14-0.95 (m, 6H), 0.94-0.80 (m, 10H), 0.69-0.58 (m, 4H). LCMS Rt = 1.253 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 31 H 51 O[M+H-2H2O] + The calculated value is 439 and the measured value is 439.

[0569] Step 8. Anhydrous Pd / C (300 mg) was added to a solution of compound 60 (150 mg, 0.317 mmol) in MeOH (5 mL) and THF (5 mL) at 15 ° C. The mixture was degassed and purged with hydrogen several times, then stirred at 55 ° C for 72 hours in 50 psi hydrogen. The reaction mixture was filtered through a celite pad and washed with THF (2x5 mL). The filtrate was concentrated. The residue was purified by Combi-flash (0% to 30% EtOAc in PE / DCM (v / v=1 / 1)) to give compound 60-A (33 mg) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 4.06-3.95 (m, 2H), 3.43-3.26 (m, 3H), 2.00-1.59 (m, 9H), 1.53-1.35 (m, 11H), 1.34-1.10 (m, 13H), 1.08-0.84 (m, 13H), 0.65 (s, 3H). LCMS Rt = 1.261 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 31 H 51 O[M+H-2H2O] +The calculated value is 439 and the measured value is 439.

[0570] Step 9. Anhydrous Pd / C (300 mg) was added to a solution of compound 60 (150 mg, 0.317 mmol) in MeOH (5 mL) and THF (5 mL) at 15 ° C. The mixture was degassed and purged with hydrogen several times, then stirred at 55 ° C for 72 hours in 50 psi hydrogen. The reaction mixture was filtered to remove Pd / C and the filtrate was concentrated. The residue was purified by Combi-flash (0% to 30% EtOAc in PE / DCM (v / v=1 / 1)) to give compound 60-B (40 mg, 26%) as an off-white solid. 1 HNMR (400MHz,CDCl3)δ4.06-3.95(m,2H),3.43-3.27(m,3H),2.03-1.91(m,1H),1.86-1.74(m,1H),1.72-1.57(m,8H),1.54-1.34(m,10H),1.33-1.15(m,8H),1.15-0.96(m,7H),0.94-0.79(m,10H),0.72-0.56(m,4H).LCMS Rt=1.250min in 2.0min chromatogram,30-90AB,MS ESIC 31 H 51 O[M+H-2H2O] + The calculated value is 439 and the measured value is 439.

[0571] Step 10. Anhydrous Pd / C (300 mg) was added to a solution of 36-5 (150 mg, 0.317 mmol) in MeOH (5 mL) and THF (5 mL) at 15 ° C. The mixture was degassed and purged with hydrogen several times, then stirred at 55 ° C for 72 hours in 50 psi hydrogen. The reaction mixture was filtered through a celite pad and washed with THF (2x5 mL). The filtrate was concentrated. The residue was purified by Combi-flash (0% to 30% EtOAc in PE / DCM (v / v=1 / 1)) to give 36-6 (30 mg) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 4.07-3.94 (m, 2H), 3.43-3.25 (m, 3H), 2.00-1.59 (m, 7H), 1.50-1.36 (m, 11H), 1.34-1.10 (m, 15H), 1.07-0.82 (m, 13H), 0.65 (s, 3H). LCMS Rt = 1.261 min in 2.0 min chromatogram, 30-90 AB, MS ESI C 31 H51 O[M+H-2H2O] + The calculated value is 439 and the measured value is 439.

[0572] Example 37. Alternative Synthesis of 10, 11, 13 and 15.

[0573]

[0574] Step 2. At 30 ° C, 37-1 (200 g, 636 mmol) / DCM (2.2 L) was added to a mixture of DMP (539 g, 1271 mmol) in DCM (800 mL). The reaction mixture was stirred at 40 ° C for 1 h. At 10 ° C, the reaction mixture was quenched with saturated NaHCO3 aqueous solution (1.2 L). The mixture was filtered. The DCM phase in the filtrate was separated, washed with saturated NaHCO3 / Na2S2O3 aqueous solution (1: 1, 2x1L), brine (1L), dried over Na2SO4, filtered and concentrated in vacuo to give a yellow solid, which was ground in MeCN (700 mL) to give 37-2 (115 g, 58%) as an off-white solid.

[0575] 1 H NMR (400MHz, CDCl3) δ5.38-5.31(m,1H),4.86(s,1H),4.72(s,1H),3.28(dd,J=2.8, 16.8Hz,1H),2.82(dd,J=1.6,16.8Hz,1H),2.56-2.40(m,1H),2.35-2.24(m,1H),2.1 1-1.99(m,3H),1.95-1.85(m,1H),1.85-1.77(m,1H),1.76(s,3H),1.73-1.61(m,3H) ,1.56-1.39(m,3H),1.31-1.19(m,2H),1.19(s,3H),1.18-0.99(m,3H),0.61(s,3H).

[0576] Step 3. AlMe3 (459 mL, 2M, 919 mmol) was added dropwise to a mixture of BHT (405 g, 1839 mmol) in toluene (400 mL) at 0°C. The resulting mixture was stirred at 15°C for 1 h. A suspension of 37-2 (115 g, 368 mmol) in toluene (500 mL) was added dropwise at -70°C. The mixture was stirred at -70°C for 1 h. EtMgBr (368 mL, 3M, 1104 mmol) was added dropwise at -70°C. The reaction mixture was stirred at -70°C for 1 h. The reaction mixture was poured into a saturated aqueous solution of citric acid (2 L). The aqueous solution was extracted with ethyl acetate (2x1.5 L). The combined organics were washed with brine (2 L), dried over Na2SO4, filtered and concentrated in vacuo to give an off-white solid, which was purified by recrystallization in MeCN (900 mL) to give 37-3 (80 g, 63%) as an off-white solid. The filtrate was concentrated in vacuo to give a solid, which was purified by silica gel chromatography (PE:EtOAc=20:1) to give an off-white solid, which was further purified by recrystallization in MeCN (150 mL) to give 37-3 (17 g, 14%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.34-5.24(m,1H),4.85(s,1H),4.71(s,1H),2.40-2.33(m,1H),2.07-1.94(m,3H),1.91-1.82(m,3H),1.8 2-1.73(m,4H),1.73-1.52(m,8H),1.50-1.32(m,4H),1.29-1.05(m,5H),1.05-0.90(m,1H),0.85(t,J=7.6Hz,3H),0.58(s,3H).

[0577] Step 4. THF (650 mL) was added to a mixture of 37-3 (97 g, 283 mmol) and 9-BBN dimer (79 g, 324 mmol) at 15 °C and nitrogen. The reaction mixture was stirred at 30 °C for 1 h. The mixture was cooled to 15 °C. Ethanol (129 g, 2.83 mmol) was added at 15 °C. NaOH aqueous solution (478 mL, 5 M, 2390 mmol) was added dropwise at 15 °C. H2O2 (320 g, 30%, 2.83 mmol) was added dropwise at 15 °C. The resulting mixture was stirred at 60 °C for 1 h. The reaction mixture was cooled to 20 °C. An off-white solid was produced. The solid was filtered and washed with water (2x800 mL). The combined solid was purified by grinding in MeCN (200 mL) to give 15-3a-1 (91 g, impure) as an off-white solid. 1H NMR (400MHz, CDCl3) δ5.32-5.23(m,1H),3.67-3.60(m,1H),3.42-3.33(m,1H),2.40-2.33(m,1H),2.08-1.90(m,3H),1.89-1.69(m,2H),1.66- 1.60(m,3H),1.56-1.24(m,9H),1.23-1.07(m,5H),1.05(d,J=6.8Hz,3 H), 1.03 (s, 3H), 1.02-0.90 (m, 2H), 0.85 (t, J = 7.2Hz, 3H), 0.70 (s, 3H).

[0578] Step 5. At 15 ° C, TsCl (132.2 g, 694 mmol) was added to a solution of 37-4 (91 g, 252 mmol) in chloroform (500 mL) and pyridine (350 mL). The mixture was stirred at 15 ° C for 2 hours. The combined reaction mixture was concentrated in vacuo to remove most of the chloroform. Water (3 L) was added to the resulting pyridine mixture. An off-white solid was produced, which was filtered to obtain an off-white solid, which was washed with water (6x4 L). The off-white solid was dissolved in DCM (3.5 L), dried with Na2SO4, filtered and concentrated in vacuo to obtain 37-5 (127 g, 98%), which was an off-white solid. 1 H NMR (400MHz, CDCl3) δ7.78(d,J=8.4Hz,2H),7.34(d,J=8.0Hz,2H),5.30-5.20(m,1H),4.00-3.90(m,1H),3.80-3.70(m,1H),2.45(s, 3H),2.40-2.30(m,1H),2.10-1.90(m,3H),1.75-1.60(m,6H),1.55-1.30(m,5H),1.25-0.95(m,13H),0.90-0.80(m,5H),0.64(s,3H).

[0579] Step 6. KI (196 g, 1.18 mol) was added to a solution of 37-5 (127 g, 246 mmol) in DMF (1 L) at 15 °C. The mixture was stirred at 50 °C for 1 h. PhSO2Na (148 g, 737 mmol) was added to the resulting mixture. The mixture was stirred at 50 °C for 16 hours. The reaction mixture was poured into water (4 L) and some yellow solids were produced. The mixture was filtered. The filter cake was washed with water (3x2 L). The resulting filter cake was dissolved in DCM (3 L), washed with water (3x1 L), brine (2x2 L), dried with Na2SO4, filtered, and concentrated in vacuo to give a crude product as a yellow solid, which was recrystallized in MeCN (400 mL) to give 32-1 (45 g, 34%) as a light yellow solid. 1 H NMR (400MHz, CDCl3) δ7.95-7.88(m,2H),7.68-7.62(m,1H),7.61-7.53(m,2H),5.30-5.22(m,1H),3.20-3.08(m,1H),2.91-2.79(m,1 H),2.40-2.30(m,1H),2.09-1.87(m,4H),1.74-1.60(m,4H),1.50-1.36(m,7H),1.24-0.98(m,13H),0.90-0.80(m,4H),0.65(s,3H).

[0580] Step 7. At -70 ° C and nitrogen, n-BuLi (27.1 mL, 2.5M, 67.9 mmol) was added to a solution of diisopropylamine (7.28 g, 72.1 mmol) in THF (20 mL). The resulting mixture was stirred at 0 ° C for 30 min. The mixture was cooled to -70 ° C again. At -70 ° C, 32-1 (10 g, 20.6 mmol) / THF (50 mL) was added to the mixture. The reaction mixture was stirred at -70 ° C for 1 h. At -70 ° C, 2-isopropyloxirane (2.12 g, 24.7 mmol) / THF (10 mL) was added. The reaction mixture was slowly warmed to 15 ° C and stirred at 15 ° C for 16 hours. At 0 ° C, the reaction mixture was quenched with saturated NH4Cl aqueous solution (100 mL). The mixture was extracted with EtOAc (2x200 mL). The combined organic phases were washed with brine (150 mL), dried over Na2SO4, filtered and concentrated in vacuo to give 37-6 (12 g, crude) as a yellow solid. LCMS Rt = 3.784 & 3.859 min in 7 min chromatography, 30-90 AB_7MIN_E.M, MS ESI C 35 H 53 O3S[M+H-H2O] +The calculated value is 553 and the measured value is 553.

[0581] Step 8. Under stirring, at 50 ° C and nitrogen, Mg powder (30.6 g, 1260 mmol) and NiCl2 (27.0 mg, 0.21 mmol) were added to a solution of 37-6 (12 g, 21.0 mmol) in 200 mL of anhydrous MeOH to induce continuous hydrogen generation. The reaction mixture was quenched by 2M HCl (100 mL) until the solid dissolved. The mixture was extracted with EtOAc (3x200 mL). The combined organic layer was washed with saturated NaHCO3 (50 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography, eluting with PE / EtOAc=20 / 1-8 / 1 to give 5.6 g of an off-white solid, which was purified by SFC (column: Chiralpak AD 250×30 mm ID, 5 um mobile phase: A: CO2 B: methanol (0.1% NH3H2O) gradient: from 35% to 35% B, flow rate: 60 mL / min) to give compound 10 (2.2 g, 24%), compound 11 (2.2 g, 24%) as an off-white solid.

[0582] Compound 10: 1 H NMR (400MHz,CDCl3)δ5.32-5.23(m,1H),3.38-3.24(m,1H),2.41-2.32(m,1H),2.10-1.92(m,3H),1.91-1.78(m,1H),1.76-1.58(m,6H),1.53-1.22(m,11H),1.19-0.98(m,9H),0.98-0.80(m,14H),0.68(s,3H).LCMS Rt=1.346min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0583] Compound 11: 1H NMR (400MHz,CDCl3)δ5.32-5.23(m,1H),3.38-3.24(m,1H),2.41-2.32(m,1H),2.10-1.92(m,3H),1.91-1.78(m,1H),1.76-1.55(m,6H),1.50-1.22(m,11H),1.19-0.98(m,9H),0.98-0.80(m,14H),0.68(s,3H).LCMS Rt=1.344min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 29 H 47 [M+H-2H2O] + The calculated value is 395 and the measured value is 395.

[0584] Step 8A. Pd / C (anhydrous, 10%, 5 g) was added to a solution of compound 10 (1.6 g, 3.71 mmol) in MeOH / THF (130 mL / 20 mL) under argon. After degassing with nitrogen three times, the reaction mixture was degassed with hydrogen three times. The reaction mixture was stirred at 55 ° C in hydrogen (50 Psi) for 16 h. The catalyst was removed by suction filtration, and the filtrate was concentrated to give a crude product, which was purified by silica gel column (EtOAc in PE, 5%-10%) to give compound 13 (815 mg, 50%) as an off-white solid. 1 HNMR (400MHz,CDCl3)δ3.31-3.30(m,1H),2.00-1.92(m,1H),1.89-1.78(m,1H),1.58(m,5H),1.57-1.48(m,3H),1.47-1.30(m,8H),1.30-1.16(m,7H),1.15-0.94(m,6H),0.93-0.85(m,13H),0.82(s,3H),0.70-0.60(m,4H).LCMS Rt=1.392min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 29 H 49 [M+H-2H2O] + The calculated value is 397 and the measured value is 397.

[0585] Step 8B. A mixture of compound 11 (1.6 g, 3.71 mmol) and Pd / C (5 g, 10%, anhydrous) in ethyl acetate (250 mL) was stirred at 50 ° C and hydrogen (50 psi) for 16 hours. The reaction mixture was filtered. The filter cake was washed with THF (4x20 mL). The combined filtrate was concentrated in vacuo to give a solid, which was purified by silica gel chromatography (PE: EtOAc = 20: 1) to give compound 15 (974 mg, 61%) as an off-white solid. 1 H NMR (400MHz,CDCl3)δ3.31-3.30(m,1H),2.00-1.92(m,1H),1.89-1.78(m,1H),1.69-1.58(m,5H),1.57-1.48(m,3H),1.47-1.30(m,8H),1.30-1.16(m,7H),1.15-0.94(m,6H),0.93-0.85(m,13H),0.82(s,3H),0.70-0.60(m,4H).LCMS Rt=1.389min in 2min chromatogram,30-90AB_2MIN_E.M,MS ESI C 29 H 49 [M+H-2H2O] + The calculated value is 397 and the measured value is 397.

[0586] Example 38. Synthesis of Compounds 66, 67, 68, and 69.

[0587]

[0588] Step 1. At 0 ° C, NaBH4 (0.21 g, 5.7 mmol) was added to a solution of compound 38-1 (1.0 g, 2.60 mmol) in MeOH (15 mL) in portions. The reaction mixture was then warmed to room temperature and stirred for 2 hours. The reaction mixture was quenched with saturated NH4Cl aqueous solution (5 mL) and extracted with CH2Cl2 (3x20 mL). The organic layer was washed with brine, dried with Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (PE / EtOAc=15 / 1 to 10 / 1) to obtain the desired product (0.82 g, 82%), which was an off-white powder. 1H NMR (400MHz, CDCl3) δ5.35-5.29(m,1H),3.76-3.73(m,1H),2.45-2.40(m,1H),2.01-1.95(m,3H),1.94-1.68(m ,4H),1.67-1.53(m,4H),1.51.63-1.19(m,18H),1.18(s,3H),1.02(s,3H),0.95(d,J=6.4Hz,3H),0.68(s,3H).

[0589] Step 2. A solution of 38-1 (0.6 g, 15.4 mmol) in MeOH (20 mL) was purified by prep-SFC to give compound 66 (180 mg, 30%) and compound 67 (240 mg, 40%). The absolute configurations of compound 66 and compound 67 were confirmed by the Mosher method.

[0590] 1 H NMR (Compound 66): (400 MHz, CDCl3) δ 5.35-5.28 (m, 1H), 3.80-3.70 (m, 1H), 2.48-2.38 (m, 1H), 2.07-1.65 (m, 10H), 1.65-1.20 (m, 13H), 1.20-0.95 (m, 12H), 0.95 (d, J = 6.8 Hz, 3H), 0.63 (s, 3H).

[0591] 1 H NMR (Compound 67): (400 MHz, CDCl3) δ 5.34-5.28 (m, 1H), 3.80-3.70 (m, 1H), 2.47-2.40 (m, 1H), 2.04-1.93 (m, 2H), 1.93-1.68 (m, 2H), 1.68-1.21 (m, 15H), 1.20-0.96 (m, 16H), 0.95 (d, J = 6.8 Hz, 3H), 0.68 (s, 3H).

[0592] Step 3A. In nitrogen, 5% Pd / C (56 mg) was added to a solution of compound 66 (140 mg, 0.36 mmol) in EtOAc (5 mL). The suspension was degassed in vacuo and purged with hydrogen several times. The mixture was then stirred at 50 ° C for 12 hours in hydrogen (50 psi). The mixture was filtered through a celite pad and the pad was washed with EtOAc (2x5 mL). The combined filtrate was concentrated to dryness to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc / EtOAc=12 / 1 to 10 / 1) to give compound 68 (80 mg, 57%) and compound 69 (18 mg, 13%), which was an off-white powder.

[0593] 1 H NMR (Compound 68) (400 MHz, CDCl3) δ 3.80-3.70 (m, 1H), 1.98-1.93 (m, 1H), 1.88-1.78 (m, 1H), 1.67-1.27 (m, 16H), 1.24-0.94 (m, 14H), 0.92 (d, J = 6.4 Hz, 3H), 0.80 (s, 3H), 1.07 (s, 3H), 0.62 (m, 4H).

[0594] 1 H NMR (Compound 69) (400 MHz, CDCl3) δ 3.80-3.70 (m, 1H), 1.98-1.95 (m, 1H), 1.95-1.79 (m, 3H), 1.64-1.23 (m, 18H), 1.23-1.00 (m, 14H), 0.96 (s, 3H) 0.92 (d, J = 6.0 Hz, 3H), 0.62 (s, 3H).

[0595] Step 3B. In nitrogen, 5% Pd / C (48 mg) was added to a solution of compound 67 (120 mg, 0.30 mmol) in EtOAc (5 mL). The suspension was degassed in vacuo and purged with hydrogen several times. The mixture was then stirred at 50 ° C for 12 hours in hydrogen (50 psi). The mixture was filtered through a celite pad and the pad was washed with EtOAc (2x5 mL). The combined filtrate was concentrated to dryness to give a crude product, which was purified by column chromatography on silica gel (PE / EtOAc / EtOAc=12 / 1 to 10 / 1) to give compound 70 (78 mg, 65%) and compound 71 (26 mg, 21%), which was an off-white powder.

[0596] Compound 70: 1H NMR: (400MHz, CDCl3) δ3.80-3.70(m,1H),1.98-1.93(m,1H),1.88-1.78(m,1 H),1.67-1.35(m,18H),1.24-0.85(m,19H),0.80(s,3H),0.67-0.61(m,4H).

[0597] Compound 71: 1 H NMR: (400MHz, CDCl3) δ3.80-3.70(m,1H),2.00-1.93(m,1H),1.93-1.77(m,3H),1.67-1.25(m,19H),1.25-0.80(m,18H),0.64(s,3H).

[0598] Example 39. Synthesis of Compounds 72, 73, 74-A, 74-B, 75-A, and 75-B.

[0599]

[0600] Step 1. At -70 ° C and nitrogen, nBuLi (2.06 mL, 2.5 M in hexane, 5.15 mmol) was added dropwise to THF (3 mL), and then a suspension of 32-1 (1 g, 2.06 mmol) in THF (5 mL) was added. After stirring at -70 ° C for 30 min, a solution of 2-(tert-butyl)oxirane (309 mg, 3.09 mmol) in THF (2 mL) was added dropwise. The mixture was stirred at -70 ° C for 30 min and warmed to 20 ° C and stirred at 20 ° C for 16 hours. At 20 ° C, the reaction mixture was quenched by adding 30 mL of saturated NH4Cl. The organic layer was separated. The aqueous phase was extracted with EtOAc (2x30 mL). The combined organic layers were dried over Na 2 SO 4 , filtered, concentrated and purified by Combi-flash (0-15% EtOAc in PE) to give impure 39-1 (700 mg, impure) as an off-white solid.

[0601] Step 2. A solution of 39-1 (700 mg, 1.19 mmol) in MeOH (30 mL) was heated at 55 ° C. Mg powder (1.15 g, 47.5 mml) was added at one time. The mixture was stirred at 55 ° C for 2 hours. The mixture was quenched with HCl (2N, 100 mL) until the reaction mixture became clear and extracted with DCM (3x50 mL). The combined organic phases were washed with saturated NaHCO (100 mL), dried with Na2SO4, filtered, concentrated and purified by Combi-flash (0-15% EtOAc in PE) to give 39-2 (400 mg, 76%) as an off-white solid. 1 H NMR (400MHz, CDCl3) δ5.30-5.29(m,1H),3.18-3.12(m,1H),2.40-2.30(m,1H),2.08-1.80(m,4H),1.76-1.69(m,1H),1.68-1.58(m,2H),1. 56-1.33(m,10H),1.32-1.22(m,5H),1.21-1.05(m,4H),1.02(s,3H), 1.01-0.96(m,5H),0.95-0.83(m,9H),0.82-0.78(m,3H),0.69(s,3H). LCMSt R = 1.375min in 2min chromatography, 30-90AB_ELSD, MSESI C 30 H 49 [M+H-2H2O] + The calculated value is 409 and the measured value is 409.

[0602] Step 3. 350 mg of 39-2 was separated by SFC (column: AD (250 mm*30 mm, 5 um), gradient: 30-30% B (A=0.05% NH3 / H2O, B=MeOH), flow rate: 60 mL / min) to give compound 72 (160 mg, 46%) and compound 73 (120 mg, 34%) as off-white solids.

[0603] Compound 72: 1H NMR (400MHz, CDCl3) δ5.30-5.29(m,1H),3.18-3.12(m,1H),2.40-2.30(m,1H),2.08-1.80(m,4H),1.76-1.69(m,1H),1.68-1.58(m,2H),1. 56-1.33(m,10H),1.32-1.22(m,5H),1.21-1.05(m,4H),1.02(s,3H), 1.01-0.96(m,5H),0.95-0.83(m,9H),0.82-0.78(m,3H),0.69(s,3H). LCMSt R = 1.389min in 2min chromatogram, 30-90AB_ELSD, MS ESIC 30 H 49 [M+H-2H2O] + The calculated value is 409 and the measured value is 409.

[0604] Compound 73: 1 H NMR (400MHz, CDCl3) δ5.30-5.29(m,1H),3.18-3.12(m,1H),2.40-2.30(m,1H),2.08-1.80(m,4H),1.76-1.69(m,1H),1.68-1.58(m,2H),1. 56-1.33(m,10H),1.32-1.22(m,5H),1.21-1.05(m,4H),1.02(s,3H), 1.01-0.96(m,5H),0.95-0.83(m,9H),0.82-0.78(m,3H),0.69(s,3H). LCMSt R = 1.424min in 2min chromatogram, 30-90AB_ELSD, MS ESIC 30 H 49 [M+H-2H2O] + The calculated value is 409 and the measured value is 409.

[0605] Step 4. Synthesis of compounds 74-A and 74-B. Pd / C (anhydrous, 200 mg) was added to a solution of compound 72 (110 mg, 0.247 mmol) in MeOH (30 mL). The mixture was stirred at 50 ° C in hydrogen (50 psi) for 72 hours. The mixture was filtered, concentrated and purified by combi-flash (0-15% EtOAc in PE) to give compound 74-A (19 mg, 17%) as an off-white solid and compound 74-B (18 mg, 16%) as an off-white solid.

[0606] Compound 74-A: 1 H NMR (400MHz, CDCl3) δ3.01-3.06(m,1H),2.01-1.94(m,1H),1.93-1.70(m,5H),1.39-1.58(m,4H),1.50-1.2 1(m,13H),1.20-1.11(m,5H),1.10-0.97(m,5H),0.96(s,3H),0.95-0.91(m,5H),0.89(s,9H),0.65(s,3H).

[0607] LCMS R = 1.425min in 2min chromatography, 30-90AB_ELSD, purity 99.4%, MS ESI C 30 H 51 [M+H-2H2O] + The calculated value is 411 and the measured value is 411.

[0608] Compound 74-B: 1 H NMR (400MHz, CDCl3) δ3.11-3.07(m,1H),1.98-1.94(m,1H),1.88-1.58(m,6H),1.56-1.40(m,5H),1.39-1.15(m,1 0H),1.13-1.02(m,5H),1.01-0.96(m,3H),0.95-0.92(m,4H),0.91-0.83(m,12H),0.81(s,3H),0.70-0.50(m,4H). LCMSt R = 1.424min in 2min chromatography, 30-90AB_ELSD, MS ESI C 30 H 51 [M+H-2H2O] + The calculated value is 411 and the measured value is 411.

[0609] Step 5. Synthesis of compounds 75-A and 75-B. Pd / C (anhydrous, 150 mg) was added to a solution of compound 73 (70 mg, 0.157 mmol) in MeOH (30 mL). The mixture was stirred at 50 ° C in hydrogen (50 psi) for 72 hours. The mixture was filtered, concentrated and purified by combi-flash (0-15% EtOAc in PE) to give compound 75-A (10 mg, 14%) as an off-white solid and compound 75-B (12 mg, 17%) as an off-white solid.

[0610] Compound 75-A:1 H NMR (400MHz, CDCl3) δ3.20-3.10(m,1H),2.00-1.94(m,1H),1.94-1.70(m,4 H),1.70-1.10(m,19H),1.20-1.00(m,9H),1.00-0.80(m,17H),0.65(s,3H). LCMSt R = 1.424min in 2min chromatography, 30-90AB_ELSD, MS ESI C 30 H 51 [M+H-2H2O] + The calculated value is 411 and the measured value is 411.

[0611] Compound 75-B: 1 H NMR (400MHz, CDCl3) δ3.16-3.13(m,1H),1.98-1.94(m,1H),1.90-1.80(m,1H),1.70-1.58(m,4H),1.56-1.36(m,8H),1. 34-1.16(m,9H),1.15-0.96(m,7H),0.95-0.91(m,4H),0.89(s,9H),0.88-0.84(m,3H),0.82(s,3H),0.70-0.60(m,4H). LCMSt R = 1.416min in 2min chromatography, 30-90AB_ELSD, purity 98.0%, MS ESI C 30 H 51 [M+H-2H2O] + The calculated value is 411 and the measured value is 411.

[0612] Materials and methods

[0613] The compounds provided herein can be prepared from readily available starting materials using the following general methods and operations (e.g., methods and operations as described in WO 2013 / 036835 and WO2014 / 160480). It should be understood that when typical or preferred process conditions are given (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), other processing conditions may also be used unless otherwise stated. The optimal reaction conditions may vary depending on the specific reactants or solvents used, but the conditions may be determined by conventional optimization by those skilled in the art.

[0614] In addition, it will be apparent to those skilled in the art that conventional blocking groups may be required to prevent undesirable reactions of specific functional groups. The selection of suitable blocking groups for specific functional groups and suitable conditions for protection and deprotection are known in the art. For example, various blocking groups and their introduction and removal are described in TW Greene and PGM Wuts, Protection Groups in Organic Synthesis, 2nd edition, Wiley, New York, 1991, which is incorporated herein by reference.

[0615] The compounds provided herein can be separated and purified by known standard procedures. Such procedures include, but are not limited to, recrystallization, column chromatography, HPLC, or supercritical fluid chromatography (SFC). The compounds provided herein can be prepared by those skilled in the art of organic synthesis from known or commercially available starting materials and reagents. Exemplary chiral columns that can be used to separate / purify the enantiomers / diastereomers provided herein include, but are not limited to, AD-10, OB, OB-H, OD, OD-H, OF, OG, OJ and OK.

[0616] This article reports 1 H-NMR (e.g., the region between about 1 to about 4 ppm δ (ppm)) should be understood as an exemplary interpretation of the NMR spectrum of the compound (e.g., exemplary peak integration). Exemplary general method for preparative HPLC: Column: Waters RBridge prep 10 μm C18, 19*250 mm. Mobile phase: acetonitrile, water (NH4HCO3) (30 L water, 24 g NH4HCO3, 30 mL NH3.H2O). Flow rate: 25 mL / min

[0617] Exemplary general method for analytical HPLC: Mobile phase: A: water (10 mM NH4HCO3), B: acetonitrile Gradient: 5%-95% B over 1.6 or 2 min; Flow rate: 1.8 or 2 mL / min; Column: XBridge C18, 4.6*50 mm, 3.5 μm@45C.

[0618] NMDA potentiation

[0619] NMDA potentiation was assessed using whole-cell patch clamp of mammalian cells expressing the NMDA receptor.

[0620] Whole-cell patch clamp of mammalian cells (Ionworks Barracuda (IWB))

[0621] The whole-cell patch clamp technique was used to study the effects of the compounds on GluN1 / GluN2A glutamate receptors expressed in mammalian cells. The results are shown in Table 1.

[0622] HEK293 cells were transformed with adenovirus 5 DNA and transfected with cDNA encoding human GRIN1 / GRIN2A genes. Stable transfectants were selected using G418 and anti-Zeocin genes incorporated into the expression plasmid, and selection pressure was maintained with G418 and Zeocin in the medium. Cells were cultured in Dulbecco's Modified Eagle culture / nutrient mixture (D-MEM / F-12), supplemented with 10% fetal bovine serum, 100 μg / ml penicillin G sodium, 100 μg / ml streptomycin sulfate, 100 μg / ml Zeocin, 5 μg / ml blasticidin and 500 μg / ml G418.

[0623] The test article effects were evaluated in an 8-point concentration-response format (4 replicate wells / concentration). All test and control solutions contained 0.3% DMSO and 0.01% EL (C5135, Sigma). The test article formulation was loaded into a 384-well compound plate using an automated liquid handling system (SciClone ALH3000, Caliper LifeScienses). The measurement was performed using the Ion Works Barracuda platform as follows:

[0624] Electrophysiological procedures:

[0625] a) Intracellular solution (mM): 50 mM CsCl, 90 mM CsF, 2 mM MgCl2, 5 mM EGTA, 10 mM HEPES. Adjust to pH 7.2 with CsOH.

[0626] b) Extracellular solution, HB-PS (composition, in mM): NaCl, 137; KCl, 1.0; CaCl2, 5; HEPES, 10; glucose, 10; adjusted to pH 7.4 with NaOH (refrigerated before use).

[0627] c) Holding potential: -70 mV, potential during agonist / PAM application: -40 mV.

[0628] Recording operations:

[0629] a) Extracellular buffer was loaded into the wells of the PPC plate (11 μL per well). Cell suspension was titrated into the wells of the PPC planar electrode (9 μL per well).

[0630] b) Whole-cell recordings were established via patch punches, where membrane currents were recorded by an on-board patch clamp amplifier.

[0631] c) Two recordings (scans) were performed. The first, during the pre-application of the test article alone (duration of pre-application - 5 min), and the second, during the co-application of the test article and the agonist (EC 20 L-glutamate and 30 μM glycine) to detect the positive regulatory effect of the test article.

[0632] Test article was administered: the first pre-application consisted of adding 20 μL of the test article solution at 2X concentration, the second consisted of adding 20 μL of the test article at 1X concentration and 10 μL / s of agonist (total application time was 2 seconds).

[0633] Table 1.

[0634]

[0635]

[0636]

[0637]

[0638] For Table 1, "A" indicates 10 to 75%, "B" indicates enhancement > 75 to 150%; "C" indicates enhancement > 150%; and "ND" indicates not measurable or not measured.

[0639] Other Implementations

[0640] In the claim items, unless otherwise indicated or obvious from the context, words such as "a", "an", and "the" may refer to one or more than one. Unless otherwise indicated or obvious from the context, a claim or description that includes "or" between one or more members of a group is considered to satisfy the condition if one, more than one, or all of the members of the group are present in, used in, or related to a given product or method. The invention includes embodiments in which exactly one member of a group is present in, used in, or related to a given product or method. The invention includes embodiments in which more than one member or all of the members of a group are present in, used in, or related to a given product or method.

[0641] In addition, the present invention encompasses all variations, combinations and arrangements in which one or more limitations, elements, clauses and descriptive terms in one or more listed claims are introduced into another claim. For example, any claim independent of other claims may be modified to include one or more limitations in any other claim that references the same basic claim. When an element is presented in a listed form, such as in a Markush form, each subgroup of the element is also disclosed, and any element may be removed from the group. It should be understood that, in general, when the present invention or multiple aspects of the present invention are pointed out to include specific elements and / or features, some embodiments of the present invention or multiple aspects of the present invention are composed of these elements and / or features, or are essentially composed of them. For the purpose of brevity, these embodiments are not specifically described in the same language here. It should also be noted that the terms "comprising" and "containing" are intended to be open-ended and allow the inclusion of other elements or steps. When a range is given, the endpoints are included. In addition, unless otherwise mentioned or obvious from the context and the understanding of those skilled in the art, the numerical values ​​expressed in the range may assume any specific numerical value or sub-range within the range in different embodiments of the present invention, to one tenth of the unit of the lower limit of the range, unless the context clearly indicates the opposite meaning.

[0642] Various granted patents, published patent applications, journal articles and other publications are mentioned herein, all of which are incorporated herein by reference. If there is a conflict between the cited documents and this specification, the present specification shall prevail. In addition, any specific embodiment of the present invention that falls within the scope of the prior art may be explicitly excluded from any one or more claims. Since the embodiments are considered to be known to those skilled in the art, they may be excluded even if they are not explicitly indicated to be excluded herein. Any specific embodiment of the present invention may be excluded from any claim for any reason, whether or not it involves the existence of prior art.

[0643] Only by using routine experimentation, those skilled in the art will recognize or be able to determine multiple variations of the specific embodiments described herein. The scope of the present embodiments described herein is not intended to be limited to the above description, but should be subject to the appended claims. It will be understood by those skilled in the art that various changes and modifications may be made to the description based on the definition of the claims without departing from the spirit or scope of the present invention.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein: in: R 1 C 1-6 alkyl; R 2 C 1-6 Alkyl, carbocyclyl or heterocyclyl; R 5 is absent or is hydrogen; and represents a single bond or a double bond, where For a double bond, the other is a single bond and R 5 Does not exist.

2. The compound of claim 1, wherein R 1 C 1-6 alkyl.

3. The compound of claim 2, wherein R 1 To replace C 1-6 alkyl.

4. The compound of claim 2, wherein R 1 For unsubstituted C 1-6 alkyl.

5. The compound of claim 1, wherein R 1 is methyl (e.g., -CH3, -CF3, -CH2OCH3 or -CH(CH3)(CF3)), ethyl or isopropyl.

6. The compound of claim 1, wherein R 1 is methyl (eg, -CH3) or ethyl (eg, -CH2CH3).

7. The compound of claim 1, wherein R 2 C 1-6 Alkyl or carbocyclic.

8. The compound of claim 1, wherein R 2 It is methyl, ethyl, isopropyl or cyclopropyl.

9. The compound of claim 1, wherein R 2 It is a carbocyclic group or a heterocyclic group.

10. The compound of claim 9, wherein R 2 It is cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

11. The compound of claim 9, wherein R 2 is an oxygen-containing heterocycle (eg, tetrahydropyran).

12. The compound of claim 1, wherein Indicates a single bond.

13. The compound of claim 1, wherein the compound of formula (I) is a compound of formula (IA) or formula (IB):

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (II):

15. The compound 14 of claim 1, wherein the compound of formula (II) is a compound of formula (II-A) or formula (II-B):

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (III):

17. The compound of claim 16, wherein the compound of formula (I) is a compound of formula (III-A) or formula (III-B):

18. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (IV):

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (IV-A) or formula (IV-B):

20. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (V):

21. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (VA) or formula (VB):

22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is selected from:

23. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

24. A method of inducing sedation or anesthesia, comprising administering to a subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

25. A method for treating or preventing a disorder described herein, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.

26. The method of claim 25, wherein the disorder is a gastrointestinal (GI) disorder such as constipation, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) (e.g., ulcerative colitis, Crohn's disease), structural disorders affecting the gastrointestinal tract, anal disorders (e.g., hemorrhoids, internal hemorrhoids, external hemorrhoids, anal fissures, perianal abscesses, anal fistulas), colon polyps, cancer, colitis.

27. The method of claim 26, wherein the disorder is inflammatory bowel disease.

28. The method of claim 26, wherein the disorder is cancer, diabetes, or a sterol synthesis disorder.

29. A method for treating or preventing a CNS-related disorder, comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a subject in need thereof.

30. The method of claim 29, wherein the CNS-related disorder is an adjustment disorder, an anxiety disorder (including obsessive-compulsive disorder, post-traumatic stress disorder, and social phobia), a cognitive disorder (including Alzheimer's disease and other forms of dementia), a dissociative disorder, an eating disorder, an affective disorder (including depression (e.g., postpartum depression), bipolar disorder and dysthymic disorder, suicidality), schizophrenia or other psychotic disorder (including schizoaffective disorder), a sleep disorder (including insomnia), a substance abuse-related disorder, a personality disorder (including obsessive-compulsive personality disorder), a self- Autism spectrum disorders (including those associated with mutations in Shank family proteins (e.g., Shank3)), neurodevelopmental disorders (including Rett syndrome, tuberous sclerosis complex), multiple sclerosis, sterol synthesis disorders, pain (including acute and chronic pain), encephalopathy secondary to a medical condition (including hepatic encephalopathy and anti-NMDA receptor encephalitis), epilepsy (including status epilepticus and monogenic forms of epilepsy such as Dravet disease), stroke, traumatic brain injury, movement disorders (including Huntington's disease and Parkinson's disease), visual impairment, hearing loss, and tinnitus.

31. The method of claim 29, wherein the disorder is a sterol synthesis disorder.

32. A method for studying the effect of a compound on GluN1 / GluN2A glutamate receptors expressed in mammalian cells using the whole-cell patch clamp technique, comprising: a. HEK293 cells were transformed with adenovirus 5 DNA and transfected with cDNA encoding human GRIN1 / GRIN2A genes; b. using G418 and Zeocin resistance genes incorporated into the expression plasmid to select stable transfectants, and maintaining the selection pressure in the medium with G418 and Zeocin; c. The cells were cultured in Dulbecco's Modified Eagle culture / nutrient mixture (D-MEM / F-12) supplemented with 10% fetal bovine serum, 100 μg / ml penicillin G sodium, 100 μg / ml streptomycin sulfate, 100 μg / ml Zeocin, 5 μg / ml blasticidin and 500 μg / ml G418; d. Evaluate the test article effect in an 8-point concentration-response format (4 pairs of replicate wells / concentration); All test and control solutions contained 0.3% DMSO and 0.01% EL (C5135, Sigma); e. The test article formulations were loaded into 384-well compound plates using an automated liquid handling system (SciCloneALH3000, Caliper LifeScienses); f. Measured using the Ion Works Barracuda platform.